Cresco Labs (CRLBF) 40-F 15 Mar 24 2023 FY Annual report (Canada) Financial data

Cover Page

Cover Page	12 Months Ended
	Dec. 31, 2023 shares
Document Information [Line Items]
Document Type	40-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Entity File Number	000-56241
Entity Registrant Name	Cresco Labs Inc.
Entity Tax Identification Number	98-1505364
Entity Address, Address Line One	400 W Erie St Suite 110
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
Entity Address, Country	US
City Area Code	312
Local Phone Number	929-0993
Annual Information Form	true
Audited Annual Financial Statements	true
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction	false
Entity Central Index Key	0001832928
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	Z4
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	400 W Erie St Suite 110
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	312
Local Phone Number	929-0993
Contact Personnel Name	Cresco Labs Inc.
Special Subordinate Voting Shares (SSVS)
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	158,940,757
Subordinate Voting Shares (SVS)
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	320,757,119
Proportionate Voting Shares (PVS)
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	94,748
MVS
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	500,000

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2023
Audit Information [Abstract]
Auditor Name	Marcum LLP
Auditor Firm ID	688
Auditor Location	Chicago, IL, USA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 103,429	$ 119,341
Restricted cash	5,091	2,169
Accounts receivable, net	51,070	56,492
Inventory, net	107,789	134,608
Loans receivable, short-term	1,421	447
Prepaid expenses	6,417	9,420
Other current assets	2,870	3,569
Total current assets	278,087	326,046
Non-current assets:
Property and equipment, net	368,308	379,722
Right-of-use assets	117,882	128,264
Intangible assets, net	296,966	407,590
Loans receivable, long-term	826	823
Investments	730	1,228
Goodwill	279,697	330,555
Deferred tax asset	11,547	26
Other non-current assets	4,424	9,438
Total non-current assets	1,080,380	1,257,646
TOTAL ASSETS	1,358,467	1,583,692
Current liabilities:
Accounts payable	27,587	28,093
Accrued liabilities	69,079	65,161
Short-term borrowings	11,817	10,976
Income taxes payable	82,343	94,842
Current portion of lease liabilities	9,416	8,959
Deferred consideration, and other payables, short-term	0	47,834
Total current liabilities	200,242	255,865
Non-current liabilities:
Long-term notes and loans payable, net	497,713	476,891
Lease liabilities	163,811	173,345
Deferred tax liability	40,457	75,138
Deferred consideration, long-term	6,577	7,770
Other long-term liabilities	21,600	7,000
Total non-current liabilities	730,158	740,144
TOTAL LIABILITIES	930,400	996,009
COMMITMENTS AND CONTINGENCIES (Note 16)
SHAREHOLDERS’ EQUITY
Share capital	1,689,452	1,617,093
Additional paid-in-capital	82,927	87,537
Accumulated other comprehensive loss	(1,151)	(1,393)
Accumulated deficit	(1,265,536)	(1,076,198)
Equity of Cresco Labs Inc.	505,692	627,039
Non-controlling interests	(77,625)	(39,356)
TOTAL SHAREHOLDERS’ EQUITY	428,067	587,683
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 1,358,467	$ 1,583,692

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)		12 Months Ended
		Dec. 31, 2023 $ / shares shares		Dec. 31, 2022 $ / shares shares
MVS
Condensed Balance Sheet Statements
Par value (in dollars per share) | $ / shares		$ 0		$ 0
Authorized (in shares)		500,000		500,000
Issued (in shares)		500,000		500,000
Outstanding (in shares)		500,000		500,000
Subordinate Voting Shares (SVS)
Condensed Balance Sheet Statements
Par value (in dollars per share) | $ / shares		$ 0		$ 0
Issued (in shares)		320,757,119		281,147,586
Outstanding (in shares)		320,757,119		281,147,586
Proportionate Voting Shares (PVS)
Condensed Balance Sheet Statements
Par value (in dollars per share) | $ / shares	[1]	$ 0		$ 0
Issued (in shares)	[1]	18,949,596		20,082,384
Outstanding (in shares)	[1]	18,949,596		20,082,384
Description of stock conversion ratio		0.005
Special Subordinate Voting Shares (SSVS)
Condensed Balance Sheet Statements
Par value (in dollars per share) | $ / shares	[2]	$ 0		$ 0
Authorized (in shares)		1,589	[2]	639
Issued (in shares)		1,589	[2]	639
Outstanding (in shares)		1,589	[2]	639
Description of stock conversion ratio		100,000
[1] 1 Proportionate Voting Shares (“PVS”) presented on an “as-converted” basis to Subordinate Voting Shares (“SVS”) (1-to-200) 2 Special Subordinate Voting Shares (“SSVS”) presented on an “as-converted” basis to SVS (1-to-0.00001)

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Profit or loss [abstract]
Revenues, net	$ 770,885	$ 842,681
Costs of goods sold	408,519	435,668
Gross profit	362,366	407,013
Operating expenses:
Selling, general and administrative	299,172	350,653
Impairment loss	151,017	140,655
Total operating expenses	450,189	491,308
Loss from operations	(87,823)	(84,295)
Other expense, net:
Interest expense, net	(60,819)	(57,837)
Other income, net	1,740	15,227
Total other expense, net	(59,079)	(42,610)
Loss before income taxes	(146,902)	(126,905)
Income tax expense	(32,950)	(88,938)
Net loss	(179,852)	(215,843)
Net loss attributable to non-controlling interests, net of tax	(4,330)	(3,796)
Net loss attributable to Cresco Labs Inc.	$ (175,522)	$ (212,047)
Earnings per share [abstract]
Diluted loss per share (in dollars per share)	$ (0.54)	$ (0.71)
Basic loss per share (in dollars per share)	$ (0.54)	$ (0.71)
Basic weighted average number of shares outstanding (in shares)	323,819,766	298,161,665
Diluted weighted average number of shares outstanding (in shares)	323,819,766	298,161,665

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of comprehensive income [abstract]
Net loss	$ (179,852)	$ (215,843)
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation differences, net of tax	242	(1,139)
Total comprehensive loss for the period	(179,610)	(216,982)
Comprehensive loss attributable to non-controlling interests, net of tax	(4,330)	(3,796)
Total comprehensive loss attributable to Cresco Labs Inc.	$ (175,280)	$ (213,186)

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Share capital	Additional paid-in capital	Accumulated other comprehensive loss, net of tax	Accumulated deficit	Non-controlling interests
Beginning balance at Dec. 31, 2021	$ 797,736	$ 1,556,941	$ 40,774	$ (254)	$ (841,907)	$ 42,182
Changes in equity [abstract]
Exercise of options and warrants	698	4,941	(4,243)
Share-based compensation	23,761	3,417	20,344
Employee taxes withheld on certain share-based payment arrangements	(427)	290	(717)
Income tax reserve	155				155
Payable pursuant to tax receivable agreements	597	597
Tax benefit from shareholder redemptions	(1,239)	(1,239)
Equity issued related to acquisitions	34,708	34,708
Tax distributions to non-controlling interest holders	(42,679)		31,379		(5,230)	(68,828)
Excess cash distributions to non-controlling interest holders	(8,645)					(8,645)
Cresco LLC shares redeemed	0	17,438			(17,169)	(269)
Foreign currency translation	(1,139)			(1,139)
Net loss	(215,843)				(212,047)	(3,796)
Ending balance at Dec. 31, 2022	587,683	1,617,093	87,537	(1,393)	(1,076,198)	(39,356)
Changes in equity [abstract]
Share-based compensation	15,339	9,059	6,280
Employee taxes withheld on certain share-based payment arrangements	(713)		(713)
Income tax reserve	7,212				7,212
Payable pursuant to tax receivable agreements	33	33
Equity issued related to settlement of acquisition related contingent consideration	47,238	47,238
Equity issuances and other adjustments	2	2
Tax distributions to non-controlling interest holders	(42,947)		(10,177)		787	(33,557)
Excess cash distributions to non-controlling interest holders	(6,170)					(6,170)
Cresco LLC shares redeemed	0	16,027			(21,815)	5,788
Foreign currency translation	242			242
Net loss	(179,852)				(175,522)	(4,330)
Ending balance at Dec. 31, 2023	$ 428,067	$ 1,689,452	$ 82,927	$ (1,151)	$ (1,265,536)	$ (77,625)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (179,852)	$ (215,843)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	62,512	51,930
Amortization of operating lease assets	6,792	5,795
Bad debt expense and provision expense for expected credit loss	10,706	1,700
Share-based compensation expense	16,356	23,221
Loss on investments	500	4,615
Loss on changes in fair value of deferred and contingent consideration	1,204	5,667
Gain on derivative instruments and warrants	0	(1,184)
Loss on inventory write-offs and provision	3,820	7,358
Change in deferred taxes	(32,659)	(4,643)
Accretion of discount and deferred financing costs on debt arrangements	4,416	3,951
Foreign currency loss (gain)	303	(940)
Loss on sale of assets	(13)	2,635
Impairment loss	151,017	140,655
Gain on lease termination and sale and leaseback transaction	(1,965)	(19,630)
Loss on other adjustments to net income	209	0
Changes in operating assets and liabilities:
Accounts receivable	(5,369)	(14,776)
Inventory	23,491	(2,668)
Prepaid and other assets	2,598	(4,512)
Accounts payable and other accrued liabilities	27,795	10,700
Operating lease liabilities	(28,002)	(22,073)
Income taxes payable	(5,295)	46,783
NET CASH PROVIDED BY OPERATING ACTIVITIES	58,564	18,741
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(55,385)	(83,026)
Purchase of intangibles	(2,498)	(3,106)
Proceeds from sale and leaseback transactions and tenant improvement allowances	2,594	47,914
Payment of acquisition consideration, net of cash acquired	0	(1,135)
Proceeds from sale and disposals of assets	11,704	1,322
Receipts from loans and advances	0	2,654
Payments of loans and advances	(1,000)	(1,200)
NET CASH USED IN INVESTING ACTIVITIES	(44,585)	(36,577)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options, warrants and sell-to-cover shares	0	3,215
Proceeds from the issuance of long-term debt	20,175	0
Payment of debt issuance costs	(1,947)	0
Payment of acquisition-related contingent consideration	(1,787)	(4,927)
Tax distribution payments in accordance with the tax receivable agreement	(222)	0
Excess cash distributions to non-controlling interest redeemable unit holders and other members	(6,170)	(8,646)
Tax distributions to non-controlling interest redeemable unit holders and other members	(32,770)	(73,859)
Principal payment of property, plant, and equipment vendor financing	(701)	0
Principal payments on finance lease obligations	(3,485)	(2,426)
NET CASH USED IN FINANCING ACTIVITIES	(26,907)	(86,643)
Effect of exchange rate changes on cash and cash equivalents	(62)	(113)
Net decrease in cash and cash equivalents	(12,990)	(104,592)
Cash and cash equivalents and restricted cash, beginning of year	121,510	226,102
Cash and cash equivalents, end of period	103,429	119,341
Restricted cash, end of period	5,091	2,169
Cash and cash equivalents and restricted cash, end of year	108,520	121,510
CASH PAID DURING THE PERIOD FOR:
Income tax, net	70,896	46,756
Interest	53,616	53,651
NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Non-cash consideration for business combination	47,238	34,708
Non-controlling interests redeemed for equity	5,788	357
Increase to net lease liability	1,474	26,487
Receivable due from seller of previous acquisition	705	797
Liability incurred to purchase property, equipment and intangibles	93	8,664
Purchase of property, plant and equipment through vendor financing	748	0
Purchase of property, plant and equipment through inventory	48	0
Cashless exercise of stock options	0	1,821
Unpaid declared distributions to non-controlling interest redeemable unit holders	10,176	9,896
Receivable related to financing lease transactions	612	612
Liability incurred in accordance with tax receivable agreement	$ 14,564	$ 1,053

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2023
Nature Of Operations [Abstract]
Nature of Operations	NOTE 1. NATURE OF OPERATIONS Cresco Labs Inc. (“Cresco Labs” or the “Company”), formerly known as Randsburg International Gold Corp. (“Randsburg”) was incorporated in the Province of British Columbia under the Company Act on July 6, 1990. The Company is one of the largest vertically-integrated multi-state cannabis operators in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products primarily through Sunnyside* ® , Cresco Labs’ national dispensary brand and third-party retail stores. Employing a consumer-packaged goods approach to cannabis, Cresco Labs’ house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco ® , High Supply ® , Mindy’s TM , Good News ® , Remedi TM , Wonder Wellness Co. ® and FloraCal ® Farms. As of December 31, 2023, the Company operates in Illinois, Pennsylvania, Ohio, California, New York, Massachusetts, Michigan and Florida pursuant to the Illinois Compassionate Use of Medical Cannabis Program Act and the Illinois Cannabis Regulation and Tax Act; the Pennsylvania Medical Marijuana Act; the Ohio Medical Marijuana Control Program; the California Medicinal and Adult-Use Cannabis Regulation and Safety Act; the New York Marihuana Regulation and Taxation Act; the Massachusetts Regulation and Taxation of Marijuana Act, the Massachusetts Act for the Humanitarian Medical Use of Marijuana and the Massachusetts Act to Ensure Safe Access to Marijuana; the Michigan Medical Marihuana Act, the Michigan Medical Marihuana Facilities Licensing Act, the Michigan Regulation and Taxation of Marihuana Act and the Michigan Marihuana Tracking Act and the Florida Compassionate Medical Cannabis Act, respectively. The Company trades on the Canadian Securities Exchange under the ticker symbol “CL,” on the Over-the-Counter Market under the ticker symbol “CRLBF” and on the Frankfurt Stock Exchange under the symbol “6CQ.” The Company’s corporate office is located at Suite 110, 400 W Erie St, Chicago, IL 60654. The registered office is located at Suite 2500, 666 Burrard Street, Vancouver, BC V6C 2X8.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Preparation The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). (b) Basis of Measurement The accompanying consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for certain loans receivable, investments, and contingent considerations, which are recorded at fair value. Historical cost is generally based upon the fair value of the consideration given in exchange for assets acquired and the contractual obligation for liabilities incurred. (c) Functional and Presentation Currency The Company’s functional currency and that of the majority of its subsidiaries is the United States (“U.S.”) dollar. The Company’s reporting currency is the U.S. dollar (“USD”). All references to “C$” refer to Canadian dollars. Foreign currency denominated assets and liabilities are re-measured into the functional currency using period-end exchange rates. Gains and losses from foreign currency transactions are included in Other income, net in the Consolidated Statements of Operations. Assets and liabilities of foreign operations having a functional currency other than USD (e.g., C$) are translated at the rate of exchange prevailing at the reporting date; revenues and expenses are translated at the monthly average rate of exchange during the period. Gains or losses on translation of foreign subsidiaries and net investments in foreign operations are included in Foreign currency translation differences, net of tax in the Consolidated Statements of Comprehensive Loss and Accumulated other comprehensive loss on the Consolidated Balance Sheets. (d) Basis of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries with intercompany balances and transactions eliminated upon consolidation. Subsidiaries are those entities over which the Company has the power over the investee, is exposed, or has rights, to variable involvement with the investee; and has the ability to use its power to affect its returns. The following are Cresco Labs’ wholly-owned or controlled entities as of December 31, 2023: Entity Location Purpose Percentage Cresco Labs Inc. British Columbia, Canada Parent Company Cali-Antifragile Corp. California Holding Company 100% River Distributing Co., LLC California Holding Company 100% Sonoma's Finest fka FloraCal California Cultivation 100% Cub City, LLC California Cultivation 100% CRHC Holdings Corp. Ontario, Canada Holding Company 100% Cannroy Delaware Inc. Delaware Holding Company 100% High Road Holdings LLC Delaware Holding Company 100% Laurel Harvest Labs, LLC Pennsylvania Cultivation and Dispensary Facility 100% JDRC Mount Joy, LLC Illinois Holding Company 100% JDRC Scranton, LLC Illinois Holding Company 100% Bluma Wellness Inc. British Columbia, Canada Holding Company 100% Cannabis Cures Investments, LLC Florida Holding Company 100% 3 Boys Farm, LLC Florida Cultivation, Production and Dispensary Facility 100% Farm to Fresh Holdings, LLC Florida Holding Company 100% Cresco U.S. Corp. Illinois Holding Company 100% MedMar Inc. Illinois Holding Company 100% MedMar Lakeview, LLC Illinois Dispensary 88% MedMar Rockford, LLC Illinois Dispensary 75% Gloucester Street Capital, LLC New York Holding Company 100% Valley Agriceuticals, LLC New York Cultivation, Production and Dispensary Facility 100% Valley Agriceuticals Real Estate New York Holding Company 100% JDRC Ellenville, LLC Illinois Holding Company 100% CMA Holdings, LLC Illinois Holding Company 100% BL Real Estate, LLC Massachusetts Holding Company 100% BL Pierce, LLC Massachusetts Holding Company 100% BL Uxbridge, LLC Massachusetts Holding Company 100% BL Main, LLC Massachusetts Holding Company 100% BL Burncoat, LLC Massachusetts Holding Company 100% BL Framingham, LLC Massachusetts Holding Company 100% BL Worcester, LLC Massachusetts Holding Company 100% Cultivate Licensing LLC Massachusetts Holding Company 100% Cultivate Worcester, Inc. Massachusetts Dispensary 100% Cultivate Leicester, Inc. Massachusetts Cultivation, Production and Dispensary Facility 100% Cultivate Framingham, Inc. Massachusetts Dispensary 100% Cultivate Cultivation, LLC Massachusetts Cultivation and Production Entity 100% GoodNews Holdings, LLC Illinois Licensing Company 100% Wonder Holdings, LLC Illinois Licensing Company 100% JDRC Seed, LLC Illinois Educational Company 100% CP Pennsylvania Holdings, LLC Illinois Holding Company 100% Bay, LLC Pennsylvania Dispensary 100% Bay Asset Management, LLC Pennsylvania Holding Company 100% Ridgeback, LLC Colorado Holding Company 100% Encanto Green Cross Dispensary, LLC Arizona Holding Company 100% Cresco Labs Texas, LLC Texas Holding Company 100% Cresco Labs, LLC Illinois Operating Entity 62% Cresco Labs Ohio, LLC Ohio Cultivation, Production and Dispensary Facility 99% Entity Location Purpose Percentage Cresco Labs Notes Issuer, LLC Illinois Holding Company Wellbeings, LLC Delaware CBD Wellness Product Development 100% Cresco Labs SLO, LLC California Holding Company 100% SLO Cultivation Inc. California Holding Company 80% Cresco Labs Joliet, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Kankakee, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Logan, LLC Illinois Cultivation and Production Facility 100% Cresco Labs PA, LLC Illinois Holding Company 100% Cresco Yeltrah, LLC Pennsylvania Cultivation, Production and Dispensary Facility 100% Strip District Education Center Pennsylvania Holding Company 100% AFS Maryland, LLC Maryland Holding Company 100% JDC Newark, LLC Ohio Holding Company 100% Verdant Creations Newark, LLC Ohio Dispensary 100% Strategic Property Concepts, LLC Ohio Holding Company 100% JDC Marion, LLC Ohio Holding Company 100% Verdant Creations Marion, LLC Ohio Dispensary 100% Strategic Property Concepts 4, LLC Ohio Holding Company 100% JDC Chillicothe, LLC Ohio Holding Company 100% Verdant Creations Chillicothe, LLC Ohio Dispensary 100% Strategic Property Concepts 5, LLC Ohio Holding Company 100% JDC Columbus, LLC Ohio Holding Company 100% Care Med Associates, LLC Ohio Dispensary 100% Arizona Facilities Supply, LLC Arizona Holding Company 100% Cresco Labs TINAD, LLC Illinois Holding Company 100% TINAD, LLC Illinois Holding Company 100% PDI Medical III, LLC Illinois Dispensary 100% Cresco Labs Phoenix Farms, LLC Illinois Holding Company 100% Phoenix Farms Partners, LLC Illinois Holding Company 100% Phoenix Farms of Illinois Asset Management, LLC Illinois Holding Company 100% Phoenix Farms of Illinois, LLC Illinois Dispensary 100% JDC Elmwood, LLC Illinois Holding Company 100% FloraMedex, LLC Illinois Dispensary 100% Cresco Edibles, LLC Illinois Holding Company 100% TSC Cresco, LLC Illinois Licensing 75% Cresco HHH, LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cresco Labs Nevada, LLC Nevada Holding Company 100% Cresco Labs Michigan Management, LLC Michigan Holding Company 100% Cresco Labs Missouri Management, LLC Missouri Holding Company 100% JDRC Acquisitions, LLC Illinois Holding Company 100% JDRC 7841 Grand LLC Illinois Holding Company 100% JDRC Lincoln, LLC Illinois Holding Company 100% JDRC Danville, LLC Illinois Holding Company 100% JDRC Kankakee, LLC Illinois Holding Company 100% JDRC Brookville, LLC Illinois Holding Company 100% Cresco Labs Michigan, LLC (a) Michigan Cultivation and Production Facility 85% (a) Legally, Cresco Labs Michigan, LLC is 85% owned by related parties of the Company. Cresco U.S. Corp., which is wholly owned by the Company, is the sole manager of Cresco Labs, LLC; Cresco Labs, LLC is the sole owner and manager of Cresco Labs Notes Issuer, LLC. Therefore, the Company controls Cresco Labs Notes Issuer, LLC and has consolidated its results into the consolidated financial statements. Non-controlling interests (“NCI”) represent ownership interests in consolidated subsidiaries by parties that are not shareholders of the Company. They are shown as a component of total equity in the Consolidated Balance Sheets, and the share of income attributable to NCI is shown as Net income attributable to non-controlling interests, net of tax in the Consolidated Statements of Operations and in the Consolidated Statements of Comprehensive Loss. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions. (e) Cash and Cash Equivalents Cash and cash equivalents include cash deposits in financial institutions, other deposits that are readily convertible into cash and cash on hand at retail locations. The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents and mainly consist of certificates of deposits. (f) Restricted Cash Restricted cash represents amounts held in escrow related to investments, acquisitions and building improvements. (g) Accounts Receivable Accounts receivable are recorded net of allowance for doubtful accounts. The Company develops a provision matrix and measures the expected credit losses based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors. The Company also estimates and provides an allowance for doubtful accounts based on contractual payment terms, actual payment history of its customers, current economic conditions and individual customer circumstances. Accounts receivable are evaluated monthly based on expected collections over its life and an adjustment is recorded as needed. When a receivable is uncollectible, it is written off against the provision. Subsequent recoveries of amounts previously written off are credited to the Consolidated Statements of Operations . See Note 17 for further discussion. (h) Inventory Inventory is primarily composed of raw materials (cannabis and non-cannabis), work-in-process and finished goods. Inventory is recorded at the lower of cost or net realizable value, with cost determined using the weighted average cost method. For manufactured inventory, costs incurred during the growing and production of cannabis and cannabis-based products are capitalized, net of yield adjustments, as incurred to the extent that costs are less than net realizable value. These costs include, but are not limited to, materials, labor, overhead and occupancy costs, cannabis taxes and depreciation expense on equipment involved in manufacturing, packaging, labeling, inspection and testing. Fixed costs associated with underutilized facilities are taken as expenses within the current period. Capacities are set using normalized operating capacity as defined by GAAP. Costs related to purchased finished goods are recorded at cost, including freight. The Company reviews inventory for obsolete, redundant and slow-moving goods and any such inventory is written down to net realizable value. (i) Property and Equipment Property and equipment is stated at cost, net of accumulated depreciation. Land is recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The Company evaluates the recoverability of property, plant and equipment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. In those cases, the assets are assessed for impairment based on the estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the carrying value of an asset exceeds its estimated future undiscounted cash flows, the Company will determine the fair value of the assets within the asset group and record an impairment loss calculated as the excess in carrying value over fair value. Equipment is derecognized upon disposal or when no future economic benefits are expected from its use. Leasehold improvements are amortized over the lesser of the life of the lease or estimated useful life of the improvement. Any gain or loss arising from derecognition or impairment of the asset (calculated as the difference between the net disposal proceeds and the carrying value of the asset) is included in the accompanying Consolidated Statements of Operations. The Company assesses property and equipment for indicators of impairment throughout the reporting period. See Note 4 for additional details. Category Estimated Leasehold Improvements 1 - 15 years Machinery and Equipment 5 - 15 years Furniture and Fixtures 3 - 7 years Vehicles 5 years Website and Software 3 years Computer Equipment 3 - 5 years Buildings and Building Improvements 5 - 39 years Repairs and maintenance that do not improve efficiency or extend economic life are charged to expense as incurred. (j) Intangible Assets Intangible assets are recorded at cost, less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date or date of consolidation/control. Amortization of definite-lived intangible assets is recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. Costs incurred during the year to renew or extend the term of a recognized intangible asset are included within additions and are amortized on a straight-line basis over the useful lives of the permit or license renewal period. See Note 7 for additional details. Intangible assets are amortized over the following terms: Category Estimated Customer Relationships 7 - 8 years Non-Compete Agreements 2 - 5 years Trade Names 10 years Permit Application Fees 1 - 2 years The estimated useful lives and residual values are reviewed at each year end and any changes in estimates are accounted for prospectively. Intangible assets that have an indefinite useful life are not subject to amortization. The Company’s indefinite-lived intangible assets consist of licenses which represent the future benefits associated with the Company’s cultivation, processing and dispensary licenses. Absent such license intangibles, the Company cannot continue as a going concern and as such, there is no foreseeable limit to the period over which these assets are expected to generate future cash inflows to the Company. Definite-lived intangible assets are tested for impairment when there is an indication of impairment. Indefinite-lived intangible assets are tested for impairment annually, or more frequently, as warranted if events or changes in circumstances indicate impairment. For the purpose of impairment testing, goodwill and indefinite-lived intangible assets have been allocated to reporting units, determined based on the smallest identifiable group of assets that generate cash inflows and outflows that are largely independent of cash inflows from other assets or group of assets. (k) Goodwill Goodwill represents the excess of the purchase price paid for the acquisition of a business over the fair value of the net assets acquired. Goodwill is allocated to the reporting unit or reporting units, which are expected to benefit from the synergies of the combination. Goodwill is not subject to amortization and is tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment may have occurred. For the purpose of impairment testing, goodwill and indefinite-lived intangible assets have been allocated to reporting units or groups of reporting units representing the lowest level at which the assets generate cash inflow and outflow independent of other assets. An impaired asset is written down to its estimated fair value based on the most recent information available. The Company assesses the fair values of its reporting units using an income-based approach. Under the income approach, fair value is based on the present value of estimated future cash flows. The income approach requires management to estimate a number of factors for each reporting unit, including projected future operating results, economic projections, anticipated future cash flows, discount rates, and the allocation of shared or corporate costs. The impairment review, which is performed October 1 of each year, begins with a qualitative assessment of all reporting units. If the Company determines, based on weighing of all available evidence, that a reporting unit’s carrying value may exceed its fair value at the testing date, the Company performs a quantitative impairment assessment. If the carrying value of these intangible assets or the reporting unit exceeds the fair values, the Company would record an impairment charge based on the excess of the carrying value over the fair value. See Note 7 for additional details. As of December 31, 2023, the Company has no goodwill recorded that is expected to be tax deductible. (l) Income Taxes Tax expense recognized in profit or loss is comprised of the sum of current and deferred taxes not recognized in other comprehensive loss or directly in equity. (i) Current Tax Current tax assets and/or liabilities are comprised of claims from, or obligations to, fiscal authorities relating to the current or prior reporting periods that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the financial statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. (ii) Deferred Tax Deferred taxes are calculated using the asset and liability method on temporary differences between the carrying amounts of assets and liabilities and their tax bases. Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their respective period of realization, provided they are enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are always provided for in full. The measurement of deferred tax assets is reduced through a valuation allowance, if necessary, by the amount of any tax benefits that, based on available evidence, are more likely than not expected to be unrealized. Deferred tax assets and liabilities are offset only when the Company has a right and intention to offset current tax assets and liabilities from the same taxation authority. Changes in deferred tax assets or liabilities are recognized as a component of tax income or expense in profit or loss, except where they relate to items that are recognized in other comprehensive loss or directly in equity, in which case the related deferred tax is also recognized in other comprehensive loss or equity, respectively. As the Company operates in the cannabis industry, the Company is subject to the limits of Internal Revenue Code (“IRC”) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. See Note 21 for additional details. (m) Fair Value of Financial Instruments The Company accounts for assets and liabilities measured at fair value on a recurring basis in accordance with Accounting Standards Codification (“ASC”) 820 Fair Value Measurements . Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the inputs to the fair value measurements. The three levels of the hierarchy are: – Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; – Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; – Level 3 – Inputs for the asset or liability that are not based on observable market data. See Note 17 for additional details. (n) Loans Receivable The Company may provide financing to various related and non-related businesses within the cannabis industry. These loans are classified as held for investment and accounted for as financial instruments in accordance with ASC 310 Receivables . At each reporting date, the Company applies its judgment to evaluate the collectability of the Loans receivable balance and records a provision based on the assessed amount of expected credit loss (“ECL”). See Note 17 for additional details. (o) Leases The Company has entered into leases primarily for its corporate offices, cultivation and processing facilities and dispensaries. At inception of a contract, the Company determines whether the contract includes a lease. A contract contains a lease if it includes enforceable rights and obligations under which the right to control the use of an identified asset is conveyed for a period of time in exchange for consideration. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the commencement date – the date when the asset is available for use by the lessee. The Company assesses at lease commencement whether it is reasonably certain to exercise extension or termination options. The Company reassesses its lease portfolio to determine whether it is reasonably certain to exercise the options if there is a significant event or significant change in circumstances within its control. The extension options, which are considered reasonably certain to be exercised, are mainly those for which operational decisions have been made that make the lease assets vital to the continued relevant business activities. Liabilities arising from a lease are initially measured at the present value of the lease payments not yet paid, using the Company’s incremental borrowing rate. Lease liabilities include the value of the following payments: (i) Fixed payments, including in-substance fixed payments, less any lease incentives receivable; (ii) The exercise price of a purchase option if the Company is reasonably certain to exercise that option; and (iii) Penalties for early termination of the lease, if the lease term reflects the Company exercising an option to terminate the lease. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is decreased by cash paid net of interest expense incurred. The lease liability is remeasured when there is a change in future lease payments, or if the Company changes its assessment of whether it will exercise an extension, purchase or termination option. ROU assets are measured at cost and are comprised of the following: (i) The amount of the initial measurement of lease liability; (ii) Lease payments made at or before the commencement date less any lease incentives received; (iii) Any initial direct costs; and (iv) An estimate of costs of dismantling and removing the underlying asset, restoring the site on which it is located or the underlying asset, if applicable. The ROU asset is depreciated on a straight-line basis from the commencement date to the end of the lease term. A fixed amount of rent expense is recognized on a straight-line basis over the lease term for operating leases. For finance leases, depreciation expense on the ROU asset and interest expense on the lease liability are recognized over the lease term. The value of the ROU asset is periodically reduced by impairment losses, if any, and adjusted for certain revaluations of the lease liability. In accordance with the guidance in ASC 842 Leases , the Company has elected not to recognize ROU assets and lease liabilities where the total lease term is less than or equal to twelve months. The payments for such leases are recognized as rent expense within Selling, general and administrative expenses or Cost of goods sold in the Consolidated Statements of Operations on a straight-line basis over the lease term. See Note 5 for additional information. (p) Change in Accounting Policy On October 1, 2023, the Company elected to change its accounting policy related to the computation of short-term versus long-term lease liabilities. Previously, the current portion of the lease liability was determined by summing the present value of lease payments for the next 12 months. Under the new methodology, the current portion of the lease liability is now calculated by summing the next 12 months lease liability reduction. The Company implemented the change to better leverage automated lease accounting software and further streamline its month-end and quarter-end close processes. Both methodologies are allowable under GAAP. The change was applied retrospectively, and all prior periods presented in the consolidated financial statements have been adjusted in accordance with the updated policy. See sections (z) Reclassifications and Note 5 for additional information. (q) Revenue Recognition Revenue is recognized by the Company in accordance with ASC 606 Revenue from Contracts with Customers . Through application of ASC 606, the Company recognizes revenue to depict the transfer of promised goods to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. In order to recognize revenue under ASC 606, the Company applies the following five (5) steps: • Identify a customer along with a corresponding contract; • Identify the performance obligation(s) in the contract to transfer goods to a customer; • Determine the transaction price the Company expects to be entitled to in exchange for transferring promised goods to a customer; • Allocate the transaction price to the performance obligation(s) in the contract; and • Recognize revenue when or as the Company satisfies the performance obligation(s). Revenue consists of wholesale and retail sales of cannabis and other cannabis-derived and related products. Wholesale and retail sales are both generally recognized at a point in time when control over the goods has been transferred to the customer and is recorded net of sales discounts. For retail sales, payment is typically due upon transferring the goods to the customer. For wholesale sales, payment is typically due upon transferring the goods to the customer or within a specified time period permitted under agreed-upon payment terms. Revenue is recognized upon the satisfaction of the performance obligation. The Company satisfies its performance obligation and transfers control upon delivery and acceptance by the customer. For some of its locations, the Company has customer loyalty programs where retail customers accumulate points based on their level of spending and use these points for discounts on cannabis and cannabis related products. These points are recorded as a contract liability until customers redeem their points for discounts. In addition, the Company records a performance obligation as a reduction of revenue based on the estimated probability of point redemption, which is calculated based on a standalone selling price and using historical redemption rates. Upon redemption, the loyalty program obligation is relieved and the offset is recorded as revenue. In the event of a product recall, the expected value method is utilized to estimate the financial impact and a reduction of revenue is recorded. See Note 13 for additional information on revenue and loyalty programs. (r) Advertising Costs Advertising costs are expensed as incurred and are included in Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations and totaled $7.4 million and $8.1 million for the years ended December 31, 2023 and 2022, respectively. (s) Excise Tax The Company recognizes excise tax and community benefit fees as Cost of goods sold or Selling, general and administrative expense based on whether the tax is generated on production of cannabis or as part of selling costs, respectively. (t) Share-Based Compensation The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. For awards with performance conditions, compensation expense is recognized over the service period of awards and adjusted for the probability of achievement of performance-based goals. Expected forfeitures are applied to awards using an expected forfeiture rate that is calculated annually. The expected forfeiture rate is reviewed quarterly and an updated forfeiture rate will be applied to all outstanding awards if there has been a material change to the rate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For share-based payments granted to non-employees, the compensation expense is measured at the fair value of the equity instrument on the grant date. See Note 9 for additional information on share-based compensation. (u) Variable Interest Entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under ASC 810 Consolidations , where the Company concludes that it is the primary beneficiary of a VIE, the Company consolidates the financial results of the entity. See Note 18 for additional information on VIEs. (v) Business Combinations and Assets and Liabilities Held for Sale A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for by applying the acquisition method. The total consideration transferred in a business combination is the sum of the fair values of assets transferred, liabilities assumed, equity interests and other consideration issued by the acquirer in exchange for control of the acquiree. The acquisition date is the date on which the Company obtains control of the acquiree. The identifiable assets acquired, and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where ASC 805 Business Combinations provides exceptions to recording the amounts at fair value. Preliminary balances recorded are subject to change during the measurement period which will conclude at the earlier of the date the Company receives the information it was seeking about facts and circumstances that existed as of the acquisition date, learns that more information is not obtainable or one year following the acquisition date. Acquisition costs of the acquirer are expensed to profit or loss; acquisition costs of the acquiree paid by the acquirer may comprise a portion of consideration transferred. Non-controlling interest in the acquiree, if any, is recognized at fair value. The Company classifies an asset or disposal group as held for sale in accordance with ASC 360 Property, Plant and Equipment, when the following criteria are met: • management, having the authority to approve the action, commits to a plan to sell the asset (disposal group); • the asset (disposal group) is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets (disposal groups); • an active program to locate a buyer and other actions required to complete the plan to sell the asset (disposal group) have been initiated; • the sale of the asset (disposal group) is probable, and transfer of the asset (disposal group) is expected to qualify for recognition as a completed sale, within one year; • the asset (disposal group) is being actively marketed for sale at a price that is reasonable in relation to its current fair value; • actions required to complete t

Inventory

Inventory	12 Months Ended
	Dec. 31, 2023
Inventory [Abstract]
Inventory	NOTE 3. INVENTORY Inventory as of December 31, 2023 and 2022, consisted of the following: December 31, December 31, ($ in thousands) 2023 2022 Raw materials $ 12,649 $ 36,233 Raw materials - non-cannabis 17,937 26,709 Work-in-process 51,538 41,164 Finished goods 25,665 30,502 Total Inventory $ 107,789 $ 134,608 The Company wrote off $3.8 million and $7.4 million of inventory during the years ended December 31, 2023 and 2022, respectively. These write-offs are included in Cost of goods sold presented in the Consolidated Statements of Operations. In addition, during the year ended December 31, 2023, the Company recorded an adjustment of $0.7 million to write down inventory to its net realizable value. The assets were sold in the fourth quarter of 2023.

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2023
Property, plant and equipment [abstract]
Property And Equipment	NOTE 4. PROPERTY AND EQUIPMENT Property and equipment consisted of the following: ($ in thousands) December 31, 2023 December 31, 2022 Land and Buildings $ 207,194 $ 176,594 Machinery and Equipment 41,928 39,928 Furniture and Fixtures 37,912 28,724 Leasehold Improvements 173,614 142,880 Website, Computer Equipment and Software 11,124 10,232 Vehicles 2,892 3,552 Construction In Progress 14,483 55,507 Total property and equipment, gross 489,147 457,417 Less: Accumulated depreciation (120,839) (77,695) Total property and equipment, net $ 368,308 $ 379,722 As of December 31, 2023 and 2022, costs related to construction at the Company’s facilities and dispensaries were capitalized in construction in progress and not depreciated. Depreciation will commence when construction is completed and the facilities and dispensaries are available for their intended use. Land costs at each balance sheet date are included in Land and Buildings. The following table reflects depreciation expense related to property and equipment: ($ in thousands) December 31, 2023 December 31, 2022 Depreciation expense included in selling, general and administrative expense $ 18,475 $ 11,255 Depreciation expense included in cost of goods sold and ending inventory 35,716 29,847 Total depreciation expense $ 54,191 $ 41,102 As of December 31, 2023 and 2022, ending inventory includes approximately $12.8 million and $10.9 million of capitalized depreciation, respectively. For the years ended December 31, 2023 and 2022, $33.9 million and $28.0 million, respectively, of depreciation was recorded to Cost of goods sold, which includes $10.8 million and $9.1 million, respectively, related to depreciation capitalized to inventory in prior years. During the year ended December 31, 2023, the Company wrote down the remaining assets at our Mendota facility with a net book value of $0.1 million and sold certain assets to a third-party and recorded a net gain on sale of assets of $0.1 million to Other income, net in the Consolidated Statements of Operations. During the year ended December 31, 2023, the Company sold $2.5 million of property and equipment at our Encanto Green Cross Dispensary in Arizona. The Company accelerated depreciation expense of $0.7 million on the property and equipment sold. See Note 11 for additional information related to dispositions. During the year ended December 31, 2023, the Company sold $2.1 million of property and equipment and recorded a $0.9 million net gain on the sale of a cultivation and manufacturing facility in Florida. The gain is recorded in Other income (expense), net in the Consolidated Statements of Operations. In the fourth quarter of 2022, management committed to a plan to restructure certain operations and activities within the California reporting unit. Related to that plan, during the first quarter of 2023, the Company adjusted the assumptions related to renewal options for certain leases at the impacted facilities. The Company accelerated depreciation on leasehold improvements related to those leases, with additional depreciation expense taken on these leasehold improvements in the amount of $1.1 million during year ended December 31, 2023. In the second quarter of 2022, the Company determined that approximately $2.4 million of materials held in construction in progress would not be used. The materials were sold in July of 2022 for $0.9 million, with a $1.5 million loss on sale recorded to Selling, general and administrative expenses in the Consolidated Statements of Operations. During the second quarter of 2022, the Company initiated a plan to shut down a cultivation facility and a production facility in California. As a result of this plan, the Company exercised its early termination right to reduce the existing lease terms to 180 days at these locations and determined that the useful life of impacted leasehold improvements had essentially ended. As such, the Company accelerated depreciation on these leasehold improvements to reduce the associated net book value down to $nil, with additional depreciation expense taken on these leasehold improvements in the amount of $2.7 million during the second quarter of 2022. During the year ended December 31, 2022, the Company recorded additional accelerated depreciation on other remaining assets at the facility in the amount of $0.5 million. On September 1, 2022, the Company closed on a sale and leaseback transaction to sell its Brookville, Pennsylvania facility to Aventine Property Group (“Aventine”). Concurrent with the closing of the sale, the Company, entered into a long-term, triple-net lease agreement with Aventine and will continue to operate the facility as a permitted cannabis cultivation and processing facility. In connection with this transaction, the Company disposed of fixed assets with a net book value of $29.7 million and recorded a net gain on sale of assets of $14.7 million to Other income, net, in the Consolidated Statements of Operations. In the fourth quarter of 2022, the Company sold materials held in construction in progress that would not be used. The cost basis was approximately $0.9 million for net proceeds of $0.3 million, with a $0.6 million loss on sale recorded to Selling, general and administrative expenses in the Consolidated Statements of Operations.

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Lease liabilities [abstract]
Leases	NOTE 5. LEASES The Company is the lessee in all of its material leasing arrangements and has entered into leases primarily for its corporate offices, cultivation and processing facilities and dispensaries. The Company has no material lessor arrangements as of December 31, 2023 and for the year ended December 31, 2022. Depending upon the type of lease, the original lease terms generally range from 1 year to 20 years. Certain leases include renewal options ranging from 3 years to 25 years. The Company is reasonably certain to exercise renewal options ranging from less than 1 year to 10 years on certain leases. Some leases may contain variable lease payments based on an index or rate. These rates are initially measured using the index or rate in effect at lease commencement, and changes to index-based lease payments are recognized in profit or loss in the period of the change and are immaterial. The following table reflects the Company’s lease balances within the Consolidated Balance Sheets: ($ in thousands) December 31, 2023 December 31, 2022 ROU assets $ 117,882 $ 128,264 Current portion of lease liabilities (a) 9,416 8,959 Non-current lease liabilities (a) 163,811 173,345 (a) December 31, 2022 balances have been reclassified to reflect current year presentation changes. See “Reclassifications” in Note 2 for further discussion. The following tables reflects the components of lease expense included in the Consolidated Statements of Operations: ($ in thousands) December 31, 2023 December 31, 2022 Lease depreciation expense included in selling, general and administrative expense $ 2,364 $ 2,466 Lease depreciation expense included in cost of goods sold and ending inventory 50 289 Total finance lease depreciation expense $ 2,414 $ 2,755 Rent expense included in selling, general and administrative expense $ 12,523 $ 9,919 Rent expense included in cost of goods sold 15,492 12,808 Total rent expense - operating leases $ 28,015 $ 22,727 Short-term rent expense included in selling, general and administrative expense $ 465 $ 627 Interest expense - leases $ 3,513 $ 3,952 As of December 31, 2023 and December 31, 2022, ending inventory includes $nil and $0.1 million of capitalized lease depreciation. For the years ended December 31, 2023 and 2022, $0.1 million and $0.3 million, respectively, of depreciation was recorded to Cost of goods sold, which includes $0.1 million for both periods related to depreciation capitalized to inventory in prior periods. In the fourth quarter of 2022, the Company committed to a plan to restructure additional operations and activities within the California reporting unit. Related to that plan, during the first quarter of 2023, the Company adjusted the values of certain leases at the facilities impacted as a result of a change in the underlying assumptions regarding renewal options for those leases. The differences between the carrying amounts of the ROU assets and lease liabilities associated with these leases, resulted in a gain on lease termination of $1.1 million for the year ended December 31, 2023 and is included in Other income, net, in the Consolidated Statements of Operations. During the second quarter of 2022, the Company initiated a plan to shut down a cultivation facility and a production facility in California. As a result of this plan, the Company has terminated the existing leases at these locations. A termination notice was issued to the landlord of these locations, which included two long-term greenhouse leases and a short-term rental of a housing facility. Due to differences between the carrying amounts of the ROU assets and lease liabilities associated with these leases, a gain on lease termination of $4.9 million was recorded for the year ended December 31, 2022 and is included in Other income, net, in the Consolidated Statements of Operations. On September 1, 2022, the Company closed on a sale and leaseback transaction to sell its Brookville, Pennsylvania, facility to Aventine. Concurrent with the closing of the sale, the Company entered into a long-term, triple-net lease agreement with Aventine and will continue to operate the facility as the permitted cannabis cultivation and processing facility. The selling price for the property was $43.7 million, net of transaction costs and a net gain on sale of assets of $14.7 million was recorded to Other income, net, in the Consolidated Statements of Operations. The lease has a term of 10 years and was recorded as an operating lease which resulted in a ROU asset and lease liability of $29.7 million. During the year ended December 31, 2023, the Company entered into no financing or sale and leaseback transactions. In the fourth quarter of 2022, the Company recorded impairment to ROU assets related to the following: • In the fourth quarter of 2022, Management committed to a plan to restructure certain operations and activities within the California reporting unit. It was determined that this was an indicator of impairment for associated assets. $1.0 million in impairment to ROU assets was recorded to the California reporting unit during the twelve months ended December 31, 2022. • During the annual impairment assessment, which is described in Note 7, Management determined it is more likely than not that the Arizona reporting unit carrying value exceeds its fair value based on updated forecasts and projections. $0.8 million in impairment to ROU assets was recorded to the Arizona reporting units, respectively, during the twelve months ended December 31, 2022. The Company has received tenant improvement allowance reimbursements of $2.5 million and $3.6 million across all finance and operating leasing arrangements for the years ended December 31, 2023 and 2022, respectively, and has received tenant improvement allowance reimbursements of $0.1 million and $0.6 million for other financing transactions for the years ended December 31, 2023 and 2022, respectively. The Company expects to receive an additional $3.3 million from finance and operating leasing arrangements and $0.7 million from other financing transactions in future periods. As of December 31, 2023, maturities of lease liabilities were as follows: ($ in thousands) Total Operating Leases Finance 2024 $ 33,299 $ 28,417 $ 4,882 2025 33,973 28,953 5,020 2026 34,365 29,219 5,146 2027 34,606 29,373 5,233 2028 34,477 29,353 5,124 Thereafter 179,586 161,249 18,337 Total lease payments $ 350,306 $ 306,564 $ 43,742 Less: imputed interest (173,769) (154,594) (19,175) Less: tenant improvement allowance (3,310) (2,865) (445) Present value of lease liabilities 173,227 149,105 24,122 Less: current lease liabilities (9,416) (7,677) (1,739) Present value of long-term lease liabilities $ 163,811 $ 141,428 $ 22,383 (a) Long-term financing liabilities The Company also has long-term financing liabilities associated with certain properties. See Note 12 for additional details on these transactions. As of December 31, 2023 and 2022, the Company had long-term financing liabilities of $93.5 million and $95.4 million, respectively. During 2023, the Company recorded payments of $13.2 million and interest expense of $11.7 million related to these liabilities. During 2022, the Company recorded payments of $12.9 million and interest expense of $11.9 million. As of December 31, 2023, maturities of financing liabilities were as follows: ($ in thousands) Financing Liabilities 2024 $ 13,534 2025 13,873 2026 14,221 2027 14,578 2028 14,944 Thereafter 96,893 Total financing payments $ 168,043 Less: interest (72,432) Less: tenant improvement allowance (94) Present value of financing liabilities $ 95,517 Less: short-term financing liabilities (2,004) Present value of long-term financing liabilities $ 93,513 Other information related to leases as of and for the years ended December 31, 2023 and 2022 was as follows: 2023 2022 ($ in thousands) Operating Leases Finance Leases Operating Leases Finance Leases Right-of-use assets $ 100,249 $ 17,633 $ 106,127 $ 22,137 Lease liabilities (current) 1 $ 7,677 $ 1,739 $ 7,274 $ 1,685 Lease liabilities (non-current) 1 $ 141,428 $ 22,383 $ 145,445 $ 27,900 Weighted- average remaining lease term 2 11.0 9.6 11.9 10.4 Weighted-average discount rate 15.0 % 14.0 % 14.5 % 13.6 % 1 December 31, 2022 balances have been updated to reflect current year presentation changes. See “Reclassifications” in Note 2 for further discussion. 2 Weighted-average remaining lease term does not include extensions which the Company is not reasonably certain to enter into. As the interest rate implicit in a lease is generally not readily determinable, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the risk-adjusted rate of interest the Company would have to pay to borrow on a collateralized basis over a similar economic environment and term. Cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2023 and 2022 are as follows: ($ in thousands) 2023 2022 Interest paid on finance leases $ 3,470 $ 3,877

Investments

Investments	12 Months Ended
	Dec. 31, 2023
Investment property [abstract]
Investments	NOTE 6. INVESTMENTS The Company currently has investments in four entities: 420 Capital Management, LLC (“420 Capital”), a cannabis investment company; Lighthouse Strategies, LLC (“Lighthouse”), a diversified cannabis investment company; IM Cannabis Corp. (“IMC”), a pharmaceutical manufacturer that specializes in cannabis and OLD PAL LLC (“Old Pal”), a cannabis operator/licensor. The 420 Capital, Lighthouse and Old Pal investments are held at fair value and are classified as equity securities without a readily determinable fair value. The IMC investment is classified as a marketable security with a readily determinable fair value. During the year ended December 31, 2022, Lighthouse, in conjunction with a spin-off transaction, issued Lighthouse shareholders a prorated interest in Infamy Brews, LLC, DBA (“Two Roots Brewing Co.”), a non-alcoholic brewing company. On September 15, 2023, Two Roots Brewing Co. ceased operations, and as a result the Company wrote off the remaining investment balance of $0.1 million in Two Roots Brewing Co. The Company currently holds 0.8% ownership interest in Two Roots Brewing Co. The investment is held at fair value and classified as an equity security without a readily determinable value. The following is a summary of the investments held at fair value as of December 31, 2023 and December 31, 2022: December 31, December 31, ($ in thousands) 2023 2022 420 Capital $ 68 $ 68 Lighthouse 81 339 Two Roots Brewing Co. — 93 Old Pal 532 592 IMC 49 136 Total Investments $ 730 $ 1,228

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2023
Intangible assets and goodwill [abstract]
Intangible Assets and Goodwill	NOTE 7. INTANGIBLE ASSETS AND GOODWILL (a) Intangible Assets Intangible assets consisted of the following as of: December 31, 2023 ($ in thousands) Gross Carrying Amount Accumulated Amortization Net Definite-Lived Intangible Assets Customer Relationships $ 31,000 $ (11,623) $ 19,377 Trade Names 2,100 (1,680) 420 Permit Application Costs 17,351 (15,980) 1,371 Other Intangibles (a) 6,013 (5,886) 127 Indefinite-Lived Intangible Assets Licenses 275,671 — 275,671 Total Intangible Assets $ 332,135 $ (35,169) $ 296,966 (a) Other Intangibles includes non-compete agreements, non-solicitation agreements and related amortization. December 31, 2022 ($ in thousands) Gross Carrying Amount Accumulated Amortization Net Definite-Lived Intangible Assets Customer Relationships $ 31,879 $ (8,127) $ 23,752 Trade Names 2,100 (1,610) 490 Permit Application Costs 15,027 (13,897) 1,130 Other Intangibles (a) 6,284 (5,573) 711 Indefinite-Lived Intangible Assets Licenses 381,507 — 381,507 Total Intangible Assets $ 436,797 $ (29,207) $ 407,590 (a) Other Intangibles includes non-compete agreements, non-solicitation agreements and related amortization. During the year ended December 31, 2023, the gross carrying amount of intangible assets decreased by $104.7 million, primarily related to impairment charges discussed below. During the year ended December 31, 2022, the gross carrying amount of intangible assets decreased by $19.7 million, primarily related to impairment charges discussed below. The following table reflects the amortization expense related to intangible assets for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Amortization expense included in selling, general and administrative expense $ 3,699 $ 6,915 Amortization expense included in cost of goods sold and ending inventory 3,347 3,444 Total amortization expense $ 7,046 $ 10,359 As of December 31, 2023 and 2022, ending inventory included $1.0 million and $1.6 million of capitalized amortization, respectively. During the year ended December 31, 2023 and 2022, the Company recorded $4.0 million and $2.9 million of amortization expense to Costs of goods sold, including $1.6 million and $1.1 million, respectively, related to amortization capitalized in inventory in prior periods. The following table outlines the estimated amortization expense related to intangible assets as of December 31, 2023: ($ in thousands) Estimated Amortization 2024 $ 5,339 2025 4,173 2026 3,877 2027 3,272 2028 2,962 Thereafter 1,672 Total estimated amortization $ 21,295 (b) Goodwill The changes in carrying amount of goodwill are as follows: ($ in thousands) Total Balance at January 1, 2022 $ 446,767 Impairment (117,024) Measurement period adjustments 812 Balance at December 31, 2022 330,555 Impairment (50,858) Balance at December 31, 2023 $ 279,697 (c) Impairment During the year ended December 31, 2023, the Company recorded impairment to goodwill and indefinite-lived intangible assets related to the following: • During the year ended December 31, 2023, the Company completed the sale of assets at our Encanto Green Cross Dispensary in Arizona. Based on an analysis of the fair value of these assets, the book value was written down by $0.2 million and impairment charges were recognized in the Consolidated Statements of Operations. • During the third quarter of 2023, management determined it is more likely than not that the California, Florida and New York reporting units' carrying value exceeded their fair value due to updated forecasts and projections of future cash flows for the reporting units. As a result, $9.9 million, $79.4 million and $40.0 million, respectively, of impairment charges reducing the carrying value of goodwill and licenses were recognized in the Consolidated Statements of Operations. • During the second quarter of 2023, management determined it is more likely than not that the Massachusetts reporting unit’s carrying value exceeded its fair value due to updated forecasts and projections for this reporting unit. As a result, a $21.5 million impairment charge reducing the carrying value of goodwill and licenses was recognized in the Consolidated Statements of Operations. During the year ended December 31, 2022, the Company recorded impairment to goodwill and indefinite-lived intangible assets related to the following: • In the fourth quarter of 2022, Management committed to a plan to restructure certain operations and activities within the California reporting unit. It was determined that this was an indicator of impairment for associated assets. $89.5 million in goodwill impairment was recorded to the California reporting unit during the twelve months ended December 31, 2022. • During the annual impairment assessment, which is described below, Management determined it is more likely than not that the Arizona, Massachusetts and Maryland reporting units carrying values exceed their fair value due to updated forecasts and projections for those reporting units. $10.1 million and $0.9 million in goodwill impairment was recorded to the Arizona and Maryland reporting units, respectively, during the twelve months ended December 31, 2022. $16.5 million and $21.8 million of goodwill and indefinite-lived intangible impairment, respectively, was recorded to the Massachusetts reporting unit during the twelve months ended December 31, 2022. Annual impairment testing involves determining the fair value, or recoverable amount, of the reporting units to which goodwill and indefinite-lived intangible assets are allocated and comparing this to the carrying value of the reporting units. The measurement of the recoverable amount of each reporting unit was calculated based on the higher of the reporting unit’s fair value less costs to sell or value in use, which are Level 3 measurements within the fair value hierarchy. The calculation of each of the recoverable amounts based on discounting the future cash flows (value in use) was based on the following key assumptions: • Cash flows were projected based on the Company’s long-term business plan for each reporting unit. Cash flows beyond the long-term business plan were projected to grow at a perpetual growth rate, which was estimated to range from 2.0% to 3.0% in most cases. • Discount rates applied in determining the recoverable amount of the reporting units noted above range between 13.0% and 18.5% based on the pre-tax weighted average cost of capital of each reporting unit and other peers in the industry. The values assigned to the key assumptions represent Management’s assessment of future trends in the industries in which the reporting units operate and are based on both external and internal sources and historical trend data.

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2023
Share Capital [Abstract]
Share Capital	NOTE 8. SHARE CAPITAL (a) Authorized The authorized share capital of the Company, which has no par value, is comprised of the following: i. Unlimited Number of Subordinate Voting Shares Holders of SVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of SVS will be entitled to one vote in respect of each SVS held. As long as any SVS remain outstanding, the Company will not, without the consent of the holders of the SVS by separate special resolution, prejudice or interfere with any right attached to the SVS. Holders of SVS will be entitled to receive as and when declared by the directors of the Company, dividends in cash or property of the Company. ii. Unlimited Number of Proportionate Voting Shares Holders of PVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of PVS will be entitled to one vote in respect of each SVS into which such PVS could ultimately be converted (200 votes per PVS). As long as any PVS remain outstanding, the Company will not, without the consent of the holders of the PVS and Super Voting Shares (“MVS”) by separate special resolution, prejudice or interfere with any right or special right attached to the PVS. Holders of PVS have the right to receive dividends, out of any cash or other assets legally available therefore, pari passu as to dividends and any declaration or payment of any dividend on the SVS. iii. 500,000 Super Voting Shares Holders of MVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of MVS will be entitled to 2,000 votes in respect of each MVS held. iv. Unlimited Number of Special Subordinate Voting Shares Holders of SSVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of SSVS will be entitled to a 0.00001 vote in respect of each SSVS held. As long as any SSVS remain outstanding, the Company will not, without the consent of the holders of the SSVS by separate special resolution, prejudice or interfere with any right attached to the SSVS. Holders of SSVS will be entitled to receive dividends in cash or property of the Company, if and when declared by the Board of Directors. v. Redeemable Units As part of a reverse takeover that occurred on November 30, 2018, unit holders of Cresco Labs, LLC exchanged their units for a new class of Redeemable Units in Cresco Labs, LLC. Each Redeemable Unit is only exchangeable for the equivalent of one SVS in Cresco Labs Inc. (without any obligation to redeem in cash). These unit holders hold an interest only in Cresco Labs, LLC; they participate in the earnings of only Cresco Labs, LLC and not the earnings of the combined entity. (b) Issued and Outstanding As of December 31, 2023 and 2022, issued and outstanding shares and units consisted of the following: (shares in thousands) Redeemable SVS* PVS** MVS SSVS*** Beginning balance, January 1, 2022 109,441 269,971 20,667 500 1 Options and warrants exercised — 1,279 — — — RSUs issued — 337 — — — Issuance of shares related to acquisitions — 5,339 — — — Cresco LLC redemptions (3,335) 3,335 — — — PVS converted to SVS — 585 (585) — — Issuances related to employee taxes on certain share-based payment arrangements — 148 — — — Share issuances — — — — — Ending balance, December 31, 2022 106,106 280,994 20,082 500 1 RSUs issued — 1,727 — — Issuance of shares related to settlement of acquisition contingent consideration — 27,091 — — — Cresco LLC redemptions (9,407) 9,407 — — — PVS converted to SVS — 1,132 (1,132) — — Issuances related to employee taxes on certain share-based payment arrangements — 406 — — — Share issuances — — — — 1 Ending balance, December 31, 2023 96,699 320,757 18,950 500 2 *SVS includes shares pending issuance or cancellation **PVS presented on an “as-converted” basis to SVS (1-to-200) ***SSVS presented on an “as-converted” basis to SVS (1-to-0.00001) (i) Share Issuances - Equity Distribution Agreement In December 2019, the Company entered into an agreement with Canaccord Genuity Corp (“Canaccord”) to sell up to C$55.0 million SVS at an at-the-market price. In April 2021, the Company announced a new agreement with Canaccord to sell up to $100.0 million of SVS to replace the prior agreement which was set to expire in August 2021. No shares were issued for the years ended December 31, 2023 and 2022, respectively, under the new agreement, which expired in the second quarter of 2023. Upon the expiration of the program, capitalized fees of $0.2 million were expensed to Selling, general and administrative expenses in the Consolidated Statements of Operations. (ii) Issuance of Shares - Acquisitions During the years ended December 31, 2023 and 2022, the Company issued shares in conjunction with certain acquisitions* as follows: (in thousands) Acquisition date SVS shares issued Equity-based consideration Year Ended December 31, 2023 Laurel Harvest - Contingent Consideration December 09, 2021 27,091 $ 47,238 Year Ended December 31, 2022 Cultivate - Contingent Consideration September 02, 2021 5,340 $ 34,708 *Laurel Harvest, LLC (“Laurel Harvest”) and Cultivate Licensing, LLC (“Cultivate”) (c) Stock Purchase Warrants Each whole warrant entitles the holder to purchase one SVS or PVS of the Company. A summary of the status of the warrants outstanding is as follows: ($ in thousands) Number of warrants* Weighted average exercise price Balance as of January 1, 2022 9,842 $ 9.63 Exercised (12) 4.24 Forfeited (9,830) 9.54 Balance as of December 31, 2022 — $ — *PVS presented on an “as-converted” basis to SVS (1-to-200) During the year ended December 31, 2022, the Company recorded $0.1 million of warrant exercises into share capital. As of December 31, 2022, all outstanding warrants expired. (d) Distribution to Non-controlling Interest Holders Tax distributions are based off the tax rate determined by Cresco Labs Inc. (which is currently the highest U.S. individual income tax rates) applied to taxable income generated from the Cresco Labs, LLC partnership (i.e., not the whole Cresco group), which is the Company’s most significant distribution, and attributable to the NCI members. The Company has other tax and non-tax distributions that are calculated in accordance with each relevant operating segment. As of December 31, 2023 and December 31, 2022, the Company accrued for tax-related distributions to 2023 and 2022 unit holders of Cresco Labs, LLC and other minority interest holders of $15.2 million and $4.9 million, respectively. These distributions will reduce non-controlling interest upon payment. In accordance with the underlying operating agreements, the Company declared and paid required distribution amounts to 2023 and 2022 unit holders of Cresco Labs, LLC and other minority holders of $38.9 million during the year ended December 31, 2023. Similarly, the Company paid required tax distribution amounts to 2022 and 2021 unit holders of Cresco Labs, LLC and other minority interest holders of $83.6 million during the year ended December 31, 2022. (e) Changes in Ownership and Non-controlling Interests During the year ended December 31, 2023 and 2022, redemptions of 9.4 million and 3.3 million Redeemable Units occurred, respectively, which were converted into an equivalent number of SVS. These redemptions resulted in a decrease of 3.7% and 1.3% in non-controlling interest in Cresco Labs, LLC, respectively. As of and for the year ended December 31, 2023, non-controlling interest included the following amounts: ($ in thousands) TSC Cresco, LLC MedMar MedMar Cresco SLO Cultivation Cresco Labs Michigan, LLC 4 Cresco Labs, LLC 1,3 Non-current assets $ 2,943 $ 28,678 $ 22,594 $ 14,703 $ 1,045 $ 30,508 $ 255,947 Current assets (8,159) 84,571 132,198 6,544 11,502 15,300 (157,691) Non-current liabilities — (10,787) (3,551) (13,674) — (26,015) (562,580) Current liabilities 45,054 (47,928) (57,388) (8,213) (49,954) (49,812) 329,160 Net assets $ 39,838 $ 54,534 $ 93,853 $ (640) $ (37,407) $ (30,019) $ (135,164) Net assets attributable to NCI $ 2,401 $ 4,150 $ 10,368 $ (156) $ (12,824) $ (258) $ (81,306) Revenue $ 1,664 $ 11,701 $ 18,657 $ 2,567 $ — $ 6,271 $ 92,266 Gross profit 863 7,623 12,323 (473) (335) 1,503 48,207 Net income (loss) $ 188 $ 4,768 $ 10,060 $ (2,450) $ (246) $ 43 $ (1,794) Net income (loss) allocated to NCI $ 47 $ 591 $ 2,515 $ (29) $ (49) $ 6 $ (879) NCI percentage at December 31, 2023 25.0 % 1 12.4 % 2 25.0 % 2 1.2 % 1 20.0 % 1 15.0 % 1 38.3 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 38.3% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments. 4 As of June 30, 2023, Cresco Labs Michigan, LLC net assets grew to a balance that exceeded the life-to-date capital contributions made by Cresco Labs Inc. As a result, the Company began recording NCI related to Cresco Labs Michigan, LLC. As of and for the year ended December 31, 2022, non-controlling interest included the following amounts: ($ in thousands) TSC Cresco, LLC MedMar MedMar Cresco SLO Cultivation Inc. Cresco Labs, LLC 1,3 Non-current assets $ 4,788 $ 31,151 $ 22,700 $ 16,736 $ 5,376 $ 286,360 Current assets (6,875) 34,706 114,843 8,144 13,097 802,774 Non-current liabilities — (10,889) (3,850) (12,515) (2,728) (538,816) Current liabilities 26,600 (13,438) (41,111) (5,768) (50,722) (594,052) Net assets $ 24,513 $ 41,530 $ 92,582 $ 6,597 $ (34,977) $ (43,734) Net assets attributable to NCI $ 4,190 $ 3,979 $ 7,468 $ (32) $ (12,434) $ (42,527) Revenue $ 10,582 $ 53,259 $ 88,645 $ 8,650 $ (24) $ 469,505 Gross profit 12,500 35,485 62,503 1,338 (10,769) 248,472 Net income (loss) $ 19,290 $ 13,322 $ 43,500 $ (4,933) $ (16,458) $ (38,863) Net income (loss) allocated to NCI $ 4,822 $ 1,652 $ 10,875 $ (49) $ (3,292) $ (16,323) NCI percentage at 25.0 % 1 12.4 % 2 25.0 % 2 1.2 % 1 20.0 % 1 42.0 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 42.0% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments. The effects of changes in the Company's ownership interests in less than 100% owned subsidiaries during the years ended December 31, 2023 and 2022 were as follows: ($ in thousands) 2023 2022 Net loss attributable to Cresco Labs Inc. $ (175,522) $ (212,047) Changes in Cresco Labs Inc. equity due to redemptions of Cresco Labs, LLC shares: Share Capital 16,027 17,438 Accumulated Deficit (21,815) (17,169) Total change from net loss attributable to Cresco Labs Inc. and change in ownership interest in Cresco Labs, LLC. $ (181,310) $ (211,778)

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangements [Abstract]
Share-Based Compensation	NOTE 9. SHARE-BASED COMPENSATION The Company has a share-based compensation plan (the “Plan”) for employees, board members and service providers. Under the Plan, options and RSUs issued have no voting rights and vest proportionately over periods ranging from the grant date to 4 years from the issuance date. Stock options exercised and RSUs issued are converted to SVS. Stock options expire after 10 years after the grant date. The maximum number of shares issued under the Plan shall not exceed 10% of the issued and outstanding shares. Stock Options A summary of the status of the stock options outstanding consisted of the following: (Options and intrinsic value in thousands) Number of stock options outstanding Weighted-average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic value Outstanding – January 1, 2023 25,528 $ 5.00 7.54 $ 921 Granted 3,478 1.72 Exercised — — Forfeited (4,903) 5.43 Outstanding - December 31, 2023 24,103 $ 4.45 6.60 $ 328 Exercisable - December 31, 2023 15,989 $ 4.27 5.75 $ 328 During the year ended December 31, 2022, options were exercised for gross proceeds of $2.9 million. During the year ended December 31, 2023, there were no options exercised. The following table summarizes the weighted average grant date fair value and total intrinsic value of options exercised for the years ended December 31, 2023 and 2022: (Per share) 2023 2022 Weighted average grant date fair value of stock option units granted $ 1.21 $ 2.59 Intrinsic value of stock option units exercised, using market price at exercise date $ — $ 5,106 Weighted average stock price of options on the dates on which options were exercised during the year ended December 31, 2022 was $4.64 per option. The fair value of stock options granted under the Plan during the years ended December 31, 2023 and 2022, was determined using the Black-Scholes option-pricing model with the following range of assumptions at the time of the grant: 2023 2022 Risk-free annual interest rate 3.7% to 4.0% 1.4% to 3.0% Expected annual dividend yield 0% 0% Expected stock price volatility 77.0% to 82.8% 74.9% to 80.4% Expected life of stock options 5.0 to 7.0 years 5.5 to 7.0 years Forfeiture rate 7.2% to 34.0% 7.2% to 28.0% Fair value at grant date $0.94 to $1.52 $1.23 to $4.90 Stock price at grant date $1.35 to $2.01 $1.81 to $6.91 Exercise price range $1.35 to $2.01 $1.81 to $6.91 Volatility was estimated by using the average historical volatility of comparable companies from a representative group of direct and indirect peers of publicly traded companies, as the Company and the cannabis industry have minimal historical share price history available. An increase in volatility would result in an increase in fair value at grant date. The expected life in years represents the period of time that options issued are expected to be outstanding. The risk-free rate is based on U.S. treasury bills with a remaining term equal to the expected life of the options. The forfeiture rate is estimated based on historical forfeitures experienced by the Company. RSUs The Company has an RSU program to provide employees an additional avenue to participate in the successes of the Company. The fair value of RSUs granted was determined by the fair value of the Company’s share price on the date of grant. A summary of outstanding RSUs is provided below: (Shares in thousands) Number of RSUs outstanding Weighted-average fair value Outstanding – January 1, 2023 4,258 $ 5.71 Granted 6,347 1.77 Vested and settled (1,769) 1.91 Forfeited (1,974) 3.20 Outstanding - December 31, 2023 6,862 $ 2.91 The following table summarizes the total fair value of RSUs vested for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Total fair value of RSUs vested, using market price at vest date $ 3,373 $ 2,396 Expense Attribution The following table sets forth the classification of share-based compensation expense related to options awards for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Cost of goods sold $ 1,059 $ 1,984 Selling, general and administrative expense 6,025 11,749 Total share-based compensation expense for option awards $ 7,084 $ 13,733 Unrecognized share-based compensation expense related to option awards as of December 31, 2023 $5.4 million and will be recorded over the course of the next four years. The following table sets forth the classification of share-based compensation expense related to RSU awards for years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Cost of goods sold $ 1,352 $ 2,097 Selling, general and administrative expense 6,899 7,914 Total share-based compensation expense for RSU awards $ 8,251 $ 10,011 Unrecognized share-based compensation expense related to RSU awards as of December 31, 2023 is $5.8 million and will be recognized over the course of the next four years. As of December 31, 2023 and December 31, 2022, ending inventory includes $0.7 million and $1.7 million capitalized share-based compensation expense related to both options and RSUs, respectively. For the year December 31, 2023 and 2022, share-based compensation expense was $3.4 million and $3.6 million, respectively, recorded to Cost of goods sold, which includes $1.7 million and $1.2 million, respectively, related to compensation expense capitalized to inventory in prior periods.

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Loss Per Share	NOTE 10. LOSS PER SHARE The following is a reconciliation for the calculation of basic and diluted loss per share: December 31, 2023 December 31, 2022 ($ in thousands, except shares and per share amounts) Numerator: Net loss $ (179,852) $ (215,843) Less: Net income attributable to non-controlling interests, net of tax (4,330) (3,796) Net loss attributable to Cresco Labs Inc. $ (175,522) $ (212,047) Denominator: Weighted-average basic and diluted shares outstanding 323,819,766 298,161,665 Loss per Share: Basic and diluted loss per share $ (0.54) $ (0.71) For the years ended December 31, 2023 and 2022 potentially dilutive shares were not included in the computation of diluted loss per common share due to the net loss during the respective periods. Potentially dilutive shares as of December 31, 2023 and 2022, consisted of the following: Year Ended (shares in thousands) 2023 2022 Redeemable Units 96,699 107,443 Options 24,103 25,528 RSUs 6,862 4,182 Total potentially dilutive shares 127,664 137,153

Acquisitions And Dispositions

Acquisitions And Dispositions	12 Months Ended
	Dec. 31, 2023
Business Combinations And Discontinued Operations [Abstract]
Acquisitions And Dispositions	NOTE 11. ACQUISITIONS AND DISPOSITIONS (a) Deferred Consideration, short-term The following is a summary of Deferred consideration, short-term balances as of December 31, 2023 and December 31, 2022: ($ in thousands) December 31, 2023 December 31, 2022 Laurel Harvest deferred consideration, short-term $ — $ 47,821 Total Deferred consideration, short-term $ — $ 47,821 In the fourth quarter of 2021, Cresco recorded a total of $46.9 million deferred consideration related to the Laurel Harvest acquisition. Total deferred consideration was payable on or before the 18-month anniversary of the acquisition, with accelerated payments required for each of five (5) new dispensaries opened during the 18-month earnout period. The liability was further adjusted to $47.8 million at December 31, 2022 based on our expectation of the value of the liability at that time. In the first quarter of 2023, a payment of $10.0 million was made, which was comprised of a stock issuance valued at $9.7 million and cash payments of $0.3 million. In the second quarter of 2023, a final earnout payment of $38.6 million was made, which was comprised of a stock issuance valued at $37.5 million and cash payments of $1.1 million. See Note 8 for further discussion of equity issued. (b) Deferred Consideration, long-term The following is a summary of Deferred consideration, long-term as of December 31, 2023 and December 31, 2022: ($ in thousands) December 31, 2023 December 31, 2022 Valley Agriceuticals, LLC (“Valley Ag”) operating cash flows deferred consideration $ 6,577 $ 7,770 Total Deferred consideration, long-term $ 6,577 $ 7,770 As of December 31, 2023, the total estimated liability related to the Valley Ag acquisition is $6.6 million. The long-term liability is based on the present value of expected payments associated with the future cash flows of Valley Ag and the expected timing of those payments. During the year ended December 31, 2023, the Company reclassified $0.3 million of deferred consideration from short-term to long-term due to timing of payment. See Note 17 for additional information. For the year ended December 31, 2023, the Company recorded a $0.4 million reduction of expense related to deferred considerations. For the year ended December 31, 2022, the Company recorded $0.1 million of expense related to deferred considerations. The expense is recorded in Interest expense, net in the Consolidated Statements of Operations. See Note 20 for additional information. (c) Dispositions During the year ended December 31, 2023, the Company completed a divestiture of its AFS Maryland production facility. The Company received cash proceeds of $3.3 million for the sale of property and equipment and intangible assets and recorded a gain of $1.4 million from the completed divestiture. The gain is recorded to Other income (expense), net in the Consolidated Statements of Operations. During the year ended December 31, 2023, the Company completed the sale of assets at our Encanto Green Cross Dispensary in Arizona. The Company received cash proceeds of $6.5 million for the sale of finished inventory products, property and equipment, license and other certain intangible assets. Based on an analysis of the fair value of these assets, the book value was written down by $0.2 million. The Company recorded a net loss of $1.0 million from the sale in 2023. (d) Terminated Acquisition On July 30, 2023, the Company and The Cannabist Company, formerly known as Columbia Care, mutually agreed to terminate the previously announced definitive arrangement agreement, including all divestitures associated with this transaction. During the second quarter of 2023, the Company wrote off a $5.0 million consent fee that was previously capitalized associated with the agreement. The expense is recorded to Interest expense, net in the Consolidated Statements of Operations. See Note 20.

Long-term Notes and Loans Payab

Long-term Notes and Loans Payable, Net	12 Months Ended
	Dec. 31, 2023
Borrowings [abstract]
Long-term Notes and Loans Payable, Net	NOTE 12. LONG-TERM NOTES AND LOANS PAYABLE, NET The following table represents the Company’s Long-term notes and loans payable, net balances as of December 31, 2023 and December 31, 2022: ($ in thousands) 2023 2022 Senior Loan $ 400,000 $ 400,000 Mortgage Loans 20,160 — Short-term borrowings and interest payable 9,813 9,500 Financing liability 95,698 96,917 Total borrowings and interest payable $ 525,671 $ 506,417 Less: Unamortized debt issuance costs (16,141) (18,550) Less: Short-term borrowings and interest payable (9,813) (9,500) Less: Current portion of financing liability 1 (2,004) (1,476) Total Long-term notes and loans payable, net $ 497,713 $ 476,891 1 December 31, 2022 balance have been updated to reflect current year presentation changes. See “Reclassifications” in Note 2 for further discussion. (a) Senior Loan On August 12, 2021, the Company closed on an agreement for a senior secured term loan with an undiscounted principal balance of $400.0 million (as amended, the “ Senior Loan ” ) and an original issue discount of $13.0 million. A portion of proceeds from the Senior Loan were used to retire the then existing term loan, with the remainder to fund capital expenditures and pursue other targeted growth initiatives within the U.S. cannabis sector. The Senior Loan accrues interest at a rate of 9.5% per annum, payable in cash semi-annually and has a stated maturity of August 12, 2026. The Company’s effective interest rate for the Senior Loan is 11.0%. The Company capitalized $10.9 million of borrowing costs related to the Senior Loan, of which $7.0 million is payable upon principal repayment of the Senior Loan and thus, is reflected within Other long-term liabilities on the Consolidated Balance Sheet. The Senior Loan is secured by a guarantee from substantially all material subsidiaries of the Company, as well as by a security interest in certain assets of the Company and such material subsidiaries. The Senior Loan contains negative covenants which restrict the actions of the Company and its subsidiaries during the term of the loan, including restrictions on paying dividends, making investments and incurring additional indebtedness. The Company is also subject to compliance with affirmative covenants, some of which may require management to exercise judgment. In addition, the Company is required to maintain a minimum cash balance of $50.0 million. On September 22, 2023, the Company amended the Senior Loan pursuant to which certain terms of the original Senior Loan were modified and consent was provided for the Company to enter into the Mortgage Loans further discussed below. The Company may prepay in whole or in part the Senior Loan at any time prior to the stated maturity date, subject to certain conditions. Any prepayment of the outstanding principal amount may be subject to a prepayment premium as defined in the loan agreement, and would include all accrued and unpaid interest and fees. Interest expense is discussed in Note 20. (b) Mortgage Loans On September 26, 2023, JDRC Ellenville, LLC ( “ Ellenville ” ) an indirect subsidiary of the Company entered into a loan agreement to borrow an undiscounted principal amount of $25.3 million (the “ Mortgage Loans ” ). Borrowings under the terms of the Mortgage Loans bear an initial interest rate of 8.4% per annum, which is equal to the Federal Home Loan Bank ( “FHLB”) Five Year Classic Regular Advance Rate, plus a 375 basis point spread. The Mortgage Loans have an effective interest rate of 10.2%. The Mortgage Loans are secured by real estate in Ellenville, New York and improvements thereto, and converts to a permanent term loan on the conversion date of November 1, 2028. The Mortgage Loans contains certain affirmative and negative covenants which restrict the actions of Ellenville during the term of the loan. As of December 31, 2023, the full commitment amount was not fully drawn, as $5.1 million of the principal balance will be advanced to Ellenville as it completes the build-out of the Ellenville cultivation center. The Company incurred $2.0 million in deferred financing fees reflected within Long-term notes and loans payable on the Consolidated Balance Sheet. During the year ended December 31, 2023, the Company capitalized interest of $0.3 million related to the loan as the build-out of the Ellenville facility is still underway. After completion, interest will be expensed as incurred. (c) Financing Liabilities The Company has additional financing liabilities for which the incremental borrowing rates range from 11.3% to 17.5% with remaining terms between 6.1 and 16.5 years, consistent with the underlying lease liabilities. The interest expense associated with financing liabilities is discussed in Note 20.

Revenues and Loyalty Programs

Revenues and Loyalty Programs	12 Months Ended
	Dec. 31, 2023
Revenue [abstract]
Revenues and Loyalty Programs	NOTE 13. REVENUES AND LOYALTY PROGRAMS (a) Revenues The following table represents the Company’s disaggregated revenue by source, due to the Company’s contracts with its customers, for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Wholesale $ 306,363 $ 367,222 Dispensary 464,522 475,459 Total Revenues $ 770,885 $ 842,681 The Company generates revenues, net of sales discounts, at the point in time the control of the product is transferred to the customer, as the Company has a right to payment and the customer has assumed significant risks and rewards of such product without any remaining performance obligation. Sales discounts were approximately 17.0% and 10.7% of gross revenue for the years ended December 31, 2023 and 2022, respectively. The Company does not enter into long-term sales contracts. (b) Loyalty Programs In the states of Illinois, Pennsylvania, New York, Florida, Ohio and Massachusetts; the Company has customer loyalty programs where retail customers accumulate points based on their level of spending. These points are recorded as a contract liability until customers redeem their points for discounts on cannabis products as part of an in-store sales transaction. Loyalty points may be redeemed by customers for $0.03 for each point off of future purchases. The Company records a performance obligation as a reduction of revenue that ranges between $0.01 and $0.02 per loyalty point, inclusive of breakage expectations in respective markets. Upon redemption, the loyalty program obligation is relieved and the offset is recorded as revenue. As of December 31, 2023 and 2022, there were 71.2 million and 126.1 million points outstanding, respectively. The contract liability totaled $1.2 million and $2.1 million, respectively, which is included in Accrued liabilities within the Consolidated Balance Sheet for the same period. The Company expects outstanding loyalty points to be redeemed within one year.

Other Income , Net

Other Income , Net	12 Months Ended
	Dec. 31, 2023
Other Operating Income (Expense) [Abstract]
Other Income , Net	NOTE 14. OTHER INCOME (EXPENSE), NET For the years ended December 31, 2023 and 2022, Other income, net consisted of the following: ($ in thousands) 2023 2022 Unrealized gain on derivative liabilities - warrants $ — $ 1,184 Realized loss on financial instruments (94) (5,698) (Loss) gain on provision - loan receivable (314) 572 Unrealized loss on investments held at fair value (406) (4,609) Gain on disposal of assets 762 14,711 Gain on conversion of investment — 22 (Loss) gain on foreign currency (303) 931 Gain on lease termination 1,263 4,876 Other income, net 832 3,238 Total Other income, net $ 1,740 $ 15,227 See Note 4 for additional information on Gain on disposition of assets. See Note 5 for additional information related to the Gain on lease termination.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related party transactions [abstract]
Related Party Transactions	NOTE 15. RELATED PARTY TRANSACTIONS (a) Transactions with Key Management Personnel and Certain Board Members Related parties, including key management personnel and certain board members, hold 85.1 million Redeemable Units of Cresco Labs, LLC, which accounts for a deficit of $71.5 million in Non-controlling interests as of December 31, 2023. During the years ended December 31, 2023 and 2022, 71.2% and 74.4%, respectively, of required tax distribution payments to holders of Cresco Labs, LLC were made to related parties including to key management personnel and certain board members. (b) Related Parties – Leases For the years ended December 31, 2023 and 2022, the Company had lease liabilities for real estate lease agreements in which the lessors have a minority interest in SLO Cultivation, Inc. (“SLO”) and MedMar Inc. (“MedMar”). The lease liabilities were incurred in January 2019 and May 2020 and expire in 2027 through 2030, except for the leases associated with SLO minority interest holders (“SLO Leases”). During the second quarter of 2022, the Company exercised its early termination right to reduce the SLO Leases term to 180 days. This early termination resulted in a reduction in lease liability and ROU assets. The remaining liability for the SLO Leases expired in the fourth quarter of 2022. The Company has liabilities for real estate leases and other financing agreements in which the lessor is Clear Heights Properties where Dominic Sergi, MVS shareholder as of December 31, 2023, is Chief Executive Officer. The liabilities were incurred by entering into operating leases, finance leases and other financing transactions with terms that will expire in 2030. During the years ended December 31, 2023 and 2022, the Company received tenant improvement allowance reimbursements of $nil and $1.4 million, respectively. The Company expects to receive further reimbursements of $0.7 million within the next twelve months. Below is a summary of the expense resulting from the related party lease liabilities for the years ended December 31, 2023 and 2022: ($ in thousands) Classification 2023 2022 Operating Leases Lessor has minority interest in SLO Rent expense $ — $ 513 Lessor has minority interest in MedMar Rent expense 288 288 Lessor is an MVS shareholder Rent expense 1,187 1,187 Finance Leases Lessor has minority interest in MedMar Depreciation expense $ 306 $ 306 Lessor has minority interest in MedMar Interest expense 246 270 Lessor is an MVS shareholder Depreciation expense 90 81 Lessor is an MVS shareholder Interest expense 69 76 Additionally, below is a summary of the ROU assets and lease liabilities attributable to related party leases as of December 31, 2023 and 2022: December 31, 2023 December 31, 2022 ($ in thousands) ROU Asset Lease Liability ROU Asset Lease Liability Operating Leases Lessor has minority interest in MedMar $ 1,294 $ 1,345 $ 1,415 $ 1,456 Lessor is an MVS shareholder 5,332 5,429 5,849 5,907 Finance Leases Lessor has minority interest in MedMar $ 1,729 $ 2,210 $ 2,034 $ 2,452 Lessor is an MVS shareholder 583 502 596 555 The Company has other financing liabilities with related parties associated with certain properties. For both years ended December 31, 2023 and 2022, the Company recorded interest expense on those financing liabilities of $0.3 million. As of December 31, 2023 and 2022, the Company had financing liabilities totaling $1.4 million and $1.5 million, respectively. All of these financing liabilities are due to an entity controlled by an MVS shareholder.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments And Contingencies [Abstract]
Commitments and Contingencies	NOTE 16. COMMITMENTS AND CONTINGENCIES (a) Claims and Litigation From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2023, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s results of operations, financial positions or cash flows. There are also no proceedings in which any of the Company’s directors, officers or affiliates are an adverse party or has a material interest adverse to the Company’s interest. (b) Contingencies The Company’s operations are subject to a variety of federal, state and local regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on the Company’s operations, suspension or revocation of permits or licenses or other disciplinary actions (collectively, “Disciplinary Actions”) that could adversely affect the Company’s financial position and results of operations. While management believes that the Company is in substantial compliance with state and local regulations as of December 31, 2023 and through the date of filing of these financial statements, these regulations continue to evolve and are subject to differing interpretations and enforcement. As a result, the Company may be subject to Disciplinary Actions in the future. (c) Commitments As of December 31, 2023, the Company had total commitments of $2.3 million related to material construction projects. During the first quarter of 2022, pursuant to the Illinois Cannabis Regulation and Tax Act, the Company issued $0.2 million in loans to an Illinois company which has secured Craft Grower Licenses to operate in the state and $1.0 million in loans to groups that have been identified by the state of Illinois as having the opportunity to receive Conditional Adult Use Dispensing Organization Licenses. These loans are discussed in Note 17. These loans fully satisfy the Company’s funding requirements under Illinois Cannabis Regulation and Tax Act; however, the Company may elect to fund similar loans in the future. The Company has employment agreements with key management personnel which include severance in the event of termination totaling approximately $3.1 million with additional equity and/or compensation benefits.

Financial Instruments And Finan

Financial Instruments And Financial Risk Management	12 Months Ended
	Dec. 31, 2023
Financial Instruments [Abstract]
Financial Instruments And Financial Risk Management	NOTE 17. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT Financial Instruments The Company’s financial instruments are held at amortized cost (adjusted for impairments or expected credit losses (“ECLs”), as applicable) or fair value. The carrying values of financial instruments held at amortized cost approximate their fair values as of December 31, 2023 and December 31, 2022 due to their nature and relatively short maturity dates. Financial assets and liabilities with embedded derivative features are carried at fair value. Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The three levels of hierarchy are: • Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; • Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and • Level 3 – Inputs for the asset or liability that are not based on observable market data. There have been no transfers into or out of level 3 for the periods ended December 31, 2023 and December 31, 2022. The following tables summarize the Company’s financial instruments as of December 31, 2023 and December 31, 2022: December 31, 2023 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 103,429 $ — $ — $ — $ 103,429 Restricted cash 1 5,091 — — — 5,091 Security deposits 2 4,408 — — — 4,408 Accounts receivable, net 51,070 — — — 51,070 Loans receivable, short-term 1,421 — — — 1,421 Loans receivable, long-term 826 — — — 826 Investments — 49 81 600 730 Financial Liabilities: Accounts payable $ 27,587 $ — $ — $ — $ 27,587 Accrued liabilities 69,079 — — — 69,079 Short-term borrowings 11,817 — — — 11,817 Current portion of lease liabilities 9,416 — — — 9,416 Lease liabilities 163,811 — — — 163,811 Deferred consideration, long-term — — — 6,577 6,577 Long-term notes and loans payable, net 497,713 — — — 497,713 Other long-term liabilities 21,600 — — — 21,600 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. December 31, 2022 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 119,341 $ — $ — $ — $ 119,341 Restricted cash 1 2,169 — — — 2,169 Security deposits 2 4,367 — — — 4,367 Accounts receivable, net 56,492 — — — 56,492 Loans receivable, short-term 447 — — — 447 Loans receivable, long-term 823 — — — 823 Investments — 136 432 660 1,228 Financial Liabilities: Accounts payable $ 28,093 $ — $ — $ — $ 28,093 Accrued liabilities 65,161 — — — 65,161 Short-term borrowings 3 10,976 — — — 10,976 Current portion of lease liabilities 3 8,959 — — — 8,959 Deferred consideration and other payables, short-term 6 7 — 47,821 47,834 Lease liabilities 3 173,345 — — — 173,345 Deferred consideration, long-term — — — 7,770 7,770 Long-term notes and loans payable, net 3 476,891 — — — 476,891 Other long-term liabilities 7,000 — — — 7,000 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. 3 Balances reflect current year presentation changes. See “Reclassifications” in Note 2 for further discussion. The following table presents a rollforward of the balance sheet amounts measured at fair value on a recurring basis and classified as Level 3. The classification of an item as Level 3 is based on inputs for assets or liabilities that are not based on observable market data. Year Ended December 31, 2023 Level 3 Fair Value Measurements ($ in thousands) Investments Deferred consideration, and other payables, short-term Deferred consideration and contingent, long-term Balance as of December 31, 2022 $ 660 $ 47,821 $ 7,770 Change in fair value recorded in Interest expense, net — 1,953 — Change in fair value recorded in Other income, net (60) — (895) Payments 1 — (50,072) — Other 2 — 298 (298) Balance as of December 31, 2023 $ 600 $ — $ 6,577 1 See Note 8 and Note 11 for additional details related to payments. 2 Other relates to reclassifications from short-term to long-term due to expecting timing of payment. See Note 11. Year Ended December 31, 2022 Level 3 Fair Value Measurements ($ in thousands) Loans receivable, short-term Investments Deferred consideration, contingent consideration, and other payables, short-term Derivative liabilities, short-term Deferred consideration and contingent, long-term Balance as of December 31, 2021 $ 565 $ 660 $ 71,816 $ 1,172 $ 17,651 Change in fair value recorded in Interest expense, net — — 900 — (881) Change in fair value recorded in Other income, net — — 5,647 (1,172) — Payments 1 (1,837) — (39,542) — — Change in fair value recorded in Selling, general and administrative 1,272 — — — — Other 2 — — 9,000 — (9,000) Balance as of December 31, 2022 $ — $ 660 $ 47,821 $ — $ 7,770 1 $39.5 million payment related to the Cultivate contingent consideration earnout. The $1.8 million payment related to Lighthouse outstanding loan receivable. 2 $9.0 million related to reclassifications from long-term to short-term due to the projected dispensary opening dates. (a) Loans receivable, short-term The following is a summary of Loans receivable, short-term balances and valuation classifications (discussed further below) as of December 31, 2023 and December 31, 2022: ($ in thousands) Valuation December 31, 2023 December 31, 2022 Short-term loans receivable - Kurvana, net of ECL Amortized cost $ 493 $ 447 Short-term loans receivable - 280E, net of ECL Amortized cost 928 — Total Loans receivable, short-term $ 1,421 $ 447 During the second quarter of 2023, the Company issued a $1.0 million short-term loan receivable to 280EZ LLC, an Illinois limited liability company (d/b/a Spark’d). The short-term loan receivable has a one-year term and interest accruing at 9.5% per annum, paid on a monthly basis. At the inception of the loan, an ECL determination was made. (b) Loans receivable, long-term ($ in thousands) Valuation December 31, 2023 December 31, 2022 Long-term loans receivable - Illinois Incubator, net of ECL Amortized cost $ 826 $ 823 Total Loans receivable, long-term $ 826 $ 823 Pursuant to the Illinois Cannabis Regulation and Tax Act, the Company has issued $0.3 million in loans to an Illinois company which has secured a Craft Grower License to operate in the state and $1.0 million in loans to groups that have been identified by the state of Illinois as having the opportunity to receive Conditional Adult Use Dispensing Organization Licenses. One (1) $0.1 million loan related to the Craft Grower License, was fully funded on July 20, 2021 and matures on July 20, 2026. The remaining loans of $1.2 million were fully funded on March 21, 2022 and mature on July 20, 2027. The loans are measured at amortized cost and bear no interest. Financial Risk Management The Company is exposed in varying degrees to a variety of financial instrument-related risks. The Board of Directors and Company management mitigate these risks by assessing, monitoring and approving the Company’s risk management processes: (a) Credit and Banking Risk Credit risk is the risk of a potential loss to the Company if a customer or a third-party to a financial instrument fails to meet its contractual obligations. The maximum credit exposure as of December 31, 2023 and December 31, 2022 is the carrying amount of cash, accounts receivable and loans receivable. The Company does not have significant credit risk with respect to its growth in its key retail markets, as payment is typically due upon transferring the goods to the customer at our dispensaries, which currently accept only cash and debit cards. Additionally, the Company does not have significant credit risk with respect to its loan counterparties as the interest rate on our Amended Senior Loan is not variable and therefore, is not materially impacted by interest rate increases enacted by the Federal Reserve. The interest rate on our Mortgage Loans is based on the FHLB Five Year Classic Regular Advance Rates which matures every five (5) years and does not pose a significant credit risk. Although all deposited cash is placed with U.S. financial institutions in good standing with regulatory authorities, changes in U.S. federal banking laws related to the deposit and holding of funds derived from activities related to the cannabis industry have passed the U.S. House of Representatives but were not voted on within the U.S. Senate, and would need to be reintroduced by Congress. Given that current U.S. federal law provides that the production and possession of cannabis is illegal, there is a strong argument that banks cannot accept or deposit funds from businesses involved with the cannabis industry, leading to an increased risk of legal actions against the Company and forfeitures of the Company’s assets. The Company’s aging of Accounts receivables as of December 31, 2023 and December 31, 2022 was as follows: ($ in thousands) December 31, 2023 December 31, 2022 0 to 60 days $ 41,820 $ 49,303 61 to 120 days 8,117 6,118 120 days + 9,097 3,698 Total accounts receivable, gross 59,034 59,119 Allowance for doubtful accounts 7,964 2,627 Total accounts receivable, net $ 51,070 $ 56,492 For the year ended December 31, 2023, one customer accounted for $7.2 million or 12% of the Company’s gross accounts receivable balance. For the year ended December 31, 2022, two customers accounted for $13.9 million or 23% of the Company’s gross accounts receivable balance. For the years ended December 31, 2023 and 2022, the Company recorded an ECL of $4.9 million and $0.4 million, respectively. An additional $5.5 million and $1.9 million in bad debt expense related to invoice write-offs was recorded for the same respective twelve month periods. In the fourth quarter of 2022, management committed to a plan to restructure certain operations and activities within the California reporting unit. Related to that plan, during the first quarter of 2023, the Company reserved for approximately $0.1 million of Accounts Receivable at the impacted California entities. Following the plan to restructure certain operations and activities in California, the Company received cash payments totaling $2.0 million for the year ended December 31, 2023. (b) Asset Forfeiture Risk Because the cannabis industry remains illegal under U.S. federal law, any property owned by participants in the cannabis industry, which are either used in the course of conducting such business, or are the proceeds of such business, could be subject to seizure by law enforcement and subsequent civil asset forfeiture. Even if the owner of the property was never charged with a crime, the property in question could still be seized and subject to an administrative proceeding by which, with minimal due process, it could be subject to forfeiture. (c) Liquidity Risk The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the year ended December 31, 2023, the Company has generated positive cash flows from operations and implemented certain cost cutting measures, which are expected to improve cash from operations. Net loss for the year ended December 31, 2023, decreased $36.0 million compared to the year ended December 31, 2022. The decrease in net loss was primarily driven by lower operating expenses and less income tax expense, offset by lower revenue. Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company primarily manages liquidity risk through the management of its capital structure by ensuring that it will have sufficient liquidity to settle obligations and liabilities when due. As of December 31, 2023, the Company had working capital (defined as current assets less current liabilities) of $77.8 million. The Company also expects to be able to continue to raise debt or equity based capital, or sell certain assets, if needed, to fund operations and the expansion of its business. In addition to the commitments outlined in Note 16, the Company has the following contractual obligations as of December 31, 2023: ($ in thousands) < 1 Year 1 to 3 Years 3 to 5 Years > 5 Years Total Accounts payable & Accrued liabilities $ 95,817 $ — $ — $ — $ 95,817 Operating leases liabilities 28,417 58,172 58,726 161,249 306,564 Finance lease liabilities 4,882 10,166 10,357 18,337 43,742 Deferred consideration, long-term — 6,577 — — 6,577 Long-term notes and loans payable and Short-term borrowings 23,347 428,276 29,522 122,112 603,257 Tax receivable agreement liability 1,065 2,587 3,199 7,713 14,564 Other long-term liabilities — 7,886 — — 7,886 Total obligations as of December 31, 2023 $ 153,528 $ 513,664 $ 101,804 $ 309,411 $ 1,078,407 (d) Market Risk (i) Currency Risk The operating results and balance sheet of the Company are reported in USD. As of December 31, 2023 and December 31, 2022, the Company’s financial assets and liabilities are primarily in USD. However, from time to time some of the Company’s financial transactions are denominated in currencies other than USD. The results of the Company’s operations are subject to currency transaction and translation risks. The Company recorded $0.3 million in foreign currency exchange losses during the year ended December 31, 2023 and $0.9 million in foreign currency exchange gains during the year ended December 31, 2022. As of December 31, 2023 and December 31, 2022, the Company had no hedging agreements in place with respect to foreign exchange rates. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks at this time. (ii) Interest Rate Risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. An increase or decrease in the Company’s incremental borrowing rate would result in an associated increase or decrease in Deferred consideration, contingent consideration and other payables and Interest expense, net. The Company’s Amended Senior Loan accrues interest at a rate of 9.5%, per annum and has an effective interest rate of 11.0%. The Company’s Mortgage Loans accrues interest at a rate of 8.4%, per annum and have an effective interest rate of 10.2%. (iii) Price Risk Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company is subject to price risk related to deferred consideration and other payables that are valued based on the Company’s own stock price. An increase or decrease in stock price would result in an associated increase or decrease to Deferred consideration and other payables, short-term with a corresponding change to Other income, net. (iv) Tax Risk Tax risk is the risk of changes in the tax environment that would have a material adverse effect on the Company’s business, results of operations and financial condition. Currently, state-licensed marijuana businesses are assessed a comparatively high effective federal tax rate due to Internal Revenue Code (“IRC”) Section 280E, which bars businesses from deducting all expenses except their cost of goods sold when calculating federal tax liability. Any increase in tax levies resulting from additional tax measures may have a further adverse effect on the operations of the Company, while any decrease in such tax levies will be beneficial to future operations. See Note 21 for the Company’s disclosure of uncertain tax positions. (v) Regulatory Risk Regulatory risk pertains to the risk that the Company’s business objectives are contingent, in part, upon the compliance of regulatory requirements. Due to the nature of the industry, the Company recognizes that regulatory requirements are more stringent and punitive in nature. Any delays in obtaining, or failure to obtain regulatory approvals can significantly delay operational and product development and can have a material adverse effect on the Company’s business, results of operations and financial condition. The Company is cognizant of the advent of regulatory changes occurring in the cannabis industry on the city, state and national levels. Although the regulatory outlook on the cannabis industry has been moving in a positive trend, any unforeseen regulatory changes could have a material adverse impact on the goals and operation of the Company’s business. (vi) Economic Risk The Company’s business, financial condition and operating results may be negatively impacted by challenging global economic conditions. A global economic slowdown would cause disruptions and extreme volatility in global financial markets, increased rates of default and bankruptcy and declining consumer and business confidence, which can lead to decreased levels of consumer spending. These macroeconomic developments could negatively impact the Company’s business, which depends on the general economic environment and levels of consumer spending. As a result, the Company may not be able to maintain its existing customers or attract new customers, or the Company may be forced to reduce the price of its products. The Company is unable to predict the likelihood of the occurrence, duration or severity of such disruptions in the credit and financial markets or adverse global economic conditions. Any general or market-specific economic downturn could have a material adverse effect on our business, financial condition and operating results. (vii) Inflation Risk The Company has experienced increased inflationary pressures, including increased cultivation costs, distribution costs and operating expenses, which have adversely impacted our operating results. The Company anticipates inflationary pressures to continue throughout 2024. The Company maintains strategies to mitigate the impact of higher raw material, energy and commodity costs, which include cost reduction, sourcing and other actions, which may help to offset a portion of the adverse impact.

Variable Interest Entities

Variable Interest Entities	12 Months Ended
	Dec. 31, 2023
Variable Interest Entities [Abstract]
Variable Interest Entities	NOTE 18. VARIABLE INTEREST ENTITIES The following table presents the summarized financial information about the Company’s consolidated variable interest entities (“VIEs”) before eliminations, which are included in the Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022. All of these entities were determined to be VIEs as the Company possesses the power to direct activities through written agreements and is subject to the risks and rewards as a primary beneficiary: December 31, 2023 December 31, 2022 ($ in thousands) Cresco Labs Michigan, LLC Cresco Labs Michigan, LLC Current assets $ 15,485 $ 17,506 Non-current assets 75,622 63,212 Current liabilities (1,476) (3,158) Non-current liabilities (124,793) (108,113) Non-controlling interests 258 — Deficit attributable to Cresco Labs Inc. 34,904 30,553 The following table presents the summarized financial information about the Company’s consolidated VIEs before eliminations, which are included in the Consolidated Statements of Operations for the years ended December 31, 2023 and 2022: ($ in thousands) Cresco Labs Michigan, LLC Cresco Labs Michigan, LLC Revenue $ 25,046 $ 12,659 Net loss attributable to non-controlling interests (258) — Net loss attributable to Cresco Labs Inc. (4,445) (8,617) Net loss (4,703) (8,617)

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2023
Disclosure of operating segments [abstract]
Segment Information	NOTE 19. SEGMENT INFORMATION The Company operates in one segment, the cultivation, manufacturing, distribution and sale of cannabis. The Chief Executive Officer, the Chief Financial Officer and the Chief Transformation Officer of the Company have been identified as the Chief Operating Decision Makers (“CODMs”) and manage the Company’s operations as a whole. For the purpose of evaluating financial performance and allocating resources, the CODMs review certain financial information presented on a consolidated basis accompanied by information by customer and geographic region. For both the years ended December 31, 2023 and 2022, the Company generate d 100.0%

Interest Expense, Net

Interest Expense, Net	12 Months Ended
	Dec. 31, 2023
Interest Income (Expense) [Abstract]
Interest Expense, Net	NOTE 20. INTEREST EXPENSE, NET Interest expense, net consisted of the following for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Interest expense – notes and loans payable (43,575) (38,528) Interest expense – financing activities (11,739) (11,887) Accretion of debt discount and amortization of deferred financing fees (4,416) (3,951) Interest expense – leases $ (3,513) $ (3,952) Interest income 2,148 679 Other interest income (expense) 1 276 (198) Total Interest expense, net $ (60,819) $ (57,837) 1 During the year ended December 31, 2023, the Company recorded $1.2 million of reductions in interest expense related to Valley Ag operating cash flows deferred consideration. See Note 11 for additional information. See Note 5 for additional information regarding Interest expense – leases and Note 12 for additional information on Interest expense – notes and loans payable, Accretion of debt discount and amortization of deferred financing fees, and Interest expense – financing activities.

Provision For Income Taxes And

Provision For Income Taxes And Deferred Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Provision For Income Taxes And Deferred Income Taxes	NOTE 21. PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES As the Company operates in the cannabis industry, the Company is subject to the limits of Internal Revenue Code (“IRC”) Section 280E for U.S. federal income tax purposes as well as some state income tax purposes. Under IRC Section 280E, the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, certain states including Arizona, California, Illinois, Maryland, Massachusetts, Michigan and New York (Adult Use) do not conform to IRC Section 280E and, accordingly, the Company generally deducts all operating expenses on its income tax returns in these states. During the second quarter of 2023, Illinois decoupled from the application of IRC Section 280E for any cannabis establishment operating in the state of Illinois and licensed under the Cannabis Regulation and Tax Act and/or Compassionate Use of Medical Cannabis Program Act beginning for taxable years beginning on or after January 1, 2023. The Company is treated as a United States corporation for U.S. federal income tax purposes under IRC Section 7874 and is subject to U.S. federal income tax on its worldwide income. However, for Canadian tax purposes the Company, regardless of any application of IRC Section 7874, is treated as a Canadian resident company, as defined in the Income Tax Act (Canada), for Canadian income tax purposes. As a result, the Company is subject to taxation both in Canada and the United States. Provision for income taxes consists of the following for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Current Federal $ 55,679 $ 69,240 State 15,858 24,341 Foreign — — Total current $ 71,537 $ 93,581 Deferred Federal $ (23,771) $ (8,332) State (18,215) (9,858) Foreign 28,749 1,190 Total deferred $ (13,237) $ (17,000) Change in valuation allowance $ (25,350) $ 12,357 Total $ 32,950 $ 88,938 As of December 31, 2023 and 2022, the components of deferred tax assets and liabilities were as follows: ($ in thousands) 2023 2022 Deferred tax assets Share-based compensation $ 3,961 $ 1,381 Financing fees 453 1,291 Net operating losses 40,580 43,629 Inventory 97 346 Lease liabilities 41,088 28,362 Tax receivable agreement 15,379 315 Other 629 386 Total deferred tax assets $ 102,187 $ 75,711 Deferred tax liabilities ROU assets $ (13,689) $ (9,560) Property, plant and equipment (11,669) (12,393) Intangible assets (64,052) (84,099) Other (23,596) (1,329) Total deferred tax liabilities $ (113,006) $ (107,381) Valuation allowance $ (18,091) $ (43,442) Net deferred tax liabilities $ (28,910) $ (75,112) As of December 31, 2023, the Company had the following loss carryforwards: • $41.9 million of non-capital Canadian losses which expire from 2038-2043, which are fully offset by a valuation allowance. • $55.7 million of U.S. federal net operating losses which have an indefinite carryforward period, a portion of which are not recorded as the Company does not consider these to be more-likely-than-not to be realized. $50.8 million of U.S. federal net operating loss carryforwards are offset by a valuation allowance. • $204.6 million of state net operating losses, which expire in 2038-2043, a portion of which are not recorded as the Company does not consider these to be more-likely-than-not to be realized. $183.3 million of state net of state net operating loss carryforwards are offset by a valuation allowance. As of December 31, 2022, the Company had the following loss carryforwards: • $63.5 million of non-capital Canadian losses which expire from 2038-2042, which are fully offset by valuation allowance. • $52.2 million of U.S. federal net operating losses which have an indefinite carryforward period, a portion of which are not recorded as the Company does not consider these to be more-likely-than-not to be realized. $45.7 million of U.S. federal net operating loss carryforwards are offset by valuation allowance. • $184.3 million of state net operating losses, which expire in 2038-2042, a portion of which are not recorded as the Company does not consider these to be more-likely-than-not to be realized. $180.8 million of state net of state net operating loss carryforwards are offset by valuation allowance. A valuation allowance to reflect management’s estimate of the temporary deductible differences that may expire prior to their utilization has been recorded at December 31, 2023 and 2022. During 2023 and 2022, the Company maintained a full valuation allowance against its net Canadian deferred tax assets, as losses are generated in Canada with no projection of future taxable income. In 2023, the Company increased its deferred tax asset related to the step-up in basis from shareholder redemptions under the tax receivable agreement for Cresco Labs LLC by $15.4 million. The Company also recognized an increase to the tax receivable agreement liability of $13.5 million related to estimated payables to certain shareholders. The reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows: ($ in thousands) 2023 2022 Expected income tax expense at statutory tax rate $ (30,711) $ (26,650) Tax rate differences (69) (2,296) Pass through and non-controlling entities (4,881) (2,183) State tax expense, net (4,898) 17,209 IRC Section 280E disallowance 47,043 50,521 Uncertain tax treatment (including penalties and interest) 7,311 12,901 Share-based compensation 2,086 2,261 Goodwill impairment 10,448 25,334 Tax penalties and interest 5,552 4,155 Change in valuation allowance (25,350) 12,357 Change in state tax rates 10,317 (471) Change in state filing methods (3,940) — Canadian reorganization basis change 28,730 — Tax receivable agreement (2,919) (395) Adjustments to prior year provisions (7,003) (5,136) Other 1,235 1,332 Income tax expense $ 32,950 $ 88,938 Effective tax rate (22.4 %) (70.1 %) During 2022, the Company adopted a tax position whereby certain expenses incurred at dispensary locations are treated as inventoriable costs for tax purposes, reducing the impact of IRC Section 280E on the 2021 tax returns and in the current period. The Company determined that the tax benefit associated with this position did not meet the more likely than not criteria under ASC 740 Income Taxes due to the evolving interpretations of IRC Section 280E. As a result, the Company recorded an additional reserve of $6.1 million for unrecognized tax benefits and accrued $1.3 million of penalties and interest related to unrecognized tax benefits as of December 31, 2023. The Company records unrecognized tax benefits as liabilities in accordance with ASC 740 Income Taxes and adjusts these liabilities when judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. It is possible that additional tax distribution liabilities may become due to certain non-controlling interest members as a result of unrecognized tax benefits. While the probable amount of any future tax distribution liability cannot reasonably be estimated, the maximum future tax distribution liability associated with these unrecognized tax benefits is estimated to be $7.8 million as of December 31, 2023. The Company accrued $6.9 million and $5.5 million in tax penalties and interest as of December 31, 2023 and 2022, respectively. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: ($ in thousands) 2023 2022 Balance at January 1 $ 12,746 $ — Additions based on tax positions related to the current year 6,054 7,380 Additions for tax positions of prior years — 5,366 Balance at the end of the year $ 18,800 $ 12,746 The Company is currently under examination by U.S. federal, state and Canadian tax authorities. As of December 31, 2023, no additional liabilities are anticipated as a result of these examinations. With few exceptions, the Company is generally not subject to examination by tax authorities for years before 2019.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Disclosure Of Subsequent Events [Abstract]
Subsequent Events	NOTE 22. SUBSEQUENT EVENTS The Company has evaluated subsequent events through March 15, 2024, which is the date on which these financial statements were issued, and concluded there were no material subsequent events for the period ended December 31, 2023.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation
Basis of Measurement	Basis of Measurement The accompanying consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for certain loans receivable, investments, and contingent considerations, which are recorded at fair value. Historical cost is generally based upon the fair value of the consideration given in exchange for assets acquired and the contractual obligation for liabilities incurred.
Functional and Presentation Currency	Functional and Presentation Currency The Company’s functional currency and that of the majority of its subsidiaries is the United States (“U.S.”) dollar. The Company’s reporting currency is the U.S. dollar (“USD”). All references to “C$” refer to Canadian dollars. Foreign currency denominated assets and liabilities are re-measured into the functional currency using period-end exchange rates. Gains and losses from foreign currency transactions are included in Other income, net in the Consolidated Statements of Operations. Assets and liabilities of foreign operations having a functional currency other than USD (e.g., C$) are translated at the rate of exchange prevailing at the reporting date; revenues and expenses are translated at the monthly average rate of exchange during the period. Gains or losses on translation of foreign subsidiaries and net investments in foreign operations are included in Foreign currency translation differences, net of tax in the Consolidated Statements of Comprehensive Loss and Accumulated other comprehensive loss on the Consolidated Balance Sheets.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries with intercompany balances and transactions eliminated upon consolidation. Subsidiaries are those entities over which the Company has the power over the investee, is exposed, or has rights, to variable involvement with the investee; and has the ability to use its power to affect its returns. The following are Cresco Labs’ wholly-owned or controlled entities as of December 31, 2023: Entity Location Purpose Percentage Cresco Labs Inc. British Columbia, Canada Parent Company Cali-Antifragile Corp. California Holding Company 100% River Distributing Co., LLC California Holding Company 100% Sonoma's Finest fka FloraCal California Cultivation 100% Cub City, LLC California Cultivation 100% CRHC Holdings Corp. Ontario, Canada Holding Company 100% Cannroy Delaware Inc. Delaware Holding Company 100% High Road Holdings LLC Delaware Holding Company 100% Laurel Harvest Labs, LLC Pennsylvania Cultivation and Dispensary Facility 100% JDRC Mount Joy, LLC Illinois Holding Company 100% JDRC Scranton, LLC Illinois Holding Company 100% Bluma Wellness Inc. British Columbia, Canada Holding Company 100% Cannabis Cures Investments, LLC Florida Holding Company 100% 3 Boys Farm, LLC Florida Cultivation, Production and Dispensary Facility 100% Farm to Fresh Holdings, LLC Florida Holding Company 100% Cresco U.S. Corp. Illinois Holding Company 100% MedMar Inc. Illinois Holding Company 100% MedMar Lakeview, LLC Illinois Dispensary 88% MedMar Rockford, LLC Illinois Dispensary 75% Gloucester Street Capital, LLC New York Holding Company 100% Valley Agriceuticals, LLC New York Cultivation, Production and Dispensary Facility 100% Valley Agriceuticals Real Estate New York Holding Company 100% JDRC Ellenville, LLC Illinois Holding Company 100% CMA Holdings, LLC Illinois Holding Company 100% BL Real Estate, LLC Massachusetts Holding Company 100% BL Pierce, LLC Massachusetts Holding Company 100% BL Uxbridge, LLC Massachusetts Holding Company 100% BL Main, LLC Massachusetts Holding Company 100% BL Burncoat, LLC Massachusetts Holding Company 100% BL Framingham, LLC Massachusetts Holding Company 100% BL Worcester, LLC Massachusetts Holding Company 100% Cultivate Licensing LLC Massachusetts Holding Company 100% Cultivate Worcester, Inc. Massachusetts Dispensary 100% Cultivate Leicester, Inc. Massachusetts Cultivation, Production and Dispensary Facility 100% Cultivate Framingham, Inc. Massachusetts Dispensary 100% Cultivate Cultivation, LLC Massachusetts Cultivation and Production Entity 100% GoodNews Holdings, LLC Illinois Licensing Company 100% Wonder Holdings, LLC Illinois Licensing Company 100% JDRC Seed, LLC Illinois Educational Company 100% CP Pennsylvania Holdings, LLC Illinois Holding Company 100% Bay, LLC Pennsylvania Dispensary 100% Bay Asset Management, LLC Pennsylvania Holding Company 100% Ridgeback, LLC Colorado Holding Company 100% Encanto Green Cross Dispensary, LLC Arizona Holding Company 100% Cresco Labs Texas, LLC Texas Holding Company 100% Cresco Labs, LLC Illinois Operating Entity 62% Cresco Labs Ohio, LLC Ohio Cultivation, Production and Dispensary Facility 99% Entity Location Purpose Percentage Cresco Labs Notes Issuer, LLC Illinois Holding Company Wellbeings, LLC Delaware CBD Wellness Product Development 100% Cresco Labs SLO, LLC California Holding Company 100% SLO Cultivation Inc. California Holding Company 80% Cresco Labs Joliet, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Kankakee, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Logan, LLC Illinois Cultivation and Production Facility 100% Cresco Labs PA, LLC Illinois Holding Company 100% Cresco Yeltrah, LLC Pennsylvania Cultivation, Production and Dispensary Facility 100% Strip District Education Center Pennsylvania Holding Company 100% AFS Maryland, LLC Maryland Holding Company 100% JDC Newark, LLC Ohio Holding Company 100% Verdant Creations Newark, LLC Ohio Dispensary 100% Strategic Property Concepts, LLC Ohio Holding Company 100% JDC Marion, LLC Ohio Holding Company 100% Verdant Creations Marion, LLC Ohio Dispensary 100% Strategic Property Concepts 4, LLC Ohio Holding Company 100% JDC Chillicothe, LLC Ohio Holding Company 100% Verdant Creations Chillicothe, LLC Ohio Dispensary 100% Strategic Property Concepts 5, LLC Ohio Holding Company 100% JDC Columbus, LLC Ohio Holding Company 100% Care Med Associates, LLC Ohio Dispensary 100% Arizona Facilities Supply, LLC Arizona Holding Company 100% Cresco Labs TINAD, LLC Illinois Holding Company 100% TINAD, LLC Illinois Holding Company 100% PDI Medical III, LLC Illinois Dispensary 100% Cresco Labs Phoenix Farms, LLC Illinois Holding Company 100% Phoenix Farms Partners, LLC Illinois Holding Company 100% Phoenix Farms of Illinois Asset Management, LLC Illinois Holding Company 100% Phoenix Farms of Illinois, LLC Illinois Dispensary 100% JDC Elmwood, LLC Illinois Holding Company 100% FloraMedex, LLC Illinois Dispensary 100% Cresco Edibles, LLC Illinois Holding Company 100% TSC Cresco, LLC Illinois Licensing 75% Cresco HHH, LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cresco Labs Nevada, LLC Nevada Holding Company 100% Cresco Labs Michigan Management, LLC Michigan Holding Company 100% Cresco Labs Missouri Management, LLC Missouri Holding Company 100% JDRC Acquisitions, LLC Illinois Holding Company 100% JDRC 7841 Grand LLC Illinois Holding Company 100% JDRC Lincoln, LLC Illinois Holding Company 100% JDRC Danville, LLC Illinois Holding Company 100% JDRC Kankakee, LLC Illinois Holding Company 100% JDRC Brookville, LLC Illinois Holding Company 100% Cresco Labs Michigan, LLC (a) Michigan Cultivation and Production Facility 85% (a) Legally, Cresco Labs Michigan, LLC is 85% owned by related parties of the Company. Cresco U.S. Corp., which is wholly owned by the Company, is the sole manager of Cresco Labs, LLC; Cresco Labs, LLC is the sole owner and manager of Cresco Labs Notes Issuer, LLC. Therefore, the Company controls Cresco Labs Notes Issuer, LLC and has consolidated its results into the consolidated financial statements. Non-controlling interests (“NCI”) represent ownership interests in consolidated subsidiaries by parties that are not shareholders of the Company. They are shown as a component of total equity in the Consolidated Balance Sheets, and the share of income attributable to NCI is shown as Net income attributable to non-controlling interests, net of tax in the Consolidated Statements of Operations and in the Consolidated Statements of Comprehensive Loss. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash deposits in financial institutions, other deposits that are readily convertible into cash and cash on hand at retail locations. The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents and mainly consist of certificates of deposits.
Restricted Cash	Restricted Cash
Accounts Receivable	Accounts Receivable Accounts receivable are recorded net of allowance for doubtful accounts. The Company develops a provision matrix and measures the expected credit losses based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors. The Company also estimates and provides an allowance for doubtful accounts based on contractual payment terms, actual payment history of its customers, current economic conditions and individual customer circumstances. Accounts receivable are evaluated monthly based on expected collections over its life and an adjustment is recorded as needed. When a receivable is uncollectible, it is written off against the provision. Subsequent recoveries of amounts previously written off are credited to the Consolidated Statements of Operations . See Note 17 for further discussion.
Inventory	Inventory Inventory is primarily composed of raw materials (cannabis and non-cannabis), work-in-process and finished goods. Inventory is recorded at the lower of cost or net realizable value, with cost determined using the weighted average cost method. For manufactured inventory, costs incurred during the growing and production of cannabis and cannabis-based products are capitalized, net of yield adjustments, as incurred to the extent that costs are less than net realizable value. These costs include, but are not limited to, materials, labor, overhead and occupancy costs, cannabis taxes and depreciation expense on equipment involved in manufacturing, packaging, labeling, inspection and testing. Fixed costs associated with underutilized facilities are taken as expenses within the current period. Capacities are set using normalized operating capacity as defined by GAAP. Costs related to purchased finished goods are recorded at cost, including freight. The Company reviews inventory for obsolete, redundant and slow-moving goods and any such inventory is written down to net realizable value.
Property and Equipment	Property and Equipment Property and equipment is stated at cost, net of accumulated depreciation. Land is recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The Company evaluates the recoverability of property, plant and equipment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not be recoverable. In those cases, the assets are assessed for impairment based on the estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the carrying value of an asset exceeds its estimated future undiscounted cash flows, the Company will determine the fair value of the assets within the asset group and record an impairment loss calculated as the excess in carrying value over fair value. Equipment is derecognized upon disposal or when no future economic benefits are expected from its use. Leasehold improvements are amortized over the lesser of the life of the lease or estimated useful life of the improvement. Any gain or loss arising from derecognition or impairment of the asset (calculated as the difference between the net disposal proceeds and the carrying value of the asset) is included in the accompanying Consolidated Statements of Operations. The Company assesses property and equipment for indicators of impairment throughout the reporting period. See Note 4 for additional details. Category Estimated Leasehold Improvements 1 - 15 years Machinery and Equipment 5 - 15 years Furniture and Fixtures 3 - 7 years Vehicles 5 years Website and Software 3 years Computer Equipment 3 - 5 years Buildings and Building Improvements 5 - 39 years Repairs and maintenance that do not improve efficiency or extend economic life are charged to expense as incurred.
Intangible Assets	Intangible Assets Intangible assets are recorded at cost, less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date or date of consolidation/control. Amortization of definite-lived intangible assets is recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. Costs incurred during the year to renew or extend the term of a recognized intangible asset are included within additions and are amortized on a straight-line basis over the useful lives of the permit or license renewal period. See Note 7 for additional details. Intangible assets are amortized over the following terms: Category Estimated Customer Relationships 7 - 8 years Non-Compete Agreements 2 - 5 years Trade Names 10 years Permit Application Fees 1 - 2 years The estimated useful lives and residual values are reviewed at each year end and any changes in estimates are accounted for prospectively. Intangible assets that have an indefinite useful life are not subject to amortization. The Company’s indefinite-lived intangible assets consist of licenses which represent the future benefits associated with the Company’s cultivation, processing and dispensary licenses. Absent such license intangibles, the Company cannot continue as a going concern and as such, there is no foreseeable limit to the period over which these assets are expected to generate future cash inflows to the Company. Definite-lived intangible assets are tested for impairment when there is an indication of impairment. Indefinite-lived intangible assets are tested for impairment annually, or more frequently, as warranted if events or changes in circumstances indicate impairment.
Goodwill	Goodwill Goodwill represents the excess of the purchase price paid for the acquisition of a business over the fair value of the net assets acquired. Goodwill is allocated to the reporting unit or reporting units, which are expected to benefit from the synergies of the combination. Goodwill is not subject to amortization and is tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment may have occurred. For the purpose of impairment testing, goodwill and indefinite-lived intangible assets have been allocated to reporting units or groups of reporting units representing the lowest level at which the assets generate cash inflow and outflow independent of other assets. An impaired asset is written down to its estimated fair value based on the most recent information available. The Company assesses the fair values of its reporting units using an income-based approach. Under the income approach, fair value is based on the present value of estimated future cash flows. The income approach requires management to estimate a number of factors for each reporting unit, including projected future operating results, economic projections, anticipated future cash flows, discount rates, and the allocation of shared or corporate costs. The impairment review, which is performed October 1 of each year, begins with a qualitative assessment of all reporting units. If the Company determines, based on weighing of all available evidence, that a reporting unit’s carrying value may exceed its fair value at the testing date, the Company performs a quantitative impairment assessment. If the carrying value of these intangible assets or the reporting unit exceeds the fair values, the Company would record an impairment charge based on the excess of the carrying value over the fair value. See Note 7 for additional details. As of December 31, 2023,
Income Taxes	Income Taxes Tax expense recognized in profit or loss is comprised of the sum of current and deferred taxes not recognized in other comprehensive loss or directly in equity. (i) Current Tax Current tax assets and/or liabilities are comprised of claims from, or obligations to, fiscal authorities relating to the current or prior reporting periods that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the financial statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. (ii) Deferred Tax Deferred taxes are calculated using the asset and liability method on temporary differences between the carrying amounts of assets and liabilities and their tax bases. Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their respective period of realization, provided they are enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are always provided for in full. The measurement of deferred tax assets is reduced through a valuation allowance, if necessary, by the amount of any tax benefits that, based on available evidence, are more likely than not expected to be unrealized. Deferred tax assets and liabilities are offset only when the Company has a right and intention to offset current tax assets and liabilities from the same taxation authority. Changes in deferred tax assets or liabilities are recognized as a component of tax income or expense in profit or loss, except where they relate to items that are recognized in other comprehensive loss or directly in equity, in which case the related deferred tax is also recognized in other comprehensive loss or equity, respectively. As the Company operates in the cannabis industry, the Company is subject to the limits of Internal Revenue Code (“IRC”) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company accounts for assets and liabilities measured at fair value on a recurring basis in accordance with Accounting Standards Codification (“ASC”) 820 Fair Value Measurements . Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the inputs to the fair value measurements. The three levels of the hierarchy are: – Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; – Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; – Level 3 – Inputs for the asset or liability that are not based on observable market data. See Note 17 for additional details.
Loans Receivable	Loans Receivable The Company may provide financing to various related and non-related businesses within the cannabis industry. These loans are classified as held for investment and accounted for as financial instruments in accordance with ASC 310 Receivables
Leases	Leases The Company has entered into leases primarily for its corporate offices, cultivation and processing facilities and dispensaries. At inception of a contract, the Company determines whether the contract includes a lease. A contract contains a lease if it includes enforceable rights and obligations under which the right to control the use of an identified asset is conveyed for a period of time in exchange for consideration. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the commencement date – the date when the asset is available for use by the lessee. The Company assesses at lease commencement whether it is reasonably certain to exercise extension or termination options. The Company reassesses its lease portfolio to determine whether it is reasonably certain to exercise the options if there is a significant event or significant change in circumstances within its control. The extension options, which are considered reasonably certain to be exercised, are mainly those for which operational decisions have been made that make the lease assets vital to the continued relevant business activities. Liabilities arising from a lease are initially measured at the present value of the lease payments not yet paid, using the Company’s incremental borrowing rate. Lease liabilities include the value of the following payments: (i) Fixed payments, including in-substance fixed payments, less any lease incentives receivable; (ii) The exercise price of a purchase option if the Company is reasonably certain to exercise that option; and (iii) Penalties for early termination of the lease, if the lease term reflects the Company exercising an option to terminate the lease. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is decreased by cash paid net of interest expense incurred. The lease liability is remeasured when there is a change in future lease payments, or if the Company changes its assessment of whether it will exercise an extension, purchase or termination option. ROU assets are measured at cost and are comprised of the following: (i) The amount of the initial measurement of lease liability; (ii) Lease payments made at or before the commencement date less any lease incentives received; (iii) Any initial direct costs; and (iv) An estimate of costs of dismantling and removing the underlying asset, restoring the site on which it is located or the underlying asset, if applicable. The ROU asset is depreciated on a straight-line basis from the commencement date to the end of the lease term. A fixed amount of rent expense is recognized on a straight-line basis over the lease term for operating leases. For finance leases, depreciation expense on the ROU asset and interest expense on the lease liability are recognized over the lease term. The value of the ROU asset is periodically reduced by impairment losses, if any, and adjusted for certain revaluations of the lease liability. In accordance with the guidance in ASC 842 Leases , the Company has elected not to recognize ROU assets and lease liabilities where the total lease term is less than or equal to twelve months. The payments for such leases are recognized as rent expense within Selling, general and administrative expenses or Cost of goods sold in the Consolidated Statements of Operations on a straight-line basis over the lease term. See Note 5 for additional information. (p) Change in Accounting Policy
Revenue Recognition	Revenue Recognition Revenue is recognized by the Company in accordance with ASC 606 Revenue from Contracts with Customers . Through application of ASC 606, the Company recognizes revenue to depict the transfer of promised goods to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. In order to recognize revenue under ASC 606, the Company applies the following five (5) steps: • Identify a customer along with a corresponding contract; • Identify the performance obligation(s) in the contract to transfer goods to a customer; • Determine the transaction price the Company expects to be entitled to in exchange for transferring promised goods to a customer; • Allocate the transaction price to the performance obligation(s) in the contract; and • Recognize revenue when or as the Company satisfies the performance obligation(s). Revenue consists of wholesale and retail sales of cannabis and other cannabis-derived and related products. Wholesale and retail sales are both generally recognized at a point in time when control over the goods has been transferred to the customer and is recorded net of sales discounts. For retail sales, payment is typically due upon transferring the goods to the customer. For wholesale sales, payment is typically due upon transferring the goods to the customer or within a specified time period permitted under agreed-upon payment terms. Revenue is recognized upon the satisfaction of the performance obligation. The Company satisfies its performance obligation and transfers control upon delivery and acceptance by the customer. For some of its locations, the Company has customer loyalty programs where retail customers accumulate points based on their level of spending and use these points for discounts on cannabis and cannabis related products. These points are recorded as a contract liability until customers redeem their points for discounts. In addition, the Company records a performance obligation as a reduction of revenue based on the estimated probability of point redemption, which is calculated based on a standalone selling price and using historical redemption rates. Upon redemption, the loyalty program obligation is relieved and the offset is recorded as revenue. In the event of a product recall, the expected value method is utilized to estimate the financial impact and a reduction of revenue is recorded. See Note 13 for additional information on revenue and loyalty programs.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and are included in Selling, general and administrative expenses in the accompanying Consolidated Statements of Operations and totaled $7.4 million and $8.1 million for the years ended December 31, 2023 and 2022, respectively.
Excise Tax	Excise Tax The Company recognizes excise tax and community benefit fees as Cost of goods sold or Selling, general and administrative expense based on whether the tax is generated on production of cannabis or as part of selling costs, respectively.
Share-Based Compensation	Share-Based Compensation The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. For awards with performance conditions, compensation expense is recognized over the service period of awards and adjusted for the probability of achievement of performance-based goals. Expected forfeitures are applied to awards using an expected forfeiture rate that is calculated annually. The expected forfeiture rate is reviewed quarterly and an updated forfeiture rate will be applied to all outstanding awards if there has been a material change to the rate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For share-based payments granted to non-employees, the compensation expense is measured at the fair value of the equity instrument on the grant date. See Note 9 for additional information on share-based compensation.
Variable Interest Entities	Variable Interest Entities A variable interest entity (“VIE”) is an entity that does not have sufficient equity at risk to finance its activities without additional subordinated financial support or is structured such that equity investors lack the ability to control the entity’s activities or do not substantially participate in the gains and losses of the entity. Upon inception of a contractual agreement, and thereafter, if a reconsideration event occurs, the Company performs an assessment to determine whether the arrangement contains a variable interest in an entity and whether that entity is a VIE. The primary beneficiary of a VIE is the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Under ASC 810 Consolidations , where the Company concludes that it is the primary beneficiary of a VIE, the Company consolidates the financial results of the entity. See Note 18 for additional information on VIEs.
Business Combinations and Assets Held for Sale	Business Combinations and Assets and Liabilities Held for Sale A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for by applying the acquisition method. The total consideration transferred in a business combination is the sum of the fair values of assets transferred, liabilities assumed, equity interests and other consideration issued by the acquirer in exchange for control of the acquiree. The acquisition date is the date on which the Company obtains control of the acquiree. The identifiable assets acquired, and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where ASC 805 Business Combinations provides exceptions to recording the amounts at fair value. Preliminary balances recorded are subject to change during the measurement period which will conclude at the earlier of the date the Company receives the information it was seeking about facts and circumstances that existed as of the acquisition date, learns that more information is not obtainable or one year following the acquisition date. Acquisition costs of the acquirer are expensed to profit or loss; acquisition costs of the acquiree paid by the acquirer may comprise a portion of consideration transferred. Non-controlling interest in the acquiree, if any, is recognized at fair value. The Company classifies an asset or disposal group as held for sale in accordance with ASC 360 Property, Plant and Equipment, when the following criteria are met: • management, having the authority to approve the action, commits to a plan to sell the asset (disposal group); • the asset (disposal group) is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets (disposal groups); • an active program to locate a buyer and other actions required to complete the plan to sell the asset (disposal group) have been initiated; • the sale of the asset (disposal group) is probable, and transfer of the asset (disposal group) is expected to qualify for recognition as a completed sale, within one year; • the asset (disposal group) is being actively marketed for sale at a price that is reasonable in relation to its current fair value; • actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.
Loss Per Share	Loss Per Share Loss per share (“EPS”) is calculated by dividing the net earnings or loss attributable to shareholders by the weighted-average shares outstanding during the period. The Company presents basic and diluted EPS in the Consolidated Statements of Operations. Basic EPS is calculated by dividing the profit or loss attributable to shareholders by the weighted-average number of shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to shareholders and the weighted-average number of shares outstanding for the effects of all dilutive potential shares, which are comprised of redeemable Cresco Labs, LLC shares (“Redeemable Units”); stock options, and restricted stock units (“RSUs”) issued. Shares with anti-dilutive impacts are excluded from the calculation. The number of shares included with respect to Redeemable Units, stock options, and RSUs is computed using the treasury stock method. See Note 10 for additional information on Loss Per Share.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements under GAAP requires management to make estimates, judgments and assumptions about the carrying amounts of certain assets and liabilities. Estimates and related assumptions are based on historical experience and other relevant factors. Actual results may differ from these estimates.
Newly Adopted Accounting Pronouncements	Newly Adopted Accounting Pronouncements The Company did not adopt any new accounting pronouncements during the year ended December 31, 2023.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) — Improvements to Income Tax Disclosures . The ASU expands disclosures in an entity’s income tax rate reconciliation table and regarding cash taxes paid both in the U.S. and foreign jurisdictions. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. Early adoption is permitted. The amendments should be applied on a prospective basis with retrospective application permitted. The Company is currently assessing the impact of the disclosure requirements on our consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) — Improvements to Reportable Segment Disclosures . This ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Early adoption is permitted. A public entity should apply the amendments in this ASU retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact of the disclosure requirements on its consolidated financial statements. In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commission's (“SEC”) Disclosure Update and Simplification Initiative . The amendments in this update represent changes to clarify or improve disclosure and presentation requirements of a variety of Topics in the ASC. The amendments should be applied on a prospective basis and allow users to more easily compare entities subject to SEC's existing disclosure with those entities that were not previously subject to the SEC's requirements. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently accessing the impact on our consolidated financial statements.
Reclassifications	Reclassifications As of December 31, 2022, $17.2 million of current portion lease liabilities were reclassified to non-current leases liabilities, and $7.8 million of short-term borrowings of financing liabilities were reclassified to long-term notes and loans payable as disclosed on the Consolidated Balance Sheets and the notes hereto. Certain amounts from unaudited prior interim periods have also been reclassified to conform with the report classifications of the current period. The current portion of lease liabilities were reduced by $17.4 million, $17.1 million and $15.9 million, as of March 31, 2023, June 30, 2023, and September 30, 2023, respectively. Non-current lease liabilities were increased by the same amounts for each respective period. Short-term borrowings were reduced by $7.5 million, $7.2 million and $6.8 million as of March 31, 2023, June 30, 2023, and September 30, 2023, respectively. Long-term notes and loans payable were increased by the same amounts for each respective period. The reclassifications had no effect on previously reported total current assets, total liabilities, total shareholders' equity, retained earnings, Consolidated Statements of Operations or Consolidated Statements of Cash Flows. Separately presented, as of December 31, 2022, the Company broke out Additional paid-in-capital balances previously included in Share Capital on the Consolidated Balance Sheets and Consolidated Statements of Changes in Shareholders' Equity. The reclassifications had no effect on total liabilities and shareholders' equity.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Summary of Significant Investments in Subsidiaries	The following are Cresco Labs’ wholly-owned or controlled entities as of December 31, 2023: Entity Location Purpose Percentage Cresco Labs Inc. British Columbia, Canada Parent Company Cali-Antifragile Corp. California Holding Company 100% River Distributing Co., LLC California Holding Company 100% Sonoma's Finest fka FloraCal California Cultivation 100% Cub City, LLC California Cultivation 100% CRHC Holdings Corp. Ontario, Canada Holding Company 100% Cannroy Delaware Inc. Delaware Holding Company 100% High Road Holdings LLC Delaware Holding Company 100% Laurel Harvest Labs, LLC Pennsylvania Cultivation and Dispensary Facility 100% JDRC Mount Joy, LLC Illinois Holding Company 100% JDRC Scranton, LLC Illinois Holding Company 100% Bluma Wellness Inc. British Columbia, Canada Holding Company 100% Cannabis Cures Investments, LLC Florida Holding Company 100% 3 Boys Farm, LLC Florida Cultivation, Production and Dispensary Facility 100% Farm to Fresh Holdings, LLC Florida Holding Company 100% Cresco U.S. Corp. Illinois Holding Company 100% MedMar Inc. Illinois Holding Company 100% MedMar Lakeview, LLC Illinois Dispensary 88% MedMar Rockford, LLC Illinois Dispensary 75% Gloucester Street Capital, LLC New York Holding Company 100% Valley Agriceuticals, LLC New York Cultivation, Production and Dispensary Facility 100% Valley Agriceuticals Real Estate New York Holding Company 100% JDRC Ellenville, LLC Illinois Holding Company 100% CMA Holdings, LLC Illinois Holding Company 100% BL Real Estate, LLC Massachusetts Holding Company 100% BL Pierce, LLC Massachusetts Holding Company 100% BL Uxbridge, LLC Massachusetts Holding Company 100% BL Main, LLC Massachusetts Holding Company 100% BL Burncoat, LLC Massachusetts Holding Company 100% BL Framingham, LLC Massachusetts Holding Company 100% BL Worcester, LLC Massachusetts Holding Company 100% Cultivate Licensing LLC Massachusetts Holding Company 100% Cultivate Worcester, Inc. Massachusetts Dispensary 100% Cultivate Leicester, Inc. Massachusetts Cultivation, Production and Dispensary Facility 100% Cultivate Framingham, Inc. Massachusetts Dispensary 100% Cultivate Cultivation, LLC Massachusetts Cultivation and Production Entity 100% GoodNews Holdings, LLC Illinois Licensing Company 100% Wonder Holdings, LLC Illinois Licensing Company 100% JDRC Seed, LLC Illinois Educational Company 100% CP Pennsylvania Holdings, LLC Illinois Holding Company 100% Bay, LLC Pennsylvania Dispensary 100% Bay Asset Management, LLC Pennsylvania Holding Company 100% Ridgeback, LLC Colorado Holding Company 100% Encanto Green Cross Dispensary, LLC Arizona Holding Company 100% Cresco Labs Texas, LLC Texas Holding Company 100% Cresco Labs, LLC Illinois Operating Entity 62% Cresco Labs Ohio, LLC Ohio Cultivation, Production and Dispensary Facility 99% Entity Location Purpose Percentage Cresco Labs Notes Issuer, LLC Illinois Holding Company Wellbeings, LLC Delaware CBD Wellness Product Development 100% Cresco Labs SLO, LLC California Holding Company 100% SLO Cultivation Inc. California Holding Company 80% Cresco Labs Joliet, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Kankakee, LLC Illinois Cultivation and Production Facility 100% Cresco Labs Logan, LLC Illinois Cultivation and Production Facility 100% Cresco Labs PA, LLC Illinois Holding Company 100% Cresco Yeltrah, LLC Pennsylvania Cultivation, Production and Dispensary Facility 100% Strip District Education Center Pennsylvania Holding Company 100% AFS Maryland, LLC Maryland Holding Company 100% JDC Newark, LLC Ohio Holding Company 100% Verdant Creations Newark, LLC Ohio Dispensary 100% Strategic Property Concepts, LLC Ohio Holding Company 100% JDC Marion, LLC Ohio Holding Company 100% Verdant Creations Marion, LLC Ohio Dispensary 100% Strategic Property Concepts 4, LLC Ohio Holding Company 100% JDC Chillicothe, LLC Ohio Holding Company 100% Verdant Creations Chillicothe, LLC Ohio Dispensary 100% Strategic Property Concepts 5, LLC Ohio Holding Company 100% JDC Columbus, LLC Ohio Holding Company 100% Care Med Associates, LLC Ohio Dispensary 100% Arizona Facilities Supply, LLC Arizona Holding Company 100% Cresco Labs TINAD, LLC Illinois Holding Company 100% TINAD, LLC Illinois Holding Company 100% PDI Medical III, LLC Illinois Dispensary 100% Cresco Labs Phoenix Farms, LLC Illinois Holding Company 100% Phoenix Farms Partners, LLC Illinois Holding Company 100% Phoenix Farms of Illinois Asset Management, LLC Illinois Holding Company 100% Phoenix Farms of Illinois, LLC Illinois Dispensary 100% JDC Elmwood, LLC Illinois Holding Company 100% FloraMedex, LLC Illinois Dispensary 100% Cresco Edibles, LLC Illinois Holding Company 100% TSC Cresco, LLC Illinois Licensing 75% Cresco HHH, LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cresco Labs Nevada, LLC Nevada Holding Company 100% Cresco Labs Michigan Management, LLC Michigan Holding Company 100% Cresco Labs Missouri Management, LLC Missouri Holding Company 100% JDRC Acquisitions, LLC Illinois Holding Company 100% JDRC 7841 Grand LLC Illinois Holding Company 100% JDRC Lincoln, LLC Illinois Holding Company 100% JDRC Danville, LLC Illinois Holding Company 100% JDRC Kankakee, LLC Illinois Holding Company 100% JDRC Brookville, LLC Illinois Holding Company 100% Cresco Labs Michigan, LLC (a) Michigan Cultivation and Production Facility 85% (a) Legally, Cresco Labs Michigan, LLC is 85% owned by related parties of the Company.
Summary of Property and Equipment	Category Estimated Leasehold Improvements 1 - 15 years Machinery and Equipment 5 - 15 years Furniture and Fixtures 3 - 7 years Vehicles 5 years Website and Software 3 years Computer Equipment 3 - 5 years Buildings and Building Improvements 5 - 39 years Property and equipment consisted of the following: ($ in thousands) December 31, 2023 December 31, 2022 Land and Buildings $ 207,194 $ 176,594 Machinery and Equipment 41,928 39,928 Furniture and Fixtures 37,912 28,724 Leasehold Improvements 173,614 142,880 Website, Computer Equipment and Software 11,124 10,232 Vehicles 2,892 3,552 Construction In Progress 14,483 55,507 Total property and equipment, gross 489,147 457,417 Less: Accumulated depreciation (120,839) (77,695) Total property and equipment, net $ 368,308 $ 379,722
Summary of Intangible Assets	Intangible assets are amortized over the following terms: Category Estimated Customer Relationships 7 - 8 years Non-Compete Agreements 2 - 5 years Trade Names 10 years Permit Application Fees 1 - 2 years Intangible assets consisted of the following as of: December 31, 2023 ($ in thousands) Gross Carrying Amount Accumulated Amortization Net Definite-Lived Intangible Assets Customer Relationships $ 31,000 $ (11,623) $ 19,377 Trade Names 2,100 (1,680) 420 Permit Application Costs 17,351 (15,980) 1,371 Other Intangibles (a) 6,013 (5,886) 127 Indefinite-Lived Intangible Assets Licenses 275,671 — 275,671 Total Intangible Assets $ 332,135 $ (35,169) $ 296,966 (a) Other Intangibles includes non-compete agreements, non-solicitation agreements and related amortization. December 31, 2022 ($ in thousands) Gross Carrying Amount Accumulated Amortization Net Definite-Lived Intangible Assets Customer Relationships $ 31,879 $ (8,127) $ 23,752 Trade Names 2,100 (1,610) 490 Permit Application Costs 15,027 (13,897) 1,130 Other Intangibles (a) 6,284 (5,573) 711 Indefinite-Lived Intangible Assets Licenses 381,507 — 381,507 Total Intangible Assets $ 436,797 $ (29,207) $ 407,590 (a) Other Intangibles includes non-compete agreements, non-solicitation agreements and related amortization. The following table reflects the amortization expense related to intangible assets for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Amortization expense included in selling, general and administrative expense $ 3,699 $ 6,915 Amortization expense included in cost of goods sold and ending inventory 3,347 3,444 Total amortization expense $ 7,046 $ 10,359

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2023
Inventory [Abstract]
Summary of Inventory	Inventory as of December 31, 2023 and 2022, consisted of the following: December 31, December 31, ($ in thousands) 2023 2022 Raw materials $ 12,649 $ 36,233 Raw materials - non-cannabis 17,937 26,709 Work-in-process 51,538 41,164 Finished goods 25,665 30,502 Total Inventory $ 107,789 $ 134,608

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, plant and equipment [abstract]
Summary of Property and Equipment	Category Estimated Leasehold Improvements 1 - 15 years Machinery and Equipment 5 - 15 years Furniture and Fixtures 3 - 7 years Vehicles 5 years Website and Software 3 years Computer Equipment 3 - 5 years Buildings and Building Improvements 5 - 39 years Property and equipment consisted of the following: ($ in thousands) December 31, 2023 December 31, 2022 Land and Buildings $ 207,194 $ 176,594 Machinery and Equipment 41,928 39,928 Furniture and Fixtures 37,912 28,724 Leasehold Improvements 173,614 142,880 Website, Computer Equipment and Software 11,124 10,232 Vehicles 2,892 3,552 Construction In Progress 14,483 55,507 Total property and equipment, gross 489,147 457,417 Less: Accumulated depreciation (120,839) (77,695) Total property and equipment, net $ 368,308 $ 379,722
Depreciation Expense Related To Property And Equipment	The following table reflects depreciation expense related to property and equipment: ($ in thousands) December 31, 2023 December 31, 2022 Depreciation expense included in selling, general and administrative expense $ 18,475 $ 11,255 Depreciation expense included in cost of goods sold and ending inventory 35,716 29,847 Total depreciation expense $ 54,191 $ 41,102

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Lease liabilities [abstract]
Summary of Lease Balances	The following table reflects the Company’s lease balances within the Consolidated Balance Sheets: ($ in thousands) December 31, 2023 December 31, 2022 ROU assets $ 117,882 $ 128,264 Current portion of lease liabilities (a) 9,416 8,959 Non-current lease liabilities (a) 163,811 173,345 (a) December 31, 2022 balances have been reclassified to reflect current year presentation changes. See “Reclassifications” in Note 2 for further discussion.
Summary of Lease Expense	The following tables reflects the components of lease expense included in the Consolidated Statements of Operations: ($ in thousands) December 31, 2023 December 31, 2022 Lease depreciation expense included in selling, general and administrative expense $ 2,364 $ 2,466 Lease depreciation expense included in cost of goods sold and ending inventory 50 289 Total finance lease depreciation expense $ 2,414 $ 2,755 Rent expense included in selling, general and administrative expense $ 12,523 $ 9,919 Rent expense included in cost of goods sold 15,492 12,808 Total rent expense - operating leases $ 28,015 $ 22,727 Short-term rent expense included in selling, general and administrative expense $ 465 $ 627 Interest expense - leases $ 3,513 $ 3,952
Summary of Maturities of Lease Liabilities	As of December 31, 2023, maturities of lease liabilities were as follows: ($ in thousands) Total Operating Leases Finance 2024 $ 33,299 $ 28,417 $ 4,882 2025 33,973 28,953 5,020 2026 34,365 29,219 5,146 2027 34,606 29,373 5,233 2028 34,477 29,353 5,124 Thereafter 179,586 161,249 18,337 Total lease payments $ 350,306 $ 306,564 $ 43,742 Less: imputed interest (173,769) (154,594) (19,175) Less: tenant improvement allowance (3,310) (2,865) (445) Present value of lease liabilities 173,227 149,105 24,122 Less: current lease liabilities (9,416) (7,677) (1,739) Present value of long-term lease liabilities $ 163,811 $ 141,428 $ 22,383
Summary of Maturities of Financial Liabilities	As of December 31, 2023, maturities of financing liabilities were as follows: ($ in thousands) Financing Liabilities 2024 $ 13,534 2025 13,873 2026 14,221 2027 14,578 2028 14,944 Thereafter 96,893 Total financing payments $ 168,043 Less: interest (72,432) Less: tenant improvement allowance (94) Present value of financing liabilities $ 95,517 Less: short-term financing liabilities (2,004) Present value of long-term financing liabilities $ 93,513
Summary of Other Information Related To Leases	Other information related to leases as of and for the years ended December 31, 2023 and 2022 was as follows: 2023 2022 ($ in thousands) Operating Leases Finance Leases Operating Leases Finance Leases Right-of-use assets $ 100,249 $ 17,633 $ 106,127 $ 22,137 Lease liabilities (current) 1 $ 7,677 $ 1,739 $ 7,274 $ 1,685 Lease liabilities (non-current) 1 $ 141,428 $ 22,383 $ 145,445 $ 27,900 Weighted- average remaining lease term 2 11.0 9.6 11.9 10.4 Weighted-average discount rate 15.0 % 14.0 % 14.5 % 13.6 % 1 December 31, 2022 balances have been updated to reflect current year presentation changes. See “Reclassifications” in Note 2 for further discussion. 2 Weighted-average remaining lease term does not include extensions which the Company is not reasonably certain to enter into.
Summary of Lease Cost	Cash paid for amounts included in the measurement of lease liabilities for the years ended December 31, 2023 and 2022 are as follows: ($ in thousands) 2023 2022 Interest paid on finance leases $ 3,470 $ 3,877

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2023
Investment property [abstract]
Summary of Investments at Fair Value	The following is a summary of the investments held at fair value as of December 31, 2023 and December 31, 2022: December 31, December 31, ($ in thousands) 2023 2022 420 Capital $ 68 $ 68 Lighthouse 81 339 Two Roots Brewing Co. — 93 Old Pal 532 592 IMC 49 136 Total Investments $ 730 $ 1,228

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2023
Intangible assets and goodwill [abstract]
Summary of Intangible Assets	Intangible assets are amortized over the following terms: Category Estimated Customer Relationships 7 - 8 years Non-Compete Agreements 2 - 5 years Trade Names 10 years Permit Application Fees 1 - 2 years Intangible assets consisted of the following as of: December 31, 2023 ($ in thousands) Gross Carrying Amount Accumulated Amortization Net Definite-Lived Intangible Assets Customer Relationships $ 31,000 $ (11,623) $ 19,377 Trade Names 2,100 (1,680) 420 Permit Application Costs 17,351 (15,980) 1,371 Other Intangibles (a) 6,013 (5,886) 127 Indefinite-Lived Intangible Assets Licenses 275,671 — 275,671 Total Intangible Assets $ 332,135 $ (35,169) $ 296,966 (a) Other Intangibles includes non-compete agreements, non-solicitation agreements and related amortization. December 31, 2022 ($ in thousands) Gross Carrying Amount Accumulated Amortization Net Definite-Lived Intangible Assets Customer Relationships $ 31,879 $ (8,127) $ 23,752 Trade Names 2,100 (1,610) 490 Permit Application Costs 15,027 (13,897) 1,130 Other Intangibles (a) 6,284 (5,573) 711 Indefinite-Lived Intangible Assets Licenses 381,507 — 381,507 Total Intangible Assets $ 436,797 $ (29,207) $ 407,590 (a) Other Intangibles includes non-compete agreements, non-solicitation agreements and related amortization. The following table reflects the amortization expense related to intangible assets for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Amortization expense included in selling, general and administrative expense $ 3,699 $ 6,915 Amortization expense included in cost of goods sold and ending inventory 3,347 3,444 Total amortization expense $ 7,046 $ 10,359
Estimated amortization expense of intangible assets	The following table outlines the estimated amortization expense related to intangible assets as of December 31, 2023: ($ in thousands) Estimated Amortization 2024 $ 5,339 2025 4,173 2026 3,877 2027 3,272 2028 2,962 Thereafter 1,672 Total estimated amortization $ 21,295
Changes In Carrying Amount Of Goodwill	The changes in carrying amount of goodwill are as follows: ($ in thousands) Total Balance at January 1, 2022 $ 446,767 Impairment (117,024) Measurement period adjustments 812 Balance at December 31, 2022 330,555 Impairment (50,858) Balance at December 31, 2023 $ 279,697

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2023
Share Capital [Abstract]
Summary of Issued And Outstanding Shares	As of December 31, 2023 and 2022, issued and outstanding shares and units consisted of the following: (shares in thousands) Redeemable SVS* PVS** MVS SSVS*** Beginning balance, January 1, 2022 109,441 269,971 20,667 500 1 Options and warrants exercised — 1,279 — — — RSUs issued — 337 — — — Issuance of shares related to acquisitions — 5,339 — — — Cresco LLC redemptions (3,335) 3,335 — — — PVS converted to SVS — 585 (585) — — Issuances related to employee taxes on certain share-based payment arrangements — 148 — — — Share issuances — — — — — Ending balance, December 31, 2022 106,106 280,994 20,082 500 1 RSUs issued — 1,727 — — Issuance of shares related to settlement of acquisition contingent consideration — 27,091 — — — Cresco LLC redemptions (9,407) 9,407 — — — PVS converted to SVS — 1,132 (1,132) — — Issuances related to employee taxes on certain share-based payment arrangements — 406 — — — Share issuances — — — — 1 Ending balance, December 31, 2023 96,699 320,757 18,950 500 2 *SVS includes shares pending issuance or cancellation **PVS presented on an “as-converted” basis to SVS (1-to-200) ***SSVS presented on an “as-converted” basis to SVS (1-to-0.00001)
Summary of Company Issued Shares In Conjunction With Acquisitions	During the years ended December 31, 2023 and 2022, the Company issued shares in conjunction with certain acquisitions* as follows: (in thousands) Acquisition date SVS shares issued Equity-based consideration Year Ended December 31, 2023 Laurel Harvest - Contingent Consideration December 09, 2021 27,091 $ 47,238 Year Ended December 31, 2022 Cultivate - Contingent Consideration September 02, 2021 5,340 $ 34,708 *Laurel Harvest, LLC (“Laurel Harvest”) and Cultivate Licensing, LLC (“Cultivate”)
Summary Of Warrants Outstanding	A summary of the status of the warrants outstanding is as follows: ($ in thousands) Number of warrants* Weighted average exercise price Balance as of January 1, 2022 9,842 $ 9.63 Exercised (12) 4.24 Forfeited (9,830) 9.54 Balance as of December 31, 2022 — $ — *PVS presented on an “as-converted” basis to SVS (1-to-200)
Summary of Noncontrolling Interest And Intercompany Eliminations	As of and for the year ended December 31, 2023, non-controlling interest included the following amounts: ($ in thousands) TSC Cresco, LLC MedMar MedMar Cresco SLO Cultivation Cresco Labs Michigan, LLC 4 Cresco Labs, LLC 1,3 Non-current assets $ 2,943 $ 28,678 $ 22,594 $ 14,703 $ 1,045 $ 30,508 $ 255,947 Current assets (8,159) 84,571 132,198 6,544 11,502 15,300 (157,691) Non-current liabilities — (10,787) (3,551) (13,674) — (26,015) (562,580) Current liabilities 45,054 (47,928) (57,388) (8,213) (49,954) (49,812) 329,160 Net assets $ 39,838 $ 54,534 $ 93,853 $ (640) $ (37,407) $ (30,019) $ (135,164) Net assets attributable to NCI $ 2,401 $ 4,150 $ 10,368 $ (156) $ (12,824) $ (258) $ (81,306) Revenue $ 1,664 $ 11,701 $ 18,657 $ 2,567 $ — $ 6,271 $ 92,266 Gross profit 863 7,623 12,323 (473) (335) 1,503 48,207 Net income (loss) $ 188 $ 4,768 $ 10,060 $ (2,450) $ (246) $ 43 $ (1,794) Net income (loss) allocated to NCI $ 47 $ 591 $ 2,515 $ (29) $ (49) $ 6 $ (879) NCI percentage at December 31, 2023 25.0 % 1 12.4 % 2 25.0 % 2 1.2 % 1 20.0 % 1 15.0 % 1 38.3 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 38.3% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments. 4 As of June 30, 2023, Cresco Labs Michigan, LLC net assets grew to a balance that exceeded the life-to-date capital contributions made by Cresco Labs Inc. As a result, the Company began recording NCI related to Cresco Labs Michigan, LLC. As of and for the year ended December 31, 2022, non-controlling interest included the following amounts: ($ in thousands) TSC Cresco, LLC MedMar MedMar Cresco SLO Cultivation Inc. Cresco Labs, LLC 1,3 Non-current assets $ 4,788 $ 31,151 $ 22,700 $ 16,736 $ 5,376 $ 286,360 Current assets (6,875) 34,706 114,843 8,144 13,097 802,774 Non-current liabilities — (10,889) (3,850) (12,515) (2,728) (538,816) Current liabilities 26,600 (13,438) (41,111) (5,768) (50,722) (594,052) Net assets $ 24,513 $ 41,530 $ 92,582 $ 6,597 $ (34,977) $ (43,734) Net assets attributable to NCI $ 4,190 $ 3,979 $ 7,468 $ (32) $ (12,434) $ (42,527) Revenue $ 10,582 $ 53,259 $ 88,645 $ 8,650 $ (24) $ 469,505 Gross profit 12,500 35,485 62,503 1,338 (10,769) 248,472 Net income (loss) $ 19,290 $ 13,322 $ 43,500 $ (4,933) $ (16,458) $ (38,863) Net income (loss) allocated to NCI $ 4,822 $ 1,652 $ 10,875 $ (49) $ (3,292) $ (16,323) NCI percentage at 25.0 % 1 12.4 % 2 25.0 % 2 1.2 % 1 20.0 % 1 42.0 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 42.0% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments. The effects of changes in the Company's ownership interests in less than 100% owned subsidiaries during the years ended December 31, 2023 and 2022 were as follows: ($ in thousands) 2023 2022 Net loss attributable to Cresco Labs Inc. $ (175,522) $ (212,047) Changes in Cresco Labs Inc. equity due to redemptions of Cresco Labs, LLC shares: Share Capital 16,027 17,438 Accumulated Deficit (21,815) (17,169) Total change from net loss attributable to Cresco Labs Inc. and change in ownership interest in Cresco Labs, LLC. $ (181,310) $ (211,778)

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangements [Abstract]
Summary of the status of the stock options outstanding	A summary of the status of the stock options outstanding consisted of the following: (Options and intrinsic value in thousands) Number of stock options outstanding Weighted-average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic value Outstanding – January 1, 2023 25,528 $ 5.00 7.54 $ 921 Granted 3,478 1.72 Exercised — — Forfeited (4,903) 5.43 Outstanding - December 31, 2023 24,103 $ 4.45 6.60 $ 328 Exercisable - December 31, 2023 15,989 $ 4.27 5.75 $ 328
Summary of weighted average grant date fair value and intrinsic value of options exercised	The following table summarizes the weighted average grant date fair value and total intrinsic value of options exercised for the years ended December 31, 2023 and 2022: (Per share) 2023 2022 Weighted average grant date fair value of stock option units granted $ 1.21 $ 2.59 Intrinsic value of stock option units exercised, using market price at exercise date $ — $ 5,106
Summary of fair value of stock options granted under the plan	The fair value of stock options granted under the Plan during the years ended December 31, 2023 and 2022, was determined using the Black-Scholes option-pricing model with the following range of assumptions at the time of the grant: 2023 2022 Risk-free annual interest rate 3.7% to 4.0% 1.4% to 3.0% Expected annual dividend yield 0% 0% Expected stock price volatility 77.0% to 82.8% 74.9% to 80.4% Expected life of stock options 5.0 to 7.0 years 5.5 to 7.0 years Forfeiture rate 7.2% to 34.0% 7.2% to 28.0% Fair value at grant date $0.94 to $1.52 $1.23 to $4.90 Stock price at grant date $1.35 to $2.01 $1.81 to $6.91 Exercise price range $1.35 to $2.01 $1.81 to $6.91
Summary of outstanding restricted stock units	A summary of outstanding RSUs is provided below: (Shares in thousands) Number of RSUs outstanding Weighted-average fair value Outstanding – January 1, 2023 4,258 $ 5.71 Granted 6,347 1.77 Vested and settled (1,769) 1.91 Forfeited (1,974) 3.20 Outstanding - December 31, 2023 6,862 $ 2.91
Summary of total fair value of restricted stock units vested	The following table summarizes the total fair value of RSUs vested for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Total fair value of RSUs vested, using market price at vest date $ 3,373 $ 2,396
Summary of expense from share-based payment transactions with employees	The following table sets forth the classification of share-based compensation expense related to options awards for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Cost of goods sold $ 1,059 $ 1,984 Selling, general and administrative expense 6,025 11,749 Total share-based compensation expense for option awards $ 7,084 $ 13,733 The following table sets forth the classification of share-based compensation expense related to RSU awards for years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Cost of goods sold $ 1,352 $ 2,097 Selling, general and administrative expense 6,899 7,914 Total share-based compensation expense for RSU awards $ 8,251 $ 10,011

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Earnings per share	The following is a reconciliation for the calculation of basic and diluted loss per share: December 31, 2023 December 31, 2022 ($ in thousands, except shares and per share amounts) Numerator: Net loss $ (179,852) $ (215,843) Less: Net income attributable to non-controlling interests, net of tax (4,330) (3,796) Net loss attributable to Cresco Labs Inc. $ (175,522) $ (212,047) Denominator: Weighted-average basic and diluted shares outstanding 323,819,766 298,161,665 Loss per Share: Basic and diluted loss per share $ (0.54) $ (0.71)
Antidilutive securities	Potentially dilutive shares as of December 31, 2023 and 2022, consisted of the following: Year Ended (shares in thousands) 2023 2022 Redeemable Units 96,699 107,443 Options 24,103 25,528 RSUs 6,862 4,182 Total potentially dilutive shares 127,664 137,153

Acquisitions And Dispositions (

Acquisitions And Dispositions (Tables)	12 Months Ended
	Dec. 31, 2023
Business Combinations And Discontinued Operations [Abstract]
Summary of deferred consideration and contingent consideration classified as short term	The following is a summary of Deferred consideration, short-term balances as of December 31, 2023 and December 31, 2022: ($ in thousands) December 31, 2023 December 31, 2022 Laurel Harvest deferred consideration, short-term $ — $ 47,821 Total Deferred consideration, short-term $ — $ 47,821
Summary of long-term deferred consideration	The following is a summary of Deferred consideration, long-term as of December 31, 2023 and December 31, 2022: ($ in thousands) December 31, 2023 December 31, 2022 Valley Agriceuticals, LLC (“Valley Ag”) operating cash flows deferred consideration $ 6,577 $ 7,770 Total Deferred consideration, long-term $ 6,577 $ 7,770

Long-term Notes and Loans Pay_2

Long-term Notes and Loans Payable, Net - (Tables)	12 Months Ended
	Dec. 31, 2023
Borrowings [abstract]
Summary of Loans Payable Balances is Follows	The following table represents the Company’s Long-term notes and loans payable, net balances as of December 31, 2023 and December 31, 2022: ($ in thousands) 2023 2022 Senior Loan $ 400,000 $ 400,000 Mortgage Loans 20,160 — Short-term borrowings and interest payable 9,813 9,500 Financing liability 95,698 96,917 Total borrowings and interest payable $ 525,671 $ 506,417 Less: Unamortized debt issuance costs (16,141) (18,550) Less: Short-term borrowings and interest payable (9,813) (9,500) Less: Current portion of financing liability 1 (2,004) (1,476) Total Long-term notes and loans payable, net $ 497,713 $ 476,891 1 December 31, 2022 balance have been updated to reflect current year presentation changes. See “Reclassifications” in Note 2 for further discussion.

Revenues and Loyalty Programs (

Revenues and Loyalty Programs (Tables)	12 Months Ended
	Dec. 31, 2023
Revenue [abstract]
Summary of Disaggregated Revenue by Source	The following table represents the Company’s disaggregated revenue by source, due to the Company’s contracts with its customers, for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Wholesale $ 306,363 $ 367,222 Dispensary 464,522 475,459 Total Revenues $ 770,885 $ 842,681

Other Income , Net (Tables)

Other Income , Net (Tables)	12 Months Ended
	Dec. 31, 2023
Other Operating Income (Expense) [Abstract]
Summary of Other Income (Expense), Net	For the years ended December 31, 2023 and 2022, Other income, net consisted of the following: ($ in thousands) 2023 2022 Unrealized gain on derivative liabilities - warrants $ — $ 1,184 Realized loss on financial instruments (94) (5,698) (Loss) gain on provision - loan receivable (314) 572 Unrealized loss on investments held at fair value (406) (4,609) Gain on disposal of assets 762 14,711 Gain on conversion of investment — 22 (Loss) gain on foreign currency (303) 931 Gain on lease termination 1,263 4,876 Other income, net 832 3,238 Total Other income, net $ 1,740 $ 15,227

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2023
Related party transactions [abstract]
Summary of Expense Resulting from the Related Party Transactions	Below is a summary of the expense resulting from the related party lease liabilities for the years ended December 31, 2023 and 2022: ($ in thousands) Classification 2023 2022 Operating Leases Lessor has minority interest in SLO Rent expense $ — $ 513 Lessor has minority interest in MedMar Rent expense 288 288 Lessor is an MVS shareholder Rent expense 1,187 1,187 Finance Leases Lessor has minority interest in MedMar Depreciation expense $ 306 $ 306 Lessor has minority interest in MedMar Interest expense 246 270 Lessor is an MVS shareholder Depreciation expense 90 81 Lessor is an MVS shareholder Interest expense 69 76
Summary of ROU Assets and Lease Liabilities Attributable to Related Party Transactions	Additionally, below is a summary of the ROU assets and lease liabilities attributable to related party leases as of December 31, 2023 and 2022: December 31, 2023 December 31, 2022 ($ in thousands) ROU Asset Lease Liability ROU Asset Lease Liability Operating Leases Lessor has minority interest in MedMar $ 1,294 $ 1,345 $ 1,415 $ 1,456 Lessor is an MVS shareholder 5,332 5,429 5,849 5,907 Finance Leases Lessor has minority interest in MedMar $ 1,729 $ 2,210 $ 2,034 $ 2,452 Lessor is an MVS shareholder 583 502 596 555

Financial Instruments And Fin_2

Financial Instruments And Financial Risk Management (Tables)	12 Months Ended
	Dec. 31, 2023
Financial Instruments [Abstract]
Financial assets measured at fair value	The following tables summarize the Company’s financial instruments as of December 31, 2023 and December 31, 2022: December 31, 2023 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 103,429 $ — $ — $ — $ 103,429 Restricted cash 1 5,091 — — — 5,091 Security deposits 2 4,408 — — — 4,408 Accounts receivable, net 51,070 — — — 51,070 Loans receivable, short-term 1,421 — — — 1,421 Loans receivable, long-term 826 — — — 826 Investments — 49 81 600 730 Financial Liabilities: Accounts payable $ 27,587 $ — $ — $ — $ 27,587 Accrued liabilities 69,079 — — — 69,079 Short-term borrowings 11,817 — — — 11,817 Current portion of lease liabilities 9,416 — — — 9,416 Lease liabilities 163,811 — — — 163,811 Deferred consideration, long-term — — — 6,577 6,577 Long-term notes and loans payable, net 497,713 — — — 497,713 Other long-term liabilities 21,600 — — — 21,600 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. December 31, 2022 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 119,341 $ — $ — $ — $ 119,341 Restricted cash 1 2,169 — — — 2,169 Security deposits 2 4,367 — — — 4,367 Accounts receivable, net 56,492 — — — 56,492 Loans receivable, short-term 447 — — — 447 Loans receivable, long-term 823 — — — 823 Investments — 136 432 660 1,228 Financial Liabilities: Accounts payable $ 28,093 $ — $ — $ — $ 28,093 Accrued liabilities 65,161 — — — 65,161 Short-term borrowings 3 10,976 — — — 10,976 Current portion of lease liabilities 3 8,959 — — — 8,959 Deferred consideration and other payables, short-term 6 7 — 47,821 47,834 Lease liabilities 3 173,345 — — — 173,345 Deferred consideration, long-term — — — 7,770 7,770 Long-term notes and loans payable, net 3 476,891 — — — 476,891 Other long-term liabilities 7,000 — — — 7,000 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. 3 Balances reflect current year presentation changes. See “Reclassifications” in Note 2 for further discussion. The following table presents a rollforward of the balance sheet amounts measured at fair value on a recurring basis and classified as Level 3. The classification of an item as Level 3 is based on inputs for assets or liabilities that are not based on observable market data. Year Ended December 31, 2023 Level 3 Fair Value Measurements ($ in thousands) Investments Deferred consideration, and other payables, short-term Deferred consideration and contingent, long-term Balance as of December 31, 2022 $ 660 $ 47,821 $ 7,770 Change in fair value recorded in Interest expense, net — 1,953 — Change in fair value recorded in Other income, net (60) — (895) Payments 1 — (50,072) — Other 2 — 298 (298) Balance as of December 31, 2023 $ 600 $ — $ 6,577 1 See Note 8 and Note 11 for additional details related to payments. 2 Other relates to reclassifications from short-term to long-term due to expecting timing of payment. See Note 11. Year Ended December 31, 2022 Level 3 Fair Value Measurements ($ in thousands) Loans receivable, short-term Investments Deferred consideration, contingent consideration, and other payables, short-term Derivative liabilities, short-term Deferred consideration and contingent, long-term Balance as of December 31, 2021 $ 565 $ 660 $ 71,816 $ 1,172 $ 17,651 Change in fair value recorded in Interest expense, net — — 900 — (881) Change in fair value recorded in Other income, net — — 5,647 (1,172) — Payments 1 (1,837) — (39,542) — — Change in fair value recorded in Selling, general and administrative 1,272 — — — — Other 2 — — 9,000 — (9,000) Balance as of December 31, 2022 $ — $ 660 $ 47,821 $ — $ 7,770 1 $39.5 million payment related to the Cultivate contingent consideration earnout. The $1.8 million payment related to Lighthouse outstanding loan receivable. 2 $9.0 million related to reclassifications from long-term to short-term due to the projected dispensary opening dates. The following is a summary of Loans receivable, short-term balances and valuation classifications (discussed further below) as of December 31, 2023 and December 31, 2022: ($ in thousands) Valuation December 31, 2023 December 31, 2022 Short-term loans receivable - Kurvana, net of ECL Amortized cost $ 493 $ 447 Short-term loans receivable - 280E, net of ECL Amortized cost 928 — Total Loans receivable, short-term $ 1,421 $ 447 ($ in thousands) Valuation December 31, 2023 December 31, 2022 Long-term loans receivable - Illinois Incubator, net of ECL Amortized cost $ 826 $ 823 Total Loans receivable, long-term $ 826 $ 823
Financial liabilities measured at fair value	The following tables summarize the Company’s financial instruments as of December 31, 2023 and December 31, 2022: December 31, 2023 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 103,429 $ — $ — $ — $ 103,429 Restricted cash 1 5,091 — — — 5,091 Security deposits 2 4,408 — — — 4,408 Accounts receivable, net 51,070 — — — 51,070 Loans receivable, short-term 1,421 — — — 1,421 Loans receivable, long-term 826 — — — 826 Investments — 49 81 600 730 Financial Liabilities: Accounts payable $ 27,587 $ — $ — $ — $ 27,587 Accrued liabilities 69,079 — — — 69,079 Short-term borrowings 11,817 — — — 11,817 Current portion of lease liabilities 9,416 — — — 9,416 Lease liabilities 163,811 — — — 163,811 Deferred consideration, long-term — — — 6,577 6,577 Long-term notes and loans payable, net 497,713 — — — 497,713 Other long-term liabilities 21,600 — — — 21,600 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. December 31, 2022 ($ in thousands) Amortized Cost Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 119,341 $ — $ — $ — $ 119,341 Restricted cash 1 2,169 — — — 2,169 Security deposits 2 4,367 — — — 4,367 Accounts receivable, net 56,492 — — — 56,492 Loans receivable, short-term 447 — — — 447 Loans receivable, long-term 823 — — — 823 Investments — 136 432 660 1,228 Financial Liabilities: Accounts payable $ 28,093 $ — $ — $ — $ 28,093 Accrued liabilities 65,161 — — — 65,161 Short-term borrowings 3 10,976 — — — 10,976 Current portion of lease liabilities 3 8,959 — — — 8,959 Deferred consideration and other payables, short-term 6 7 — 47,821 47,834 Lease liabilities 3 173,345 — — — 173,345 Deferred consideration, long-term — — — 7,770 7,770 Long-term notes and loans payable, net 3 476,891 — — — 476,891 Other long-term liabilities 7,000 — — — 7,000 1 Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. 2 Security deposits are included in “Other non-current assets” on the Consolidated Balance Sheets. 3 Balances reflect current year presentation changes. See “Reclassifications” in Note 2 for further discussion. The following table presents a rollforward of the balance sheet amounts measured at fair value on a recurring basis and classified as Level 3. The classification of an item as Level 3 is based on inputs for assets or liabilities that are not based on observable market data. Year Ended December 31, 2023 Level 3 Fair Value Measurements ($ in thousands) Investments Deferred consideration, and other payables, short-term Deferred consideration and contingent, long-term Balance as of December 31, 2022 $ 660 $ 47,821 $ 7,770 Change in fair value recorded in Interest expense, net — 1,953 — Change in fair value recorded in Other income, net (60) — (895) Payments 1 — (50,072) — Other 2 — 298 (298) Balance as of December 31, 2023 $ 600 $ — $ 6,577 1 See Note 8 and Note 11 for additional details related to payments. 2 Other relates to reclassifications from short-term to long-term due to expecting timing of payment. See Note 11. Year Ended December 31, 2022 Level 3 Fair Value Measurements ($ in thousands) Loans receivable, short-term Investments Deferred consideration, contingent consideration, and other payables, short-term Derivative liabilities, short-term Deferred consideration and contingent, long-term Balance as of December 31, 2021 $ 565 $ 660 $ 71,816 $ 1,172 $ 17,651 Change in fair value recorded in Interest expense, net — — 900 — (881) Change in fair value recorded in Other income, net — — 5,647 (1,172) — Payments 1 (1,837) — (39,542) — — Change in fair value recorded in Selling, general and administrative 1,272 — — — — Other 2 — — 9,000 — (9,000) Balance as of December 31, 2022 $ — $ 660 $ 47,821 $ — $ 7,770 1 $39.5 million payment related to the Cultivate contingent consideration earnout. The $1.8 million payment related to Lighthouse outstanding loan receivable. 2 $9.0 million related to reclassifications from long-term to short-term due to the projected dispensary opening dates.
Summary of Aging Accounts Receivables	The Company’s aging of Accounts receivables as of December 31, 2023 and December 31, 2022 was as follows: ($ in thousands) December 31, 2023 December 31, 2022 0 to 60 days $ 41,820 $ 49,303 61 to 120 days 8,117 6,118 120 days + 9,097 3,698 Total accounts receivable, gross 59,034 59,119 Allowance for doubtful accounts 7,964 2,627 Total accounts receivable, net $ 51,070 $ 56,492
Summary of Contractual Obligations	In addition to the commitments outlined in Note 16, the Company has the following contractual obligations as of December 31, 2023: ($ in thousands) < 1 Year 1 to 3 Years 3 to 5 Years > 5 Years Total Accounts payable & Accrued liabilities $ 95,817 $ — $ — $ — $ 95,817 Operating leases liabilities 28,417 58,172 58,726 161,249 306,564 Finance lease liabilities 4,882 10,166 10,357 18,337 43,742 Deferred consideration, long-term — 6,577 — — 6,577 Long-term notes and loans payable and Short-term borrowings 23,347 428,276 29,522 122,112 603,257 Tax receivable agreement liability 1,065 2,587 3,199 7,713 14,564 Other long-term liabilities — 7,886 — — 7,886 Total obligations as of December 31, 2023 $ 153,528 $ 513,664 $ 101,804 $ 309,411 $ 1,078,407

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	12 Months Ended
	Dec. 31, 2023
Variable Interest Entities [Abstract]
Summary of Assets Liabilities and Networth of Variable Interest Entities	The following table presents the summarized financial information about the Company’s consolidated variable interest entities (“VIEs”) before eliminations, which are included in the Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022. All of these entities were determined to be VIEs as the Company possesses the power to direct activities through written agreements and is subject to the risks and rewards as a primary beneficiary: December 31, 2023 December 31, 2022 ($ in thousands) Cresco Labs Michigan, LLC Cresco Labs Michigan, LLC Current assets $ 15,485 $ 17,506 Non-current assets 75,622 63,212 Current liabilities (1,476) (3,158) Non-current liabilities (124,793) (108,113) Non-controlling interests 258 — Deficit attributable to Cresco Labs Inc. 34,904 30,553
Summary of Income Expenses and Net Income Loss of Variable Interest Entities	The following table presents the summarized financial information about the Company’s consolidated VIEs before eliminations, which are included in the Consolidated Statements of Operations for the years ended December 31, 2023 and 2022: ($ in thousands) Cresco Labs Michigan, LLC Cresco Labs Michigan, LLC Revenue $ 25,046 $ 12,659 Net loss attributable to non-controlling interests (258) — Net loss attributable to Cresco Labs Inc. (4,445) (8,617) Net loss (4,703) (8,617)

Interest Expense, Net (Tables)

Interest Expense, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Interest Income (Expense) [Abstract]
Summary of Interest expense, net	Interest expense, net consisted of the following for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Interest expense – notes and loans payable (43,575) (38,528) Interest expense – financing activities (11,739) (11,887) Accretion of debt discount and amortization of deferred financing fees (4,416) (3,951) Interest expense – leases $ (3,513) $ (3,952) Interest income 2,148 679 Other interest income (expense) 1 276 (198) Total Interest expense, net $ (60,819) $ (57,837) 1 During the year ended December 31, 2023, the Company recorded $1.2 million of reductions in interest expense related to Valley Ag operating cash flows deferred consideration. See Note 11 for additional information.

Provision For Income Taxes An_2

Provision For Income Taxes And Deferred Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Summary of provision for income taxes	Provision for income taxes consists of the following for the years ended December 31, 2023 and 2022: ($ in thousands) 2023 2022 Current Federal $ 55,679 $ 69,240 State 15,858 24,341 Foreign — — Total current $ 71,537 $ 93,581 Deferred Federal $ (23,771) $ (8,332) State (18,215) (9,858) Foreign 28,749 1,190 Total deferred $ (13,237) $ (17,000) Change in valuation allowance $ (25,350) $ 12,357 Total $ 32,950 $ 88,938
Summary of components of deferred tax assets and liabilities	As of December 31, 2023 and 2022, the components of deferred tax assets and liabilities were as follows: ($ in thousands) 2023 2022 Deferred tax assets Share-based compensation $ 3,961 $ 1,381 Financing fees 453 1,291 Net operating losses 40,580 43,629 Inventory 97 346 Lease liabilities 41,088 28,362 Tax receivable agreement 15,379 315 Other 629 386 Total deferred tax assets $ 102,187 $ 75,711 Deferred tax liabilities ROU assets $ (13,689) $ (9,560) Property, plant and equipment (11,669) (12,393) Intangible assets (64,052) (84,099) Other (23,596) (1,329) Total deferred tax liabilities $ (113,006) $ (107,381) Valuation allowance $ (18,091) $ (43,442) Net deferred tax liabilities $ (28,910) $ (75,112)
Summary of reconciliation between the effective tax rate	The reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows: ($ in thousands) 2023 2022 Expected income tax expense at statutory tax rate $ (30,711) $ (26,650) Tax rate differences (69) (2,296) Pass through and non-controlling entities (4,881) (2,183) State tax expense, net (4,898) 17,209 IRC Section 280E disallowance 47,043 50,521 Uncertain tax treatment (including penalties and interest) 7,311 12,901 Share-based compensation 2,086 2,261 Goodwill impairment 10,448 25,334 Tax penalties and interest 5,552 4,155 Change in valuation allowance (25,350) 12,357 Change in state tax rates 10,317 (471) Change in state filing methods (3,940) — Canadian reorganization basis change 28,730 — Tax receivable agreement (2,919) (395) Adjustments to prior year provisions (7,003) (5,136) Other 1,235 1,332 Income tax expense $ 32,950 $ 88,938 Effective tax rate (22.4 %) (70.1 %)
Summary of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: ($ in thousands) 2023 2022 Balance at January 1 $ 12,746 $ — Additions based on tax positions related to the current year 6,054 7,380 Additions for tax positions of prior years — 5,366 Balance at the end of the year $ 18,800 $ 12,746

Nature of Operations - Addition

Nature of Operations - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2023
Nature Of Operations [Abstract]
Date of incorporation	Jul. 06, 1990

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Significant Investments in Subsidiaries (Detail)	12 Months Ended
	Dec. 31, 2023
Cali-Antifragile Corp.
Disclosure of subsidiaries [line items]
Location	California
Purpose	Holding Company
Percentage Held	100%
River Distributing Co., LLC
Disclosure of subsidiaries [line items]
Location	California
Purpose	Holding Company
Percentage Held	100%
Sonoma's Finest fka FloraCal
Disclosure of subsidiaries [line items]
Location	California
Purpose	Cultivation
Percentage Held	100%
Cub City, LLC
Disclosure of subsidiaries [line items]
Location	California
Purpose	Cultivation
Percentage Held	100%
CRHC Holdings Corp.
Disclosure of subsidiaries [line items]
Location	Ontario, Canada
Purpose	Holding Company
Percentage Held	100%
Cannroy Delaware Inc.
Disclosure of subsidiaries [line items]
Location	Delaware
Purpose	Holding Company
Percentage Held	100%
High Road Holdings LLC
Disclosure of subsidiaries [line items]
Location	Delaware
Purpose	Holding Company
Percentage Held	100%
Laurel Harvest Labs, LLC
Disclosure of subsidiaries [line items]
Location	Pennsylvania
Purpose	Cultivation and Dispensary Facility
Percentage Held	100%
JDRC Mount Joy, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
JDRC Scranton, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Bluma Wellness Inc.
Disclosure of subsidiaries [line items]
Location	British Columbia, Canada
Purpose	Holding Company
Percentage Held	100%
Cannabis Cures Investments, LLC
Disclosure of subsidiaries [line items]
Location	Florida
Purpose	Holding Company
Percentage Held	100%
3 Boys Farm, LLC
Disclosure of subsidiaries [line items]
Location	Florida
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
Farm to Fresh Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Florida
Purpose	Holding Company
Percentage Held	100%
Cresco U.S. Corp.
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
MedMar Inc.
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
MedMar Lakeview, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	88%
MedMar Rockford, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	75%
Gloucester Street Capital, LLC
Disclosure of subsidiaries [line items]
Location	New York
Purpose	Holding Company
Percentage Held	100%
Valley Agriceuticals, LLC
Disclosure of subsidiaries [line items]
Location	New York
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
Valley Agriceuticals Real Estate
Disclosure of subsidiaries [line items]
Location	New York
Purpose	Holding Company
Percentage Held	100%
JDRC Ellenville, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
CMA Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
BL Real Estate, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
BL Pierce, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
BL Uxbridge, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
BL Main, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
BL Burncoat, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
BL Framingham, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
BL Worcester, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
Cultivate Licensing LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Holding Company
Percentage Held	100%
Cultivate Worcester, Inc.
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Dispensary
Percentage Held	100%
Cultivate Leicester, Inc.
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
Cultivate Framingham, Inc.
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Dispensary
Percentage Held	100%
Cultivate Cultivation, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Cultivation and Production Entity
Percentage Held	100%
GoodNews Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Licensing Company
Percentage Held	100%
Wonder Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Licensing Company
Percentage Held	100%
JDRC Seed, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Educational Company
Percentage Held	100%
CP Pennsylvania Holdings, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Bay, LLC
Disclosure of subsidiaries [line items]
Location	Pennsylvania
Purpose	Dispensary
Percentage Held	100%
Bay Asset Management, LLC
Disclosure of subsidiaries [line items]
Location	Pennsylvania
Purpose	Holding Company
Percentage Held	100%
Ridgeback, LLC
Disclosure of subsidiaries [line items]
Location	Colorado
Purpose	Holding Company
Percentage Held	100%
Encanto Green Cross Dispensary, LLC
Disclosure of subsidiaries [line items]
Location	Arizona
Purpose	Holding Company
Percentage Held	100%
Cresco Labs Texas, LLC
Disclosure of subsidiaries [line items]
Location	Texas
Purpose	Holding Company
Percentage Held	100%
Cresco Labs, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Operating Entity
Percentage Held	62%
Cresco Labs Ohio, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	99%
Cresco Labs Notes Issuer, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held
Wellbeings, LLC
Disclosure of subsidiaries [line items]
Location	Delaware
Purpose	CBD Wellness Product Development
Percentage Held	100%
Cresco Labs SLO, LLC
Disclosure of subsidiaries [line items]
Location	California
Purpose	Holding Company
Percentage Held	100%
SLO Cultivation Inc.
Disclosure of subsidiaries [line items]
Location	California
Purpose	Holding Company
Percentage Held	80%
Cresco Labs Joliet, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Cultivation and Production Facility
Percentage Held	100%
Cresco Labs Kankakee, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Cultivation and Production Facility
Percentage Held	100%
Cresco Labs Logan, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Cultivation and Production Facility
Percentage Held	100%
Cresco Labs PA, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Cresco Yeltrah, LLC
Disclosure of subsidiaries [line items]
Location	Pennsylvania
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
Strip District Education Center
Disclosure of subsidiaries [line items]
Location	Pennsylvania
Purpose	Holding Company
Percentage Held	100%
AFS Maryland, LLC
Disclosure of subsidiaries [line items]
Location	Maryland
Purpose	Holding Company
Percentage Held	100%
JDC Newark, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
Verdant Creations Newark, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Dispensary
Percentage Held	100%
Strategic Property Concepts, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
JDC Marion, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
Verdant Creations Marion, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Dispensary
Percentage Held	100%
Strategic Property Concepts 4, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
JDC Chillicothe, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
Verdant Creations Chillicothe, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Dispensary
Percentage Held	100%
Strategic Property Concepts 5, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
JDC Columbus, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Holding Company
Percentage Held	100%
Care Med Associates, LLC
Disclosure of subsidiaries [line items]
Location	Ohio
Purpose	Dispensary
Percentage Held	100%
Arizona Facilities Supply, LLC
Disclosure of subsidiaries [line items]
Location	Arizona
Purpose	Holding Company
Percentage Held	100%
Cresco Labs TINAD, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
TINAD, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
PDI Medical III, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	100%
Cresco Labs Phoenix Farms, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Phoenix Farms Partners, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Phoenix Farms of Illinois Asset Management, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Phoenix Farms of Illinois, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	100%
JDC Elmwood, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
FloraMedex, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Dispensary
Percentage Held	100%
Cresco Edibles, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
TSC Cresco, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Licensing
Percentage Held	75%
Cresco HHH, LLC
Disclosure of subsidiaries [line items]
Location	Massachusetts
Purpose	Cultivation, Production and Dispensary Facility
Percentage Held	100%
Cresco Labs Nevada, LLC
Disclosure of subsidiaries [line items]
Location	Nevada
Purpose	Holding Company
Percentage Held	100%
Cresco Labs Michigan Management, LLC
Disclosure of subsidiaries [line items]
Location	Michigan
Purpose	Holding Company
Percentage Held	100%
Cresco Labs Missouri Management, LLC
Disclosure of subsidiaries [line items]
Location	Missouri
Purpose	Holding Company
Percentage Held	100%
JDRC Acquisitions, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
JDRC 7841 Grand LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
JDRC Lincoln, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
JDRC Danville, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
JDRC Kankakee, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
JDRC Brookville, LLC
Disclosure of subsidiaries [line items]
Location	Illinois
Purpose	Holding Company
Percentage Held	100%
Cresco Labs Michigan, LLC
Disclosure of subsidiaries [line items]
Location	Michigan
Purpose	Cultivation and Production Facility
Percentage Held	85%
Cresco Labs Michigan, LLC | Within the Management of the Company
Disclosure of subsidiaries [line items]
Percentage Held	85%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Useful Lives of Property And Equipment (Detail)	12 Months Ended
	Dec. 31, 2023
Leasehold Improvements | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	1 year
Leasehold Improvements | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	15 years
Machinery and Equipment | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	5 years
Machinery and Equipment | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	15 years
Furniture and Fixtures | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	3 years
Furniture and Fixtures | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	7 years
Vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	5 years
Website and Software | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	3 years
Computer Equipment | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	3 years
Computer Equipment | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	5 years
Buildings and Building Improvements | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	5 years
Buildings and Building Improvements | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	39 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Useful Lives of Finite Lived Intangible Assets Other Than Goodwill (Detail)	12 Months Ended
	Dec. 31, 2023
Customer Relationships | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	7 years
Customer Relationships | Top of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	8 years
Non-Compete Agreements | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	2 years
Non-Compete Agreements | Top of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	5 years
Trade Names
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	10 years
Permit Application Fees | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	1 year
Permit Application Fees | Top of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	2 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Significant Accounting Policies [Line Items]
Advertising costs				$ 7.4	$ 8.1
Current Portion Lease Liabilities Reclassified To Non-Current
Disclosure Of Significant Accounting Policies [Line Items]
Amount of reclassifications or changes in presentation	$ 15.9	$ 17.1	$ 17.4		17.2
Short-Term Borrowings Of Financing Liabilities Reclassified To Long-Term Notes And Loans Payable
Disclosure Of Significant Accounting Policies [Line Items]
Amount of reclassifications or changes in presentation	$ 6.8	$ 7.2	$ 7.5		$ 7.8

Inventory - Summary of Inventor

Inventory - Summary of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Detailed Information About Inventories [Line Items]
Work-in-process	$ 51,538	$ 41,164
Finished goods	25,665	30,502
Total Inventory	107,789	134,608
Cannabis
Disclosure of Detailed Information About Inventories [Line Items]
Raw materials	12,649	36,233
Non-Cannabis
Disclosure of Detailed Information About Inventories [Line Items]
Raw materials	$ 17,937	$ 26,709

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Inventory [Abstract]
Write-downs (reversals of write-downs) of inventories	$ 3.8	$ 7.4
Adjustment for write-downs of inventories	$ 0.7

Property And Equipment - Summar

Property And Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	$ 368,308	$ 379,722
Gross Carrying Amount
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	489,147	457,417
Gross Carrying Amount | Land and Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	207,194	176,594
Gross Carrying Amount | Machinery and Equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	41,928	39,928
Gross Carrying Amount | Furniture and Fixtures
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	37,912	28,724
Gross Carrying Amount | Leasehold Improvements
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	173,614	142,880
Gross Carrying Amount | Website, Computer Equipment and Software
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	11,124	10,232
Gross Carrying Amount | Vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	2,892	3,552
Gross Carrying Amount | Construction In Progress
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	14,483	55,507
Accumulated Amortization
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	$ (120,839)	$ (77,695)

Property And Equipment - Deprec

Property And Equipment - Depreciation Expense Related To Property And Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment	$ 54,191	$ 41,102
Selling, general and administrative expense
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment	18,475	11,255
Cost of goods sold and ending inventory
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment	$ 35,716	$ 29,847

Property And Equipment - Additi

Property And Equipment - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 01, 2022	Jul. 31, 2022	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					$ 54,191,000	$ 41,102,000
Property, plant and equipment			$ 379,722,000		368,308,000	379,722,000
Mendota Facility
Disclosure of detailed information about property, plant and equipment [line items]
Write-downs (reversals of write-downs) of property, plant and equipment					100,000
Gains on disposals of non-current assets					100,000
Encanto Green Cross Dispensary, LLC
Disclosure of detailed information about property, plant and equipment [line items]
Disposals, property, plant and equipment					2,500,000
Depreciation expense					700,000
Brookville, Pennsylvania Facility
Disclosure of detailed information about property, plant and equipment [line items]
Gains on disposals of non-current assets	$ 14,700,000
Proceeds from sales of property, plant and equipment	43,700,000
Ending Inventories
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					12,800,000	10,900,000
Ending Inventories | Cost of goods sold
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					33,900,000	28,000,000
Ending Inventories | Previously stated | Cost of goods sold
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					10,800,000	9,100,000
Land and Buildings | Florida Cultivation And Manufacturing Facility
Disclosure of detailed information about property, plant and equipment [line items]
Gains on disposals of non-current assets					900,000
Disposals, property, plant and equipment					2,100,000
Land and Buildings | Brookville, Pennsylvania Facility
Disclosure of detailed information about property, plant and equipment [line items]
Gains on disposals of non-current assets	14,700,000
Non-current assets or disposal groups classified as held for sale or as held for distribution to owners	$ 29,700,000
Leasehold Improvements | Impacted California Facilities
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment					$ 1,100,000
Leasehold Improvements | Cultivation Facility And Production Facility, California
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment				$ 2,700,000
Property, plant and equipment				0
Construction In Progress, Materials Not Used
Disclosure of detailed information about property, plant and equipment [line items]
Non-current assets or disposal groups classified as held for sale			900,000	$ 2,400,000		900,000
Proceeds from sales of property, plant and equipment		$ 900,000
Gains (losses) arising from sale of property, plant and equipment		$ (1,500,000)	600,000
Proceeds from sales of property, plant and equipment			$ 300,000
Other property, plant and equipment | Cultivation Facility And Production Facility, California
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment						$ 500,000

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)		12 Months Ended
	Sep. 01, 2022	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Leases [Line Items]
Lease depreciation capitalized		$ 0	$ 100,000
Finance lease depreciation expense		2,414,000	2,755,000
ROU Asset		117,882,000	128,264,000
Lease Liability		173,227,000
Reimbursements of tenant improvement allowance, finance and operating lease		2,500,000	3,600,000
Reimbursements of tenant improvement allowance, other financing transactions		100,000	600,000
Reimbursements of tenant improvement allowance in future periods, finance and operating lease		3,300,000
Reimbursements of tenant improvement allowance in future periods, other financing transactions		700,000
Present value of long-term financing liabilities		93,513,000	95,400,000
Interest payable		13,200,000	12,900,000
Interest expense – financing activities and sale and leasebacks		11,700,000	11,900,000
Cost of goods sold
Disclosure of Leases [Line Items]
Finance lease depreciation expense		100,000	300,000
Depreciation capitalized in inventory		100,000	100,000
Arizona Reporting Unit
Disclosure of Leases [Line Items]
Impairment of right-of-use assets			800,000
California Reporting Unit
Disclosure of Leases [Line Items]
Impairment of right-of-use assets			1,000,000
Impacted California Facilities
Disclosure of Leases [Line Items]
Gain (loss) on termination of lease		$ 1,100,000
Cultivation Facility And Production Facility, California
Disclosure of Leases [Line Items]
Gain (loss) on termination of lease			$ 4,900,000
Brookville, Pennsylvania Facility
Disclosure of Leases [Line Items]
Lease term (in years)	10 years
Proceeds from sales of property, plant and equipment	$ 43,700,000
Gains on disposals of non-current assets	14,700,000
ROU Asset	29,700,000
Lease Liability	$ 29,700,000
Bottom of range
Disclosure of Leases [Line Items]
Lease term (in years)		1 year
Lease renewal term (in years)		3 years
Lease exercise renewal options term (in years) (less than for bottom of range)		1 year
Top of range
Disclosure of Leases [Line Items]
Lease term (in years)		20 years
Lease renewal term (in years)		25 years
Lease exercise renewal options term (in years) (less than for bottom of range)		10 years

Leases - Lease Balances (Detail

Leases - Lease Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Lease liabilities [abstract]
ROU Asset	$ 117,882	$ 128,264
Current portion of lease liabilities	9,416	8,959
Non-current lease liabilities	$ 163,811	$ 173,345

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Leases [Line Items]
Finance lease depreciation expense	$ 2,414	$ 2,755
Rent expense	28,015	22,727
Interest expense - leases	3,513	3,952
Selling, general and administrative expense
Disclosure of Leases [Line Items]
Finance lease depreciation expense	2,364	2,466
Rent expense	12,523	9,919
Short-term rent expense	465	627
Cost of goods sold and ending inventory
Disclosure of Leases [Line Items]
Finance lease depreciation expense	50	289
Cost of goods sold
Disclosure of Leases [Line Items]
Finance lease depreciation expense	100	300
Rent expense	$ 15,492	$ 12,808

Leases - Summary of Maturities

Leases - Summary of Maturities of Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	$ 350,306
Less: imputed interest	(173,769)
Less: tenant improvement allowance	(3,310)
Present value of lease liabilities	173,227
Less: current lease liabilities	(9,416)	$ (8,959)
Lease liabilities	163,811	173,345
Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	306,564
Less: imputed interest	(154,594)
Less: tenant improvement allowance	(2,865)
Present value of lease liabilities	149,105
Less: current lease liabilities	(7,677)	(7,274)
Lease liabilities	141,428	145,445
Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	43,742
Less: imputed interest	(19,175)
Less: tenant improvement allowance	(445)
Present value of lease liabilities	24,122
Less: current lease liabilities	(1,739)	(1,685)
Lease liabilities	22,383	$ 27,900
2024
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	33,299
2024 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	28,417
2024 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	4,882
2025
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	33,973
2025 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	28,953
2025 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	5,020
2026
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	34,365
2026 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	29,219
2026 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	5,146
2027
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	34,606
2027 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	29,373
2027 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	5,233
2028
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	34,477
2028 | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	29,353
2028 | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	5,124
Thereafter
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	179,586
Thereafter | Operating Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	161,249
Thereafter | Finance Leases
Disclosure of Maturity Analysis of Lease Payments [Line Items]
Total lease payments	$ 18,337

Leases - Summary of Maturitie_2

Leases - Summary of Maturities of Financing Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	$ 168,043
Less: interest	(72,432)
Less: tenant improvement allowance	(94)
Present value of financing liabilities	95,517
Less: short-term financing liabilities	(2,004)	$ (1,476)
Present value of long-term financing liabilities	93,513	$ 95,400
2024
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	13,534
2025
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	13,873
2026
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	14,221
2027
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	14,578
2028
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	14,944
Thereafter
Disclosure of maturity analysis for derivative financial liabilities [line items]
Total financing payments	$ 96,893

Leases - Other Information Rela

Leases - Other Information Related To Leases (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Lease Cost [Line Items]
Right-of-use assets	$ 117,882	$ 128,264
Current lease liabilities	9,416	8,959
Non-current lease liabilities	163,811	173,345
Operating Leases
Lease Cost [Line Items]
Right-of-use assets	100,249	106,127
Current lease liabilities	7,677	7,274
Non-current lease liabilities	$ 141,428	$ 145,445
Weighted average remaining lease term (in years)	11 years	11 years 10 months 24 days
Weighted-average discount rate (in percent)	0.150	0.145
Finance Leases
Lease Cost [Line Items]
Right-of-use assets	$ 17,633	$ 22,137
Current lease liabilities	1,739	1,685
Non-current lease liabilities	$ 22,383	$ 27,900
Weighted average remaining lease term (in years)	9 years 7 months 6 days	10 years 4 months 24 days
Weighted-average discount rate (in percent)	0.140	0.136

Leases - Cash Paid For Amounts

Leases - Cash Paid For Amounts Included In Measurement Of Lease Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Lease liabilities [abstract]
Interest paid on finance leases	$ 3,470	$ 3,877

Investments - Additional Inform

Investments - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($) entity	Dec. 31, 2022 USD ($)
Disclosure Of Significant Investments [Line Items]
Number of entities where investments are held | entity	4
Two Roots Brewing Co.
Disclosure Of Significant Investments [Line Items]
Decrease through write-off, financial assets		$ 0.1
Ownership interest (in percent)	0.80%
Market risk
Disclosure Of Significant Investments [Line Items]
Mark to market loss of investments held	$ (0.3)	$ (4.6)

Investments - Summary of Invest

Investments - Summary of Investments at Fair Value (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	$ 730	$ 1,228
420 Capital
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	68	68
Lighthouse
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	81	339
Two Roots Brewing Co.
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	0	93
Old Pal
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	532	592
IMC
Disclosure Of Investments Measured At Fair Value [Line Items]
Total Investments	$ 49	$ 136

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Summary Of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	$ 296,966	$ 407,590
Licenses
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	275,671	381,507
Customer Relationships
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	19,377	23,752
Trade Names
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	420	490
Permit Application Costs
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	1,371	1,130
Other Intangibles
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	127	711
Gross Carrying Amount
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	332,135	436,797
Gross Carrying Amount | Licenses
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	275,671	381,507
Gross Carrying Amount | Customer Relationships
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	31,000	31,879
Gross Carrying Amount | Trade Names
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	2,100	2,100
Gross Carrying Amount | Permit Application Costs
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	17,351	15,027
Gross Carrying Amount | Other Intangibles
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	6,013	6,284
Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	(35,169)	(29,207)
Accumulated Amortization | Licenses
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	0	0
Accumulated Amortization | Customer Relationships
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	(11,623)	(8,127)
Accumulated Amortization | Trade Names
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	(1,680)	(1,610)
Accumulated Amortization | Permit Application Costs
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	(15,980)	(13,897)
Accumulated Amortization | Other Intangibles
Disclosure of detailed information about intangible assets [line items]
Total Intangible Assets	$ (5,886)	$ (5,573)

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Increase (decrease) in intangible assets other than goodwill			$ (104,700)	$ (19,700)
Ending inventory	$ 1,000		1,000	1,600
Total amortization expense			7,046	10,359
Impairment			50,858	117,024
Encanto Green Cross Dispensary, LLC
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment charge			$ 200
Bottom of range
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Growth rate used to extrapolate cash flow projections (in percent)	2%		2%
Discount rate applied to cash flow projections (in percent)	13%		13%
Top of range
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Growth rate used to extrapolate cash flow projections (in percent)	3%		3%
Discount rate applied to cash flow projections (in percent)	18.50%		18.50%
California Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment	$ 9,900			89,500
Florida Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment	79,400
New York Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment	40,000
Massachusetts Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment charge				21,800
Impairment		$ 21,500		16,500
Arizona Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment				10,100
Maryland Reporting Unit
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Impairment				900
Cost of goods sold
Disclosure of Detailed Information About Intangible Assets And Goodwill [Line Items]
Total amortization expense			$ 4,000	2,900
Amortization capitalized to inventory in prior years	$ 1,600		$ 1,600	$ 1,100

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Amortization Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about intangible assets [line items]
Total amortization expense	$ 7,046	$ 10,359
Selling, general and administrative expense
Disclosure of detailed information about intangible assets [line items]
Total amortization expense	3,699	6,915
Cost of goods sold and ending inventory
Disclosure of detailed information about intangible assets [line items]
Total amortization expense	$ 3,347	$ 3,444

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Estimated Amortization Expense Of Intangible Assets (Detail) $ in Thousands	Dec. 31, 2023 USD ($)
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	$ 21,295
2024
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	5,339
2025
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	4,173
2026
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	3,877
2027
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	3,272
2028
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	2,962
Thereafter
Disclosure Of Estimated Amortization Expense Of Intangible Assets Other Than Goodwill [Line Items]
Total estimated amortization	$ 1,672

Intangible Assets and Goodwil_6

Intangible Assets and Goodwill - Changes In Carrying Amount Of Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of changes in goodwill [abstract]
Beginning balance	$ 330,555	$ 446,767
Impairment	(50,858)	(117,024)
Measurement period adjustments		812
Ending balance	$ 279,697	$ 330,555

Share Capital - Additional Info

Share Capital - Additional Information (Details) $ in Thousands, $ in Millions		1 Months Ended		3 Months Ended	12 Months Ended
		Apr. 30, 2021 USD ($)	Dec. 31, 2019 CAD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) vote shares		Dec. 31, 2022 USD ($) shares
Share Capital [Line Items]
Warrant exercises into share capital							$ 100
Redeemable units, redeemed during period (in shares) | shares					9,400,000		3,300,000
Decrease in noncontrolling interest (in percent)					3.70%		1.30%
2023 and 2022 Unit and Other Minority Holders
Share Capital [Line Items]
Accrued dividends recognised as distributions to unit holders					$ 15,200		$ 4,900
Dividends recognised as distributions to owners					$ 38,900
2022 and 2021 Unit and Other Minority Interest Holders
Share Capital [Line Items]
Required tax distribution amounts							$ 83,600
Selling, general and administrative expense
Share Capital [Line Items]
Capitalized fees				$ 200
Subordinate Voting Shares (SVS)
Share Capital [Line Items]
Voting rights | vote					1
Issued (in shares) | shares					320,757,119		281,147,586
Subordinate Voting Shares (SVS) | Canacord Genuity Corp.
Share Capital [Line Items]
Proceeds from issue of ordinary shares		$ 100,000
Number of shares issued during period (in shares) | shares					0		0
Subordinate Voting Shares (SVS) | Canacord Genuity Corp. | ATM Offering
Share Capital [Line Items]
Proceeds from issue of ordinary shares			$ 55
Proportionate Voting Shares (PVS)
Share Capital [Line Items]
Voting rights | vote					1
Voting rights conversion | vote					200
Issued (in shares) | shares	[1]				18,949,596		20,082,384
Description of stock conversion ratio					0.005
MVS
Share Capital [Line Items]
Voting rights | vote					2,000
Issued (in shares) | shares					500,000		500,000
Special Subordinate Voting Shares (SSVS)
Share Capital [Line Items]
Voting rights | vote					0.00001
Issued (in shares) | shares					1,589	[2]	639
Description of stock conversion ratio					100,000
[1] 1 Proportionate Voting Shares (“PVS”) presented on an “as-converted” basis to Subordinate Voting Shares (“SVS”) (1-to-200) 2 Special Subordinate Voting Shares (“SSVS”) presented on an “as-converted” basis to SVS (1-to-0.00001)

Share Capital - Summary of Issu

Share Capital - Summary of Issued And Outstanding Shares (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Redeemable  Units
Disclosure of classes of share capital [line items]
Beginning balance	106,106	109,441
Ending balance	96,699	106,106
Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Beginning balance	280,994	269,971
Ending balance	320,757	280,994
Proportionate Voting Shares (PVS)
Disclosure of classes of share capital [line items]
Beginning balance	20,082	20,667
Ending balance	18,950	20,082
MVS
Disclosure of classes of share capital [line items]
Beginning balance	500	500
Ending balance	500	500
Special Subordinate Voting Shares (SSVS)
Disclosure of classes of share capital [line items]
Beginning balance	1	1
Ending balance	2	1
Options and warrants exercised | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding		1,279
Issuance of shares related to settlement of acquisition contingent consideration | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	27,091
RSUs issued | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	1,727	337
Issuance of shares related to acquisitions | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding		5,339
Cresco LLC redemptions | Redeemable  Units
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	(9,407)	(3,335)
Cresco LLC redemptions | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	9,407	3,335
PVS converted to SVS | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	1,132	585
PVS converted to SVS | Proportionate Voting Shares (PVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	(1,132)	(585)
Issuances related to employee taxes on certain share-based payment arrangements | Subordinate Voting Shares (SVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	406	148
Share issuances | Special Subordinate Voting Shares (SSVS)
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding	1

Share Capital - Summary Of Comp

Share Capital - Summary Of Company Issued Shares In Conjunction Acquisitions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Laurel Harvest - Contingent Consideration
Disclosure Of Shares Issued During Acquisition [Line Items]
Acquisition date	Dec. 09, 2021
SVS shares issued	27,091,000
Equity-based consideration	$ 47,238
Cultivate - Contingent Consideration
Disclosure Of Shares Issued During Acquisition [Line Items]
Acquisition date		Sep. 02, 2021
SVS shares issued		5,340,000
Equity-based consideration		$ 34,708

Share Capital - Summary Of Warr

Share Capital - Summary Of Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share Capital [Abstract]
Number of warrants, beginning balance (in shares) | shares	9,842
Number of warrants, exercised (in shares) | shares	(12)
Number of warrants, forfeited (in shares) | shares	(9,830)
Number of warrants, ending balance (in shares) | shares	0
Weighted average exercise price, beginning balance (in dollars per share) | $ / shares	$ 9.63
Weighted average exercise price, exercised (in dollars per share) | $ / shares	4.24
Weighted average exercise price, forfeited (in dollars per share) | $ / shares	9.54
Weighted average exercise price, ending balance (in dollars per share) | $ / shares	$ 0

Share Capital - Summary Of Chan

Share Capital - Summary Of Changes In Ownership And Noncontrolling Interests (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	$ 1,080,380	$ 1,257,646
Current assets	278,087	326,046
Non-current liabilities	(730,158)	(740,144)
Current liabilities	(200,242)	(255,865)
Revenue	770,885	842,681
Net (loss) income	(179,852)	(215,843)
Net income (loss) allocated to NCI	(4,330)	(3,796)
Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net (loss) income	(4,330)	(3,796)
TSC Cresco, LLC
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	2,943	4,788
Current assets, including adjustments	(8,159)	(6,875)
Non-current liabilities	0	0
Current liabilities, including adjustments	(45,054)	26,600
Net assets	39,838	24,513
Revenue	1,664	10,582
Gross profit	863	12,500
Net (loss) income	188	19,290
Net income (loss) allocated to NCI	$ 47	$ 4,822
NCI percentage	25%	25%
TSC Cresco, LLC | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ 2,401	$ 4,190
MedMar Lakeview, LLC
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	28,678	31,151
Current assets	84,571	34,706
Non-current liabilities	(10,787)	(10,889)
Current liabilities	(47,928)	(13,438)
Net assets	54,534	41,530
Revenue	11,701	53,259
Gross profit	7,623	35,485
Net (loss) income	4,768	13,322
Net income (loss) allocated to NCI	$ 591	$ 1,652
NCI percentage	12.40%	12.40%
MedMar Lakeview, LLC | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ 4,150	$ 3,979
MedMar Rockford, LLC
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	22,594	22,700
Current assets	132,198	114,843
Non-current liabilities	(3,551)	(3,850)
Current liabilities	(57,388)	(41,111)
Net assets	93,853	92,582
Revenue	18,657	88,645
Gross profit	12,323	62,503
Net (loss) income	10,060	43,500
Net income (loss) allocated to NCI	$ 2,515	$ 10,875
NCI percentage	25%	25%
MedMar Rockford, LLC | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ 10,368	$ 7,468
Cresco Labs Ohio, LLC
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	14,703	16,736
Current assets	6,544	8,144
Non-current liabilities	(13,674)	(12,515)
Current liabilities	(8,213)	(5,768)
Net assets	(640)	6,597
Revenue	2,567	8,650
Gross profit	(473)	1,338
Net (loss) income	(2,450)	(4,933)
Net income (loss) allocated to NCI	$ (29)	$ (49)
NCI percentage	1.20%	1.20%
Cresco Labs Ohio, LLC | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ (156)	$ (32)
SLO Cultivation Inc.
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	1,045	5,376
Current assets	11,502	13,097
Non-current liabilities	0	(2,728)
Current liabilities	(49,954)	(50,722)
Net assets	(37,407)	(34,977)
Revenue	0	(24)
Gross profit	(335)	(10,769)
Net (loss) income	(246)	(16,458)
Net income (loss) allocated to NCI	$ (49)	$ (3,292)
NCI percentage	20%	20%
SLO Cultivation Inc. | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ (12,824)	$ (12,434)
Cresco Labs Michigan, LLC
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	30,508
Current assets	15,300
Non-current liabilities	(26,015)
Current liabilities	(49,812)
Net assets	(30,019)
Revenue	6,271
Gross profit	1,503
Net (loss) income	43
Net income (loss) allocated to NCI	$ 6
NCI percentage	15%
Cresco Labs Michigan, LLC | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ (258)
Cresco Labs, LLC
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Non-current assets	255,947	286,360
Current assets, including adjustments	(157,691)
Current assets		802,774
Non-current liabilities	(562,580)	(538,816)
Current liabilities, including adjustments	329,160
Current liabilities		(594,052)
Net assets	(135,164)	(43,734)
Revenue	92,266	469,505
Gross profit	48,207	248,472
Net (loss) income	(1,794)	(38,863)
Net income (loss) allocated to NCI	$ (879)	$ (16,323)
NCI percentage	38.30%	42%
Cresco Labs, LLC | Non-controlling interests
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items]
Net assets	$ (81,306)	$ (42,527)

Share Capital - Summary Of Effe

Share Capital - Summary Of Effects Of Changes In Ownership Interest (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share Capital [Line Items]
Net loss attributable to Cresco Labs Inc.	$ (175,522)	$ (212,047)
Increase (decrease) in Cresco Labs Inc. equity due to redemptions of Cresco Labs, LLC shares	0	0
Total change from net loss attributable to Cresco Labs Inc. and change in ownership interest in Cresco Labs, LLC.	(181,310)	(211,778)
Share capital
Share Capital [Line Items]
Increase (decrease) in Cresco Labs Inc. equity due to redemptions of Cresco Labs, LLC shares	16,027	17,438
Accumulated deficit
Share Capital [Line Items]
Increase (decrease) in Cresco Labs Inc. equity due to redemptions of Cresco Labs, LLC shares	$ (21,815)	$ (17,169)

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($) shares $ / shares	Dec. 31, 2022 USD ($) $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock option expiration period (in years)	10 years
Proceeds from exercise of options		$ 2.9
Number of stock options exercised (in shares) | shares	0
Weighted average exercise price, exercised | $ / shares	$ 0
Unrecognized compensation expense	$ 5.4
Unrecognized compensation expense of option awards, period of recognition	4 years
Capitalized compensation expense	$ 0.7	1.7
Expense from share-based payment transactions, including opening balance	1.7	1.2
Restricted share units (RSUs)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unrecognized compensation expense	$ 5.8
Unrecognized compensation expense of other equity awards, period of recognition	4 years
Cost of goods sold
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense from share-based payment transactions	$ 3.4	$ 3.6
Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period (in years)	4 years
Number of shares issued under the plan not exceed the percentage of issued and outstanding shares	10%
Weighted average
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, exercised | $ / shares		$ 4.64

Share-Based Compensation - Summ

Share-Based Compensation - Summary of the Status of the Stock Options Outstanding (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) shares $ / shares	Dec. 31, 2022 USD ($) shares $ / shares
Share-Based Payment Arrangements [Abstract]
Number of stock options outstanding, beginning balance (in shares) | shares	25,528,000
Number of stock options granted (in shares) | shares	3,478,000
Number of stock options forfeited (in shares) | shares	(4,903,000)
Number of stock options outstanding, ending balance (in shares) | shares	24,103,000	25,528,000
Number of stock options exercisable (in shares) | shares	15,989,000
Weighted average exercise price of stock options outstanding, beginning balance (in dollars per share) | $ / shares	$ 5
Weighted average exercise price of stock options granted (in dollars per share) | $ / shares	1.72
Weighted average exercise price of stock options forfeited (in dollars per share) | $ / shares	5.43
Weighted average exercise price of stock options outstanding, ending balance (in dollars per share) | $ / shares	4.45	$ 5
Weighted average exercise price of stock options exercisable (in dollars per share) | $ / shares	$ 4.27
Weighted average remaining contractual life of outstanding share options	6 years 7 months 6 days	7 years 6 months 14 days
Weighted average remaining contractual life of exercisable stock options	5 years 9 months
Aggregate intrinsic value of outstanding stock options | $	$ 328	$ 921
Aggregate intrinsic value of outstanding of exercisable stock options | $	$ 328

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Weighted Average Grant Date Fair Value and Intrinsic Value of Options Exercised (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangements [Abstract]
Weighted average fair value at measurement date, share options granted (in dollars per share)	$ 1.21	$ 2.59
Intrinsic value of stock option units exercised, using market price at exercise date	$ 0	$ 5,106

Share-Based Compensation - Su_3

Share-Based Compensation - Summary Of Fair Value Of Stock Options Granted Under the Plan (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period [Line Items]
Expected annual dividend yield (in percent)	0%	0%
Bottom of range
Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period [Line Items]
Risk-free annual interest rate (in percent)	3.70%	1.40%
Expected stock price volatility (in percent)	77%	74.90%
Expected life of stock options (in years)	5 years	5 years 6 months
Forfeiture rate (in percent)	7.20%	7.20%
Fair value at grant date (in dollars per share)	$ 0.94	$ 1.23
Stock price at grant date (in dollars per share)	1.35	1.81
Exercise price range (in dollars per share)	$ 1.35	$ 1.81
Top of range
Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period [Line Items]
Risk-free annual interest rate (in percent)	4%	3%
Expected stock price volatility (in percent)	82.80%	80.40%
Expected life of stock options (in years)	7 years	7 years
Forfeiture rate (in percent)	34%	28%
Fair value at grant date (in dollars per share)	$ 1.52	$ 4.90
Stock price at grant date (in dollars per share)	2.01	6.91
Exercise price range (in dollars per share)	$ 2.01	$ 6.91

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Outstanding Restricted Stock Units (Details) - Restricted share units (RSUs)	12 Months Ended
	Dec. 31, 2023 shares $ / shares
Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]
Number of RSUs outstanding, beginning balance (in shares) | shares	4,258,000
Number of RSUs granted (in shares) | shares	6,347,000
Number of RSUs vested and settled (in shares) | shares	(1,769,000)
Number of RSUs forfeited (in shares) | shares	(1,974,000)
Number of RSUs outstanding, ending balance (in shares) | shares	6,862,000
Weighted average fair value of RSUs, beginning balance (in dollars per share) | $ / shares	$ 5.71
Weighted average fair value of RSUs, granted (in dollars per share) | $ / shares	1.77
Weighted average fair value of RSUs, vested and settled (in dollars per share) | $ / shares	1.91
Weighted average fair value of RSUs, forfeited (in dollars per share) | $ / shares	3.20
Weighted average fair value of RSUs, ending balance (in dollars per share) | $ / shares	$ 2.91

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of Total Fair Value of Restricted Stock Units Vested (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Restricted share units (RSUs)
Total Fair Value Of Units Vested Other Equity Instruments [line Items]
Total fair value of RSUs vested, using market price at vest date	$ 3,373	$ 2,396

Share-Based Compensation - Su_6

Share-Based Compensation - Summary Of Classification Of Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense for option awards	$ 7,084	$ 13,733
Stock Options | Cost of goods sold
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense for option awards	1,059	1,984
Stock Options | Selling, general and administrative expense
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense for option awards	6,025	11,749
Restricted share units (RSUs)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense for option awards	8,251	10,011
Restricted share units (RSUs) | Cost of goods sold
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense for option awards	1,352	2,097
Restricted share units (RSUs) | Selling, general and administrative expense
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense for option awards	$ 6,899	$ 7,914

Loss Per Share - Basic And Dilu

Loss Per Share - Basic And Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings per share [abstract]
Net loss	$ (179,852)	$ (215,843)
Net loss attributable to non-controlling interests, net of tax	(4,330)	(3,796)
Net loss attributable to Cresco Labs Inc.	$ (175,522)	$ (212,047)
Weighted-average basic shares outstanding (in shares)	323,819,766	298,161,665
Weighted-average diluted shares outstanding (in shares)	323,819,766	298,161,665
Basic loss per share (in dollars per share)	$ (0.54)	$ (0.71)
Diluted loss per share (in dollars per share)	$ (0.54)	$ (0.71)

Loss Per Share - Antidilutive S

Loss Per Share - Antidilutive Shares (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings per share [line items]
Total potentially dilutive shares	127,664	137,153
Redeemable  Units
Earnings per share [line items]
Total potentially dilutive shares	96,699	107,443
Options
Earnings per share [line items]
Total potentially dilutive shares	24,103	25,528
RSUs
Earnings per share [line items]
Total potentially dilutive shares	6,862	4,182

Acquisitions And Dispositions -

Acquisitions And Dispositions - Summary of Deferred and Contingent Consideration Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Detailed Information Of Deferred Consideration Contingent And Consideration [Line Items]
Total Deferred consideration, short-term	$ 0	$ 47,821
Laurel Harvest
Disclosure of Detailed Information Of Deferred Consideration Contingent And Consideration [Line Items]
Laurel Harvest deferred consideration, short-term	$ 0	$ 47,821

Acquisitions And Dispositions_2

Acquisitions And Dispositions - Additional Information (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) dispensary	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Disclosure of detailed information about business combination [line items]
Cash payments of deferred consideration			$ 701	$ 0
Valley Agriceuticals, LLC (“Valley Ag”) operating cash flows deferred consideration			6,577	7,770
Encanto Green Cross Dispensary, LLC
Disclosure of detailed information about business combination [line items]
Impairment charge			200
Discontinued operations | AFS Maryland, LLC
Disclosure of detailed information about business combination [line items]
Consideration paid (received)			(3,300)
Gain (loss) on disposal of business			1,400
Discontinued operations | Encanto Green Cross Dispensary, LLC
Disclosure of detailed information about business combination [line items]
Consideration paid (received)			(6,500)
Gain (loss) on disposal of business			$ (1,000)
Laurel Harvest
Disclosure of detailed information about business combination [line items]
Total deferred consideration					$ 46,900
Total deferred consideration, payable period			18 months
Accelerated payment of deferred consideration required on each number of dispensaries opened (in dispensaries) | dispensary			5
Total deferred payment				47,800
Payment of deferred consideration	$ 38,600	$ 10,000
Stock issuance as payment of deferred consideration	37,500	9,700
Cash payments of deferred consideration	1,100	300
Valley Agriceuticals, LLC
Disclosure of detailed information about business combination [line items]
Valley Agriceuticals, LLC (“Valley Ag”) operating cash flows deferred consideration			$ 6,600
Long-term deferred consideration reclassified to short-term		$ 300
Decrease in deferred consideration			$ (400)
Deferred consideration expense				$ 100
Columbia Care Inc.
Disclosure of detailed information about business combination [line items]
Write-off of consent fee	$ 5,000

Acquisitions And Dispositions_3

Acquisitions And Dispositions - Summary of Long-Term Deferred Consideration (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Business Combinations And Discontinued Operations [Abstract]
Valley Agriceuticals, LLC (“Valley Ag”) operating cash flows deferred consideration	$ 6,577	$ 7,770
Total Long-term deferred and contingent consideration	$ 6,577	$ 7,770

Long-term Notes and Loans Pay_3

Long-term Notes and Loans Payable, Net - Summary of Loans Payable Balances as Follows (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Aug. 12, 2021
Disclosure of detailed information about borrowings [line items]
Short-term borrowings and interest payable	$ 9,813	$ 9,500
Financing liability	95,698	96,917
Total borrowings and interest payable	525,671	506,417
Less: Unamortized debt issuance costs	(16,141)	(18,550)
Less: Short-term borrowings and interest payable	(9,813)	(9,500)
Less: Current portion of financing liability1	(2,004)	(1,476)
Total Long-term notes and loans payable, net	497,713	476,891
Senior Loan
Disclosure of detailed information about borrowings [line items]
Borrowings	400,000	400,000	$ 400,000
Mortgage Loans
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 20,160	$ 0

Long-term Notes and Loans Pay_4

Long-term Notes and Loans Payable, Net - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Aug. 12, 2021	Dec. 31, 2023	Dec. 31, 2022	Sep. 26, 2023
Disclosure of detailed information about borrowings [line items]
Adjustments for finance income (cost)		$ (4,416)	$ (3,951)
Payments for debt issue costs		$ 1,947	0
Bottom of range
Disclosure of detailed information about borrowings [line items]
Weighted average lessee's incremental borrowing rate (in percent)		11.30%
Weighted average remaining lease term (in years)		6 years 1 month 6 days
Top of range
Disclosure of detailed information about borrowings [line items]
Weighted average lessee's incremental borrowing rate (in percent)		17.50%
Weighted average remaining lease term (in years)		16 years 6 months
Senior Loan
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 400,000	$ 400,000	400,000
Adjustments for finance income (cost)	$ (13,000)
Borrowings, interest rate (in percent)	9.50%
Borrowings, maturity	August 12, 2026
Borrowings, effective interest rate (in percent)	11%
Borrowing costs capitalised	$ 10,900
Principal repayment of the Senior Loan	$ 7,000
Minimum cash balance required to be maintained		50,000
Mortgage Loans
Disclosure of detailed information about borrowings [line items]
Borrowings		20,160	$ 0
Mortgage Loans | JDRC Ellenville, LLC
Disclosure of detailed information about borrowings [line items]
Borrowings				$ 25,300
Borrowings, interest rate (in percent)				8.40%
Borrowings, effective interest rate (in percent)				10.20%
Borrowings, adjustment to interest rate basis				3.75%
Undrawn borrowing facilities		5,100
Payments for debt issue costs		2,000
Borrowings, capitalized interest		$ 300

Revenues and Loyalty Programs -

Revenues and Loyalty Programs - Summary of Disaggregated Revenue by Source (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Revenues	$ 770,885	$ 842,681
Wholesale
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Revenues	306,363	367,222
Dispensary
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Revenues	$ 464,522	$ 475,459

Revenues and Loyalty Programs_2

Revenues and Loyalty Programs - Additional Information (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Sales discounts (in percent)	0.170	0.107
Discount on future purchases	$ 0.03
Loyalty points outstanding	71,200,000	126,100,000
Loyalty points outstanding value	$ 1,200,000	$ 2,100,000
Loyalty point expected redemption period	1 year
Bottom of range
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue reduction per loyalty point	0.01
Top of range
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue reduction per loyalty point	0.02

Other Income , Net - Summary of

Other Income , Net - Summary of Other Income, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Other Operating Income (Expense) [Abstract]
Unrealized gain on derivative liabilities - warrants	$ 0	$ 1,184
Realized loss on financial instruments	(94)	(5,698)
(Loss) gain on provision - loan receivable	(314)	572
Unrealized loss on investments held at fair value	(406)	(4,609)
Gain on disposal of assets	762	14,711
Gain on conversion of investment	0	22
(Loss) gain on foreign currency	(303)	931
Gain on lease termination	1,263	4,876
Other income, net	832	3,238
Total Other income, net	$ 1,740	$ 15,227

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) redeemableUnit in Millions	12 Months Ended
	Dec. 31, 2023 USD ($) redeemableUnit	Dec. 31, 2022 USD ($)
Disclosure of transactions between related parties [line items]
Non-controlling interests	$ (77,625,000)	$ (39,356,000)
Interest expense - leases	$ 3,513,000	$ 3,952,000
Key management personnel of entity or parent
Disclosure of transactions between related parties [line items]
Number of redeemable units held by related party | redeemableUnit	85.1
Non-controlling interests	$ 71,500,000
Tax distribution payments to related party (in percent)	71.20%	74.40%
Reimbursements of tenant improvement allowance	$ 0	$ 1,400,000
Expected reimbursements of tenant improvement allowance	700,000
MVS shareholder
Disclosure of transactions between related parties [line items]
Interest expense - leases	300,000	300,000
Finance liabilities	$ 1,400,000	$ 1,500,000

Related Party Transactions - Su

Related Party Transactions - Summary of Expense Resulting From The Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of transactions between related parties [line items]
Interest expense - leases	$ 3,513	$ 3,952
MVS shareholder
Disclosure of transactions between related parties [line items]
Interest expense - leases	300	300
MVS shareholder | Operating Leases
Disclosure of transactions between related parties [line items]
Rent expense	1,187	1,187
MVS shareholder | Finance Leases
Disclosure of transactions between related parties [line items]
Depreciation expense	90	81
Interest expense - leases	69	76
SLO Cultivation Inc. | Subsidiaries | Operating Leases
Disclosure of transactions between related parties [line items]
Rent expense	0	513
MedMar Inc. | Subsidiaries | Operating Leases
Disclosure of transactions between related parties [line items]
Rent expense	288	288
MedMar Inc. | Subsidiaries | Finance Leases
Disclosure of transactions between related parties [line items]
Depreciation expense	306	306
Interest expense - leases	$ 246	$ 270

Related Party Transactions - _2

Related Party Transactions - Summary of ROU Assets And Lease Liabilities Attributable To Related Party Transactions (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of transactions between related parties [line items]
ROU Asset	$ 117,882	$ 128,264
Lease Liability	173,227
Finance Leases
Disclosure of transactions between related parties [line items]
ROU Asset	17,633	22,137
Lease Liability	24,122
MVS shareholder | Operating Leases
Disclosure of transactions between related parties [line items]
ROU Asset	5,332	5,849
Lease Liability	5,429	5,907
MVS shareholder | Finance Leases
Disclosure of transactions between related parties [line items]
ROU Asset	583	596
Lease Liability	502	555
MedMar Inc. | Subsidiaries | Operating Leases
Disclosure of transactions between related parties [line items]
ROU Asset	1,294	1,415
Lease Liability	1,345	1,456
MedMar Inc. | Subsidiaries | Finance Leases
Disclosure of transactions between related parties [line items]
ROU Asset	1,729	2,034
Lease Liability	$ 2,210	$ 2,452

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2023
Commitments And Contingencies [Line Items]
Severance costs		$ 3.1
Construction projects
Commitments And Contingencies [Line Items]
Total commitments		$ 2.3
Illinois Company, Secured Craft Grower Licenses
Commitments And Contingencies [Line Items]
Loans issued	$ 0.2
Groups Identified by State of Illinois, Opportunity To Receive Conditional Adult Use Dispensing Organization Licenses
Commitments And Contingencies [Line Items]
Loans issued	$ 1

Financial Instruments And Fin_3

Financial Instruments And Financial Risk Management - Summary Of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounts payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	$ 27,587	$ 28,093
Financial liabilities, fair value	27,587	28,093
Accrued liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	69,079	65,161
Financial liabilities, fair value	69,079	65,161
Short-term borrowings
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	11,817	10,976
Financial liabilities, fair value	11,817	10,976
Current portion of lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	9,416	8,959
Financial liabilities, fair value	9,416	8,959
Deferred consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost		6
Financial liabilities, fair value		47,834
Lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	163,811	173,345
Financial liabilities, fair value	163,811	173,345
Deferred consideration, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	0	0
Financial liabilities, fair value	6,577	7,770
Long-term notes and loans payable, net
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	497,713	476,891
Financial liabilities, fair value	497,713	476,891
Other long-term liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, amortised cost	21,600	7,000
Financial liabilities, fair value	21,600	7,000
Level 1 | Accounts payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Accrued liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Short-term borrowings
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Current portion of lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Deferred consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value		7
Level 1 | Lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Deferred consideration, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Long-term notes and loans payable, net
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 1 | Other long-term liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Accounts payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Accrued liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Short-term borrowings
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Current portion of lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Deferred consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value		0
Level 2 | Lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Deferred consideration, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Long-term notes and loans payable, net
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 2 | Other long-term liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Accounts payable
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Accrued liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Short-term borrowings
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Current portion of lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Deferred consideration and other payables, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	47,821
Level 3 | Lease liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Deferred consideration, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	6,577	7,770	$ 17,651
Level 3 | Long-term notes and loans payable, net
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Level 3 | Other long-term liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, fair value	0	0
Cash and cash equivalents
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	103,429	119,341
Financial assets, fair value	103,429	119,341
Cash and cash equivalents | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Cash and cash equivalents | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Cash and cash equivalents | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Restricted cash
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	5,091	2,169
Financial assets, fair value	5,091	2,169
Restricted cash | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Restricted cash | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Restricted cash | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Security deposits
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	4,408	4,367
Financial assets, fair value	4,408	4,367
Security deposits | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Security deposits | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Security deposits | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Accounts receivable, net
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	51,070	56,492
Financial assets, fair value	51,070	56,492
Accounts receivable, net | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Accounts receivable, net | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Accounts receivable, net | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	1,421	447
Financial assets, fair value	1,421	447
Loans receivable, short-term | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, short-term | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, short-term | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0	565
Loans receivable, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	826	823
Financial assets, fair value	826	823
Loans receivable, long-term | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, long-term | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Loans receivable, long-term | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	0	0
Investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	0	0
Financial assets, fair value	730	1,228
Investments | Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	49	136
Investments | Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	81	432
Investments | Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, fair value	$ 600	$ 660	$ 660

Financial Instruments And Fin_4

Financial Instruments And Financial Risk Management - Rollforward of Level 3 Amounts Measured At Fair Value On Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Deferred consideration and other payables, short-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	$ 47,834	$ 47,834
Ending balance			$ 47,834
Deferred consideration, long-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	7,770	7,770
Ending balance		6,577	7,770
Level 3
Reconciliation of changes in fair value measurement, liabilities [abstract]
Reclassifications from long-term to short-term	9,000
Level 3 | Deferred consideration and other payables, short-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	47,821	47,821
Change in fair value		1,953
Payments		(50,072)
Other		298
Ending balance		0	47,821
Level 3 | Deferred consideration and other payables, short-term | Other Income
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value		0
Level 3 | Deferred consideration and other payables, short-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	47,821	47,821	71,816
Change in fair value			900
Payments			(39,542)
Other			9,000
Ending balance			47,821
Level 3 | Deferred consideration and other payables, short-term | Other Income
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value			5,647
Level 3 | Deferred consideration and other payables, short-term | Selling, general and administrative expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value			0
Level 3 | Derivative liabilities, short-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	0	0	1,172
Change in fair value			0
Payments			0
Other			0
Ending balance			0
Level 3 | Derivative liabilities, short-term | Other Income
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value			(1,172)
Level 3 | Derivative liabilities, short-term | Selling, general and administrative expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value			0
Level 3 | Deferred consideration, long-term
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance	7,770	7,770	17,651
Change in fair value		0	(881)
Payments		0	0
Other		(298)	(9,000)
Ending balance		6,577	7,770
Level 3 | Deferred consideration, long-term | Other Income
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value		(895)	0
Level 3 | Deferred consideration, long-term | Selling, general and administrative expense
Reconciliation of changes in fair value measurement, liabilities [abstract]
Change in fair value			0
Loans receivable, short-term
Changes in fair value measurement, assets [abstract]
Beginning balance	447	447
Ending balance		1,421	447
Loans receivable, short-term | Level 3
Changes in fair value measurement, assets [abstract]
Beginning balance	0	0	565
Change in fair value			0
Payments			(1,837)
Other			0
Ending balance		0	0
Loans receivable, short-term | Level 3 | Other Income
Changes in fair value measurement, assets [abstract]
Change in fair value			0
Loans receivable, short-term | Level 3 | Selling, general and administrative expense
Changes in fair value measurement, assets [abstract]
Change in fair value			1,272
Loans receivable, long-term
Changes in fair value measurement, assets [abstract]
Beginning balance	823	823
Ending balance		826	823
Loans receivable, long-term | Level 3
Changes in fair value measurement, assets [abstract]
Beginning balance	0	0
Ending balance		0	0
Investments
Changes in fair value measurement, assets [abstract]
Beginning balance	1,228	1,228
Ending balance		730	1,228
Investments | Level 3
Changes in fair value measurement, assets [abstract]
Beginning balance	$ 660	660	660
Change in fair value		0	0
Payments		0	0
Other		0	0
Ending balance		600	660
Investments | Level 3 | Other Income
Changes in fair value measurement, assets [abstract]
Change in fair value		$ (60)	0
Investments | Level 3 | Selling, general and administrative expense
Changes in fair value measurement, assets [abstract]
Change in fair value			$ 0

Financial Instruments And Fin_5

Financial Instruments And Financial Risk Management - Summary of Loans Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Loans receivable, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	$ 1,421	$ 447
Financial assets	1,421	447
Loans receivable, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	826	823
Financial assets	826	823
Kurvana, Net Of ECL | Loans receivable, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	493	447
280E, Net Of ECL | Loans receivable, short-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	928	0
Illinois Incubator, Net Of ECL | Loans receivable, long-term
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial assets, amortized cost	$ 826	$ 823

Financial Instruments And Fin_6

Financial Instruments And Financial Risk Management - Additional Information (Details) - USD ($) $ in Thousands			3 Months Ended			12 Months Ended
	Mar. 21, 2022	Jul. 20, 2021	Jun. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Sep. 26, 2023	Aug. 12, 2021
Disclosure of detailed information about financial instruments [line items]
Total accounts receivable, net						$ 51,070	$ 56,492
Expenses for bad and doubtful debt						4,900	400
Bad debts write-offs						5,500	1,900
Increase (decrease) in net loss						(36,000)
(Loss) gain on foreign currency						(303)	931
One Customer
Disclosure of detailed information about financial instruments [line items]
Total accounts receivable, net						$ 7,200
Entity's accounts receivable (in percent)						12%
Two Customers
Disclosure of detailed information about financial instruments [line items]
Total accounts receivable, net							$ 13,900
Entity's accounts receivable (in percent)							23%
Senior Loan
Disclosure of detailed information about financial instruments [line items]
Borrowings, interest rate (in percent)									9.50%
Borrowings, effective interest rate (in percent)									11%
Mortgage Loans | JDRC Ellenville, LLC
Disclosure of detailed information about financial instruments [line items]
Borrowings, interest rate (in percent)								8.40%
Borrowings, effective interest rate (in percent)								10.20%
Liquidity risk
Disclosure of detailed information about financial instruments [line items]
Working capital						$ 77,800
Currency risk
Disclosure of detailed information about financial instruments [line items]
Average rate of hedging instrument						0%	0%
California Reporting Unit
Disclosure of detailed information about financial instruments [line items]
Accounts receivable reserve				$ 100
Cash payments received after implementations of plans to reduce operations						$ 2,000
Illinois Company, Secured Craft Grower Licenses
Disclosure of detailed information about financial instruments [line items]
Loans issued					$ 200
Groups Identified by State of Illinois, Opportunity To Receive Conditional Adult Use Dispensing Organization Licenses
Disclosure of detailed information about financial instruments [line items]
Loans issued					$ 1,000
Loans receivable, short-term
Disclosure of detailed information about financial instruments [line items]
Issuance of financial assets			$ 1,000
Term of financial assets (in years)			1 year
Interest rate of financial assets (in percent)			9.50%
Financial assets at amortised cost, category | Loans and receivables, category
Disclosure of detailed information about financial instruments [line items]
Loans issued, fully funded	$ 1,200
Financial assets at amortised cost, category | Illinois Company, Secured Craft Grower Licenses | Loans and receivables, category
Disclosure of detailed information about financial instruments [line items]
Loans issued							$ 300
Loans issued, fully funded		$ 100
Financial assets at amortised cost, category | Groups Identified by State of Illinois, Opportunity To Receive Conditional Adult Use Dispensing Organization Licenses | Loans and receivables, category
Disclosure of detailed information about financial instruments [line items]
Loans issued							$ 1,000

Financial Instruments And Fin_7

Financial Instruments And Financial Risk Management - Summary of Aging Accounts Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Aging Trade Receivable [Line Items]
Total accounts receivable, gross	$ 59,034	$ 59,119
Allowance for doubtful accounts	7,964	2,627
Total accounts receivable, net	51,070	56,492
One Customer
Disclosure Of Aging Trade Receivable [Line Items]
Total accounts receivable, net	7,200
0 to 60 days
Disclosure Of Aging Trade Receivable [Line Items]
Total accounts receivable, gross	41,820	49,303
61 to 120 days
Disclosure Of Aging Trade Receivable [Line Items]
Total accounts receivable, gross	8,117	6,118
120 days +
Disclosure Of Aging Trade Receivable [Line Items]
Total accounts receivable, gross	$ 9,097	$ 3,698

Financial Instruments And Fin_8

Financial Instruments And Financial Risk Management - Summary of Contractual Obligations (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	$ 1,078,407
Less Than 1 Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	153,528
1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	513,664
3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	101,804
More than 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	309,411
Accounts payable & Accrued liabilities
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	95,817
Accounts payable & Accrued liabilities | Less Than 1 Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	95,817
Accounts payable & Accrued liabilities | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Accounts payable & Accrued liabilities | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Accounts payable & Accrued liabilities | More than 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Operating leases liabilities
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	306,564
Operating leases liabilities | Less Than 1 Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	28,417
Operating leases liabilities | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	58,172
Operating leases liabilities | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	58,726
Operating leases liabilities | More than 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	161,249
Finance lease liabilities
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	43,742
Finance lease liabilities | Less Than 1 Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	4,882
Finance lease liabilities | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	10,166
Finance lease liabilities | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	10,357
Finance lease liabilities | More than 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	18,337
Deferred consideration, long-term
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	6,577
Deferred consideration, long-term | Less Than 1 Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Deferred consideration, long-term | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	6,577
Deferred consideration, long-term | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Deferred consideration, long-term | More than 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Long-term notes and loans payable and Short-term borrowings
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	603,257
Long-term notes and loans payable and Short-term borrowings | Less Than 1 Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	23,347
Long-term notes and loans payable and Short-term borrowings | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	428,276
Long-term notes and loans payable and Short-term borrowings | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	29,522
Long-term notes and loans payable and Short-term borrowings | More than 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	122,112
Tax receivable agreement liability
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	14,564
Tax receivable agreement liability | Less Than 1 Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	1,065
Tax receivable agreement liability | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	2,587
Tax receivable agreement liability | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	3,199
Tax receivable agreement liability | More than 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	7,713
Other long-term liabilities
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	7,886
Other long-term liabilities | Less Than 1 Year
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Other long-term liabilities | 1 to 3 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	7,886
Other long-term liabilities | 3 to 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	0
Other long-term liabilities | More than 5 Years
Disclosure Of Contractual Obligations [Line Items]
Contractual Obligations	$ 0

Variable Interest Entities - Su

Variable Interest Entities - Summary of Assets Liabilities and Networth of Variable Interest Entities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Summary of Assets Liabilities and Networth of Variable Interest Entities [line Items]
Current assets	$ 278,087	$ 326,046
Non-current assets	1,080,380	1,257,646
Current liabilities	(200,242)	(255,865)
Non-current liabilities	(730,158)	(740,144)
Non-controlling interests	(77,625)	(39,356)
Deficit attributable to Cresco Labs Inc.	505,692	627,039
Cresco Labs Michigan, LLC
Summary of Assets Liabilities and Networth of Variable Interest Entities [line Items]
Current assets	15,485	17,506
Non-current assets	75,622	63,212
Current liabilities	(1,476)	(3,158)
Non-current liabilities	(124,793)	(108,113)
Non-controlling interests	258	0
Deficit attributable to Cresco Labs Inc.	$ 34,904	$ 30,553

Variable Interest Entities - _2

Variable Interest Entities - Summary of Income Expenses and Net Income Loss of Variable Interest Entities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Summary of Income Expenses and Net Income Loss of Variable Interest Entities [line Items]
Revenue	$ 770,885	$ 842,681
Net loss attributable to non-controlling interests, net of tax	(4,330)	(3,796)
Net loss attributable to Cresco Labs Inc.	(175,522)	(212,047)
Net (loss) income	(179,852)	(215,843)
Cresco Labs Michigan, LLC
Summary of Income Expenses and Net Income Loss of Variable Interest Entities [line Items]
Revenue	25,046	12,659
Net loss attributable to non-controlling interests, net of tax	(258)	0
Net loss attributable to Cresco Labs Inc.	(4,445)	(8,617)
Net (loss) income	$ (4,703)	$ (8,617)

Segment Information - Additiona

Segment Information - Additional Information (Detail) - segment	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of operating segments [line items]
Number of operating segments	1
USA
Disclosure of operating segments [line items]
Percentage of entity's revenue	100%	100%

Interest Expense, Net - Summary

Interest Expense, Net - Summary of Interest Expense, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Interest Income (Expense) [Line Items]
Interest expense – notes and loans payable	$ (43,575)	$ (38,528)
Interest expense – financing activities	(11,739)	(11,887)
Accretion of debt discount and amortization of deferred financing fees	(4,416)	(3,951)
Interest expense – leases	(3,513)	(3,952)
Other interest income	276
Other interest (expense)		(198)
Interest income	2,148	679
Total Interest expense, net	(60,819)	$ (57,837)
Valley Agriceuticals, LLC
Disclosure Of Interest Income (Expense) [Line Items]
Reduction of interest expense	$ 1,200

Provision For Income Taxes An_3

Provision For Income Taxes And Deferred Income Taxes - Summary of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current	$ 71,537	$ 93,581
Deferred	(13,237)	(17,000)
Change in valuation allowance	(25,350)	12,357
Total	32,950	88,938
Federal
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current	55,679	69,240
Deferred	(23,771)	(8,332)
State
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current	15,858	24,341
Deferred	(18,215)	(9,858)
Foreign
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current	0	0
Deferred	$ 28,749	$ 1,190

Provision For Income Taxes An_4

Provision For Income Taxes And Deferred Income Taxes - Summary of Components of Deferred Tax Assets And Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	$ 102,187	$ 75,711
Deferred tax liabilities	(113,006)	(107,381)
Valuation allowance	(18,091)	(43,442)
Net deferred tax liabilities	(28,910)	(75,112)
Share-based compensation
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	3,961	1,381
Financing fees
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	453	1,291
Net operating losses
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	40,580	43,629
Inventory
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	97	346
Lease liabilities
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	41,088	28,362
Tax receivable agreement
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	15,379	315
Other
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	629	386
Deferred tax liabilities	(23,596)	(1,329)
ROU assets
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	(13,689)	(9,560)
Property, plant and equipment
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	(11,669)	(12,393)
Intangible assets
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	$ (64,052)	$ (84,099)

Provision For Income Taxes An_5

Provision For Income Taxes And Deferred Income Taxes - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Increase (decrease) through business combinations, deferred tax liability (asset)	$ 15.4
Deferred tax liability (asset)	13.5	$ 7.8
Unrecognized tax benefits reserve		6.1
Unrecognized tax benefits, penalties and interest	1.3
Accrued tax penalties and interest	6.9	5.5
Canadian non-capital
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Operating loss carryforward, offset by valuation allowance	41.9	63.5
U.S Federal
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Operating loss carryforward, offset by valuation allowance	50.8	45.7
Operating loss carryforward	55.7	52.2
State and Local Jurisdiction
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Operating loss carryforward, offset by valuation allowance	183.3	180.8
Operating loss carryforward	$ 204.6	$ 184.3

Provision For Income Taxes An_6

Provision For Income Taxes And Deferred Income Taxes - Summary of Reconciliation Between The Effective Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Expected income tax expense at statutory tax rate	$ (30,711)	$ (26,650)
Tax rate differences	(69)	(2,296)
Pass through and non-controlling entities	(4,881)	(2,183)
State tax expense, net	(4,898)	17,209
IRC Section 280E disallowance	47,043	50,521
Uncertain tax treatment (including penalties and interest)	7,311	12,901
Share-based compensation	2,086	2,261
Goodwill impairment	10,448	25,334
Tax penalties and interest	5,552	4,155
Change in valuation allowance	(25,350)	12,357
Change in state tax rates	10,317	(471)
Change in state filing methods	(3,940)	0
Canadian reorganization basis change	28,730	0
Tax receivable agreement	(2,919)	(395)
Adjustments to prior year provisions	(7,003)	(5,136)
Other	1,235	1,332
Total	$ 32,950	$ 88,938
Effective tax rate	(22.40%)	(70.10%)

Provision For Income Taxes An_7

Provision For Income Taxes And Deferred Income Taxes - Schedule Of Reconciliation Of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Reconciliation Of Unrecognized Tax Benefits [Roll Forward]
Balance at January 1	$ 12,746	$ 0
Additions based on tax positions related to the current year	6,054	7,380
Additions for tax positions of prior years	0	5,366
Balance at the end of the year	$ 18,800	$ 12,746